

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/SE04/001814

International filing date: 06 December 2004 (06.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: SE
Number: 0303268-7
Filing date: 05 December 2003 (05.12.2003)

Date of receipt at the International Bureau: 28 December 2004 (28.12.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

PCT : SE 2004 / 0 0 1 8 1 4

21 -12- 2004

Intyg Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.



(71) Sökande AngioGenetics Sweden AB, Göteborg SE
Applicant (s)

(21) Patentansökningsnummer 0303268-7
Patent application number

(86) Ingivningsdatum 2003-12-05
Date of filing

Stockholm, 2004-12-09

För Patent- och registreringsverket
For the Patent- and Registration Office


Gunilla Larsson

Avgift
Fee

PATENT- OCH
REGISTRERINGSVERKET
SWEDEN

Postadress/Adress
Box 5055
S-102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00

Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

Title

Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof.

Field of the Invention

The invention relates to polypeptides and proteins encoded thereby which are involved in vasculogenesis and/or angiogenesis. These agents may be targeted when producing materials and methods used in the diagnosis and therapy of angiogenesis-related conditions. The invention further relates to such diagnostic and therapeutic methods and agents.

Background of the Invention

Both vasculogenesis, the development of an interactive vascular system comprising arteries and veins, and angiogenesis, the generation of new blood vessels, play a role in embryonic development. In contrast, angiogenesis is limited in a normal adult to the placenta, ovary, endometrium, and sites of wound healing. Angiogenesis, or its absence, plays an important role in the maintenance of a variety of pathological states. Some of these states are characterized by neovascularization, e.g., cancer, diabetic retinopathy, glaucoma, and age related macular degeneration. Others, e.g., stroke, infertility, heart disease, ulcers, and scleroderma, are diseases of angiogenic insufficiency.

Angiogenesis has a number of stages (see, e.g., Zhu and Witte, Invest New Drugs 17:195-212, 1999). The early stages of angiogenesis include endothelial cell protease production, migration of cells, and proliferation. The early stages also appear to require some growth factors, with VEGF, TGF- α and selected chemokines all putatively playing a role. Later stages of angiogenesis include population of the vessels with mural cells (pericytes or smooth muscle cells), basement membrane production, and the induction of vessel bed specializations. The final stages of vessel formation include what is known as remodelling wherein a forming vasculature becomes a stable, mature vessel bed. Thus, the process is highly dynamic, often requiring coordinated spatial and temporal waves of gene expression.

The complex angiogenesis process is subject to disruption through interference with one or more critical steps, and numerous disease states can result from or be exacerbated by the disruption. Unregulated angiogenesis can cause or worsen disease, for example, ocular neovascularization has been implicated as the most common cause of blindness and underlies the pathology of approximately 20 eye diseases. In certain previously existing conditions such as arthritis, newly formed capillary blood vessels invade the joints and destroy cartilage. In diabetes, new capillaries formed in the retina invade the vitreous humour, causing bleeding and blindness.

In addition to pathologies linked to unregulated angiogenesis, insufficient angiogenesis can also lead to undesirable results. Dead or damaged tissue can lead to numerous pathologies, revascularization of damaged tissues through a healthy, normal angiogenic process is essential to preventing further complications.

Therefore, new targets and treatments that inhibit or enhance angiogenesis are needed. Identification of more key factors involved in any stage of angiogenesis could lead to new diagnostic methods for pathologic conditions related to angiogenesis. Further, elucidation and understanding of the key factors involved in angiogenesis could form the basis for new methods to investigate potential therapies for angiogenesis-related conditions.

Brief Summary of the Invention

In accordance with the objects outlined above, the present invention discloses eleven nucleic acid sequences and associated proteins which have key roles in vasculogenesis and/or angiogenesis. One object of the present invention is to present approaches for using the eleven novel factors as molecular targets for therapeutic intervention in angiogenesis-related disease states. It is a further object of the present invention to provide materials and methods that can be used to screen compounds for the ability to modulate angiogenesis or angiogenesis-related conditions.

Therapeutics specifically targeting the sequences and proteins identified herein are also provided as agents or compositions which modulate vasculogenesis or angiogenesis.

According to one embodiment of the invention, an isolated nucleic acid molecule according to any one of SEQ ID NO:s 2, 4, 7, 9, 12, 14, 17, 19, 21, 24, 26, 29, 31, 34, 36, 39, 41, 44, 46, 49, 51, 54, and 56 or a fragment or analogue thereof is provided which has the ability to stimulate or inhibit at least one biological activity selected from the group consisting of vasculogenesis, angiogenesis, vascular permeability, endothelial cell proliferation, endothelial cell differentiation, endothelial cell migration, and endothelial cell survival, or an isolated nucleic acid molecule which hybridizes to one of the foregoing sequences under stringent conditions. The invention is also directed to isolated nucleic acid molecules which hybridizes to a complement of a nucleic acid molecule described above, and an isolated siRNA molecule of at least 19 base pairs targeted to an isolated nucleic acid molecule described above.

According to a further embodiment of the invention, an expression vector comprising one of the novel nucleic acids is provided. The nucleic acid may be operatively associated with a regulatory nucleic acid controlling the expression of the polypeptide encoded by the nucleic acid.

The invention further comprises host cells genetically engineered to contain a nucleic acid as described above, or transfected by an expression vector described above.

According to a further embodiment of the invention, a method of treating an angiogenesis-related condition in a cell, group of cells, or organism is provided, comprising administering an expression vector as described above to the cell, group of cells, or organism.

The invention further comprises antibodies with specific reactivity to the nucleic acid molecules described above. The antibodies may be polyclonal or monoclonal and may further comprise detectable labels, such as fluorescent labels.

According to a further embodiment of the invention, a transgenic, non-human animal is provided which has been genetically engineered to contain a transgene comprising a nucleic acid as described above, and animals which contain and express the transgene.

According to a further embodiment of the invention, a pharmaceutical composition is provided which comprises a nucleic acid sequence as described above. The compound may be administered to a cell, group of cells, or organism to affect vasculogenesis or angiogenesis. The effect may be to increase or decrease vasculogenesis or angiogenesis, and the method may be employed where the cells, group of cells, or organism has an angiogenesis-related disorder. Such angiogenesis-related disorders include cancer, retinopathy, macular degeneration, corneal ulceration, stroke, ischemic heart disease, infertility, ulcers, sclerodoma, wound healing, ischemia, ischemic heart disease, myocardial infarction, myocarditis, angina pectoris, unstable angina, coronary arteriosclerosis, arteriosclerosis obliterans, Berger's disease, arterial embolism, arterial thrombosis, cerebrovascular occlusion, cerebral infarction, cerebral thrombosis, cerebral embolism, rubeosis proliferative vitreoretinopathy, chronic inflammation, inflammatory bowel disease, psoriasis, sarcoidosis, and rheumatoid arthritis.

According to a further embodiment of the present invention, an isolated polypeptide comprising a sequence of amino acids substantially corresponding to the amino acid sequence in any one of SEQ ID NO:s 3, 5, 8, 10, 13, 15, 18, 20, 22, 25, 27, 30, 32, 35, 37, 40, 42, 45, 47, 50, 52, 55, and 57 or a fragment or analogue thereof is provided which has the ability to affect angiogenesis in a cell, a group of cells, or an organism.

The invention further comprises host cells genetically engineered to express a polypeptide as described above, as well as antibodies specifically reactive with the polypeptides. The antibody may be polyclonal or monoclonal, and may further comprise a detectable label such as fluorescence.

According to a further embodiment of the invention, a transgenic, non-human animal is provided which has been genetically engineered to contain a transgene comprising a nucleic acid which encodes a polypeptide as described above, and animals that contain and express the transgene.

The invention further provides pharmaceutical compositions comprising an isolated polypeptide as described above. The pharmaceutical composition may be administered to a cell, group of cells, or organism in order to affect vasculogenesis or angiogenesis therein. Vasculogenesis or angiogenesis may be increased or decreased. The cell, group of cells, or organism may have an angiogenesis-related disorder. Representative angiogenesis-related disorders are noted above.

According to a further embodiment of the invention, a method of detecting an angiogenesis-related transcript in a cell in a patient is provided, the method

comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence according to any one of SEQ ID NO:s 2, 4, 7, 9, 12, 14, 17, 19, 21, 24, 26, 29, 31, 34, 36, 39, 41, 44, 46, 49, 51, 54, and 56, wherein an angiogenesis-related transcript is detected where hybridization is detected. The polynucleotide may comprise a sequence according to any one of SEQ ID NO:s 2, 4, 7, 9, 12, 14, 17, 19, 21, 24, 26, 29, 31, 34, 36, 39, 41, 44, 46, 49, 51, 54, and 56. The biological sample may be a tissue sample, or sample of isolated nucleic acids such as mRNA. According to this method, the nucleic acids may be amplified prior to contacting the biological sample with the polynucleotide. Further, the polynucleotide is immobilized on a solid surface.

According to a further embodiment of the present invention, a method of affecting at least one bioactivity selected from angiogenesis and vasculogenesis in a vertebrate organism is provided, where method comprises the step of administering an effective angiogenesis or vasculogenesis affecting amount of a nucleotide or polypeptide described herein to the organism. The organism may be mammal, such as mice, rats, rabbits, guinea pigs, cats, dogs, pigs, cows, monkeys, and humans. Vasculogenesis or angiogenesis may be enhanced, increased, inhibited, or decreased. This method may be used on organisms that have an angiogenesis-related disorder, such as those disorders described above.

According to a further embodiment of the invention, a transgenic increased angiogenesis laboratory animal is provided which comprises one or more cells in which the expression of a sequence according to any one of SEQ ID NO:s 2, 4, 7, 9, 12, 14, 17, 19, 21, 24, 26, 29, 31, 34, 36, 39, 41, 44, 46, 49, 51, 54, and 56 is upregulated. Transgenic decreased angiogenesis laboratory animals are also provided, which comprise one or more cells in which the expression of a sequence according to any one of SEQ ID NO:s 2, 4, 7, 9, 12, 14, 17, 19, 21, 24, 26, 29, 31, 34, 36, 39, 41, 44, 46, 49, 51, 54, and 56 is down regulated or absent.

The terms "angiogenesis-related condition" or "angiogenesis-related disease (state)" as used herein mean a condition which is marked by either an excess or a deficit of vessel development or which is improved by an increase or decrease in vessel development. Disorders associated with increased angiogenesis include, but are not limited to, cancer (including solid tumors, leukemias, and tumor metastases), benign tumors (including hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas), retinopathy, macular degeneration, and corneal ulceration. Pathological states linked to decreased angiogenesis or states which can improve with increased angiogenesis include, but are not limited to, ischemic heart disease, infertility, ulcers, sclerodoma, (insufficient) wound healing, ischemia, myocardial infarction, myocardosis, angina pectoris, unstable angina, coronary arteriosclerosis, arteriosclerosis obliterans (ASO), Berger's disease, arterial embolism, arterial thrombosis, cerebrovascular occlusion, cerebral infarction, cerebral thrombosis, cerebral embolism, and stroke. Other angiogenesis related diseases include, but are not limited to, diseases associated with rubeosis (neovascularization of the angle) and diseases caused by the abnormal proliferation of fibrovascular or fibrous tissue including all forms of proliferative vitreoretinopathy, whether or not associated with diabetes, diseases with symptoms of chronic inflammation, such as inflammatory bowel disease, psoriasis, sarcoidosis and rheumatoid arthritis.

A "host cell" is a naturally occurring cell or a transformed cell that contains an expression vector and supports the replication or expression of the expression vector. Host cells may be cultured cells, explants, cells in vivo, and the like. Host cells may be prokaryotic cells such as *E. coli*, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells such as CHO, HeLa, and the like (see, e.g., the American Type Culture Collection catalog or web site, www.atcc.org).

The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.

The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, gamma-carboxyglutamate, and O-phosphoserine. "Amino acid analogs" refers to compounds that have the same basic chemical structure as a naturally occurring amino acid. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid. Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

The term "conservative modifications" or "conservatively modified variants" as used herein applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence with respect to the expression product, but not with respect to actual probe sequences.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.

As used herein, "label" or "detectable moiety" refers to a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. Examples of such labels include ^{32}P , fluorescent dyes, electron-dense reagents, enzymes, biotin, digoxigenin, or haptens and proteins which can be made detectable, e.g., by incorporating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide.

As used herein, "vector" or "expression vector" refers to a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.

The phrase "stringent hybridization conditions" as used herein refers to conditions under which sequences will hybridize. Stringent conditions are sequence-dependent and will be different in different circumstances. Skilled workers have access to significant amounts of descriptive material detailing reaction conditions that are appropriate for a given sequence. One example is Innis et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. N.Y.).

As used herein, the terms "inhibitors," "activators," and "modulators" of angiogenic polynucleotide and polypeptide sequences and angiogenic activity refer to inhibitory, activating, or modulating molecules. "Inhibitors" are compounds that, e.g., bind to, partially or totally block activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of angiogenesis proteins, e.g., antagonists. "Activators" are compounds that increase, open, activate, facilitate, enhance activation, sensitize, agonize, or up regulate angiogenesis protein activity. Inhibitors, activators, or modulators include genetically modified versions of angiogenesis proteins, e.g., versions with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, antibodies, small chemical molecules and the like. Assays for inhibitors and activators include, e.g., expressing the angiogenic protein in vitro, in cells, or cell membranes, applying putative modulator compounds, and then determining the functional effects on activity, as described above.

Brief Description of the Figures

Figure 1 shows a ratio-ratio plot with the \log_2 expression ratio of genes in a cDNA library when compared to embryonic brain endothelial cell portion versus embryonic

brain left over portion and adult brain endothelial cell portion versus adult brain left over portion;

Figure 2 shows a ratio-intensity plot with average intensity versus \log_2 expression ratio of genes in a cDNA library when compared to embryonic brain, heart, and skin endothelial cell versus left over embryonic portions and all adult endothelial cells and left over portions;

Figure 3 schematically depicts microarray data for gene HUP8001J6;

Figure 4 shows a wild type zebrafish embryo at 28 hpf;

Figure 5 shows a HUP8001J6 morphant embryo at 28 hpf;

Figure 6 shows a wild type zebrafish embryo at 56 hpf;

Figure 7 shows a HUP8001J6 morphant embryo at 56 hpf;

Figure 8 shows a wild type zebrafish at 48-56 hpf;

Figure 9 shows a HUP8001J6 morphant embryo at 48-56 hpf;

Figure 10 schematically depicts microarray data for gene HUP8001K17;

Figure 11 shows a HUP8001K17 morphant embryo at 28 hpf;

Figure 12 shows a HUP8001K17 morphant embryo at 56 hpf;

Figure 13 shows a HUP8001K17 morphant embryo at 48-56 hpf;

Figure 14 schematically depicts microarray data for gene HUP8001K21;

Figure 15 shows a HUP8001K21 morphant embryo at 28 hpf;

Figure 16 shows a HUP8001K21 morphant embryo at 56 hpf;

Figure 17 shows a HUP8001K21 morphant embryo at 48-56 hpf;

Figure 18 schematically depicts microarray data for gene HUP8003D24;

Figure 19 shows a HUP8003D24 morphant embryo at 48-56 hpf;

Figure 20 schematically depicts microarray data for gene HUP8004N1;

Figure 21 shows a HUP8004N1 morphant embryo at 28 hpf;

Figure 22 shows a HUP8004N1 morphant embryo at 56 hpf;

Figure 23 shows a HUP8004N1 morphant embryo at 48-56 hpf;

Figure 24 schematically depicts microarray data for gene HUP8010A10;

Figure 25 shows a HUP8010A10 morphant embryo at 28 hpf;

Figure 26 shows a HUP8010A10 morphant embryo at 56 hpf;

Figure 27 shows a HUP8010A10 morphant embryo at 48-56 hpf;

Figure 28 schematically depicts microarray data for gene NOC8003L17;

Figure 29 shows a NOC8003L17 morphant embryo at 28 hpf;

Figure 30 shows a NOC8003L17 morphant embryo at 56 hpf;

Figure 31 shows a NOC8003L17 morphant embryo at 48-56 hpf;

Figure 32 schematically depicts microarray data for gene NOC8009C9;

Figure 33 shows a NOC8009C9 morphant embryo at 28 hpf;

Figure 34 shows a NOC8009C9 morphant embryo at 56 hpf;

Figure 35 shows a NOC8009C9 morphant embryo at 48-56 hpf;

Figure 36 schematically depicts microarray data for gene NOC8009G23;

Figure 37 shows a NOC8009G23 morphant embryo at 28 hpf;

Figure 38 shows a NOC8009G23 morphant embryo at 56 hpf;

Figure 39 shows a NOC8009G23 morphant embryo at 48-56 hpf;

Figure 40 schematically depicts microarray data for gene OJC8003C9;

Figure 41 shows a OJC8003C9 morphant embryo at 28 hpf;

Figure 42 shows a OJC8003C9 morphant embryo at 56 hpf;

Figure 43 shows a OJC8003C9 morphant embryo at 48-56 hpf;

Figure 44 schematically depicts microarray data for gene OJC8009J7;

Figure 45 shows a OJC8009J7 morphant embryo at 28 hpf;

Figure 46 shows a OJC8009J7 morphant embryo at 56 hpf; and

Figure 47 shows a OJC8009J7 morphant embryo at 48-56 hpf.

Detailed Description

While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention. Materials, the synthesis of which are not specifically described, are either commercially available or can be prepared using methods well known to those of skill in the art. Except as otherwise noted, all amounts including quantities, percentages, portions, and proportions, are understood to be modified by the word "about", and amounts are not intended to indicate significant digits. Except as otherwise noted, the articles "a", "an", and "the" mean "one or more". All documents cited are, in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention.

Identification of Candidate Genes

A cDNA Library was prepared by collecting the mRNA from purely isolated adult and embryonic mice vascular fragments. The collected mRNA was used to develop cDNA libraries with a broad coverage of genes expressed in the vasculature. Because of the variety in mouse age, the vascular genes represented those active at different times and in different situations in the vasculature.

After creation of the cDNA library, microarrays were created by printing DNA from the cDNA library onto a solid support as known in the art. The microarrays were used to reveal the gene candidates through gene expression profiling. Select tissues from adult and E 18.5 embryonic mice were collected. Tissue selection was based on the amount and purity of RNA available for extraction. After tissues were removed, they were separated into two portions using antibodies or lectins. The first portion, the endothelial cell fraction or EC, contained endothelial cells as well as pericytes and vascular smooth muscle cells which are tightly associated with the vascular fragments. The second portion, also referred to as the left over portion or LO, were those cells remaining after the EC was isolated.

From adult mice, brain and heart tissues were used, both the EC and LO of each. From embryonic mice, brain, heart, and skin, both EC and LO of each, were utilized. The RNA from each fraction was extracted. A common reference RNA (Universal Mouse Reference RNA; Stratagene, Inc.) was employed at this stage for reference purposes. The isolated RNA and the reference RNA were reverse transcribed then amplified twice through two rounds of antisense RNA amplification. The isolated RNA was labelled with the fluorophore cyanine-3 and the reference RNA with cyanine-5.

After labelling, the RNA was assayed through hybridization with the microarrays described above. The hybridized microarrays were scanned and image analysis used to process the experimental data. Normalizing the data through a signal intensity-based normalization algorithm allowed for statistical evaluation of differentially

expressed genes. Genes exhibiting differential expression were selected for further analysis.

Selection of Genes with Differential Expression

Using data collected as described above, certain genes were designated as selectively expressed in blood vessels. This was based on comparisons between adult and embryonic EC and LO values. Figure 1 shows a ratio-ratio plot of the data values obtained through comparisons between embryonic brain EC and LO genes and between adult brain EC and LO genes. A comparison of total adult EC with total embryonic EC was also conducted, data not shown. Data points represented with 'DT1 candidates' or 'DT2 candidates' were generally upregulated ($>0 \log_2$ expression ratio).

Other genes were designated as selectively expressed during angiogenesis through a different comparison of data. The total embryonic EC portion (i.e., brain, heart, and skin EC portions) was compared to all remaining tissues, including the total embryonic LO portion and all adult RNA (EC and LO of both brain and heart). Figure 2 shows a ratio-intensity plot with the average intensity versus \log_2 expression ratio of all genes. The data points marked DT3 candidates and DT4 candidates are those genes shown to be up regulated through this selective analysis. A comparison was also undertaken to analyze all EC portions versus all LO portions, data not shown.

A total of eleven genes of interest were selected for further analysis. Specific expression data for each gene follows throughout and includes a graph showing that gene's expression profile. Tables are used to show the intensity of the microarray signal, the \log_2 expression ratio, p-value, and rank (rank given only for certain fields). The highest rank was awarded to the gene with the highest expression ratio value, the lowest rank was assigned to the gene with the lowest expression value, based on expression ratio values. P-values are given as a value from zero to one. Values close to one indicate a gene that is upregulated, whereas values close to zero indicate a statistically down regulated gene. A statistically significant p-value of 0.05 corresponds to a p-value of 0.05 or 0.95.

For graphs, tables, and text the abbreviation eec/r refers to embryonic EC portions versus all remaining portions, ec/lo refers to all EC portions versus all LO portions, abeclo refers to adult brain EC portion versus adult brain LO portion, abecebec refers to adult brain EC portion versus embryonic brain EC portion, aheclo refers to adult heart EC portion versus adult heart LO portion, ebeclo refers to embryonic brain EC portion versus embryonic brain LO portion, eheclo refers to embryonic heart EC portion versus embryonic heart LO portion, and eseclo refers to embryonic skin EC portion versus embryonic skin LO portion..

Evaluation of Selected Genes

Further analysis of selected genes was conducted through knockdown technology in zebrafish. The process involves the use of specific antisense oligonucleotides that block translation from targeted mRNA molecule(s). This allows for inhibition of the gene of interest and allows for a determination of gene function in the development and health of the zebrafish. Zebrafish share genes for vertebrate functions with mammalian vertebrates such as mice and humans. Studies have demonstrated that

organ and/or tissue development in zebrafish can reliably predict effects in humans (See, *inter alia*, Shin and Fishman, From zebrafish to humans: Modular medical models, Ann. Rev. Genomics and Human Genet. 2002: 3: 311-340; Clark *et al.*, An oligonucleotide fingerprint normalized and expressed sequence tag characterized zebrafish library, Genome Res 2001 Sep;11(9):1594-602. Because of their rapid external development, zebrafish embryo development can be easily monitored and analyzed. The presence of a yolk sac helps provide data from the development of a critically deficient embryo further than that possible with other research organisms, such as mice.

To prepare the embryos, the zebrafish homolog of the target gene was identified. Then, a specific morpholino phosphorodiamidate oligonucleotide was designed to match the AUG initiation codon or splice acceptor/donor site of the target gene. To create a stock solution of morpholino, pellets containing 100 nmoles of the phosphorodiamidate oligonucleotides were dissolved in 33.3 µl milli-Q water, giving a concentration of 25 mg/ml, and stored at -20°C. To create injection solution, 8 µl of the stock solution was added to 92 µl of sterile-filtered 1X Danieau buffer (58 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO₄, 0.6 mM Ca(NO₃)₂, 5 mM HEPES, pH 7.6) supplemented with 15mM Tris-Cl, pH 8.0. The 2 mg/ml injection solution was also stored at -20°C.

During injection, the materials and embryos were maintained at approximately 28°C. Injection needles were calibrated so that injection times could optimally be within a range of 100-600 msec. Embryos from the one cell stage to the early eight cell stage were used. The morpholinos were microinjected into the yolk sac. Specific injection volumes, or effective dose of the morpholino, are described below. Typical initial doses included 3, 6, and 12 ng (1.5, 3, and 6 nl, respectively). Toxicity at the 3 nl dose resulted in subsequent doses of 0.5, 1, and 2 ng (1, 2, and 4 nl, respectively). Approximately 40 embryos were injected at each dose level, and approximately 40 embryos were retained as non-injected controls.

After the morpholinos were injected into fertilized egg cells, the embryos engineered to have a knockdown of the specific gene were allowed to develop (See Nasevicius and Ekker, Effective targeted gene 'knockdown' in zebrafish, Nature Genetics vol 26, October 2000.). The embryos were monitored throughout development, both by examining morphology and undertaking specific analysis and assays of developing tissues.

In addition to single morpholino injections, double morpholino injections were performed as well. Specific injection volumes for double injections are described below. At the end of the first post-injection day, with embryos at the blastula or gastrula stage, propyl thioracil (PTU) 2x solution was added to the embryos, doubling their suspension volume. 48 hours post fertilization (hpf) the double injected embryos were fixed with cadherin 5 (cdh5) for *in situ* hybridization.

When 20% or more of the double injected embryos displayed low effect defects in the vasculature observed with cdh5, or when 10% or more of the embryos displayed medium or high effect defects, then microangiopathy and *in situ* hybridization with fli-1, flk-1, flt-4, tie-1, tie-2, and cdh5 were conducted. At least 120 embryos were administered the double morpholino dose, of which at least 100 were harvested at 24

hpf for *in situ* hybridization with the above-noted molecular markers. Remaining embryos were used for microangiopathy.

Data specific to the evaluation of each of the eleven targets are described below. In general, the morphology observations conducted at 24-28 hpf included an indication of whether the embryos exhibited general delay relative to control embryos. Further, cell death type and degree were recorded, general embryo shape and brain morphology were recorded as well. Finally, yolk sac edema, if present, was evaluated and recorded, as was heart morphology.

Also, at approximately 24 hpf, double morpholino embryos were evaluated for *in situ* hybridization of *fli-1*, *flk-1*, *flt-4*, *tie-1*, *tie-2*, and *cdh5*. Overall morphology and the degree of reduction of staining in the intersegmental vessels as compared to control embryos, correlating to a percentage of lost expression, were noted. Those embryos showing a loss of 1-35% of intersegmental expression were considered to have a low effect, those embryos showing a loss of 36-70% of intersegmental expression were considered to have a medium effect, and those embryos showing a loss of 71-100% of intersegmental expression were considered to have a high effect.

At 48-56 hpf various parameters were reviewed and recorded, such as general embryo shape, degree of cell death, blood circulation, and heart morphology. For the embryos fixed with *cdh5*, staining was evaluated throughout the vasculature as described immediately above.

Microangiopathy was also evaluated at 48hpf in double morpholino embryos. In order to observe the blood vessels, the embryos were transferred into a tricaine solution and the sinus venosa/common cardinal vein was injected with 10 µl FITC-Dextran solution (2,000,000 Da, 20 mg/ml).

Gene HUP8001J6

The gene having the sequence shown in SEQ ID NO:1 was identified as selectively expressed during angiogenesis based on microarray data, see Figure 3. Specific data are given below in Table 1. Using sequence and annotation databases the equivalent gene in mice (SEQ ID NO:2) and the human homolog (SEQ ID NO:4) was also deduced. Proteins encoded by these sequences are given at SEQ ID NO:s 3 and 5, respectively.

	intensity	log2 exp ratio	p-value	rank
ec/r	8,2	0,88		600
ec/lo	8,1	0,80		449
abeclo	7,6	0,60	1,00	
abecbec	8,3	0,27	0,76	
ahaclo	7,3	1,17	1,00	
ebeclo	9,1	-0,29	0,23	
ehaclo	8,1	1,21	1,00	
eseclo	8,1	-0,13	0,25	

Table 1: Expression profile data for gene HUP8001J6.

Based on this expression profile, the gene was further analyzed in zebrafish embryos. Two corresponding zebrafish genes were identified for targeting. Two morpholinos were prepared, sz265 and

sz266, each targeted to one of the zebrafish genes. Six (6) ng of sz265 morpholino and 2 ng of sz266 morpholino were administered to each fertilized egg. The embryos were allowed to develop. At 24 hpf a secondary *in situ* hybridization screen with six different probes was conducted.

Intersegmental expression was analyzed in the assay and results differed somewhat based on the probe used. The probe *fli-1* revealed that 13% of the 16 morphant embryos assayed had high effects, that is, loss of 71-100% of intersegmental expression. The probe *flk-1*, VEGF receptor 2, indicated that 7% of the 15 morphants reviewed had high effects. When analyzed through the probe *tie-1*, all 15 morphants observed were normal. The probe *cdh5*, VE cadherin, indicated that all 23 morphants observed were normal. The probe *flt-4*, VEGF receptor 3, indicated that all 15 morphants observed were normal. And the probe *tie-2* showed all 15 observed morphants as normal.

The following table, Table 2, summarizes this data.

Probe	Number analyzed	Results
<i>fli-1</i>	16	13%H
<i>flk-1</i>	15	7%H
<i>tie-1</i>	15	normal
<i>cdh5</i>	23	normal
<i>flt-4</i>	15	normal
<i>tie-2</i>	15	normal

Table 2: secondary *in situ* hybridization data

At 28 hpf embryos were observed morphologically. Both the wild type embryos, used as control, and the morphant embryos observed showed normal morphology. Figures 4 and 5 show the wild type and morphant embryos at 28 hpf, respectively. At 56 hpf the embryos were again observed, a wild type embryo is shown in Figure 6 and a morphant embryo in Figure 7. As highlighted by an arrow in the representative embryo of Figure 7, 82% of the 56 morphant embryos showed severe yolk sac edema. Further, 70% showed severely reduced blood flow and 14% showed reduced intersegmental blood flow.

Additional analyses were conducted on 48-56 hpf morphant embryos. A primary *in situ* hybridization screen with *cdh5* on 22 morphants revealed that 18% had reduced intersegmental expression, at a low effect level, whereas the remaining 82% were normal. Microangiography on 22 morphants was used to locate the presence of FITC-Dextran in various regions of the embryo. No FITC-Dextran was observed in the heart, head, nor was there any leaky vasculature. 14% of the morphants showed high effects of reduced intersegmental vasculature, and another 14% showed low effects of the same. Thus, 28% were affected by some changes to the intersegmental vasculature and 72% appeared normal. A wild type embryo at this time stage is shown in Figure 8, whereas Figure 9 shows a representative of the 48-56 hpf embryos analyzed. The arrow points to an area of reduced intersegmental vasculature.

Gene HUP8001K17

The gene having the sequence shown in SEQ ID NO:6 was identified as selectively expressed in blood vessels based on microarray data, see Figure 10. Specific data are given below in Table 3. Using sequence and annotation databases the equivalent gene in mice (SEQ ID NO:7) and the human homolog (SEQ ID NO:9) was also deduced. Proteins encoded by these sequences are given at SEQ ID NO:s 8 and 10, respectively.

	Intensity	log2 exp ratio	p-value	rank
ecct	7,8	-0,11		6732
ecfb	7,8	0,59		804
abeclo	7,9	3,52	1,00	
abecobec	8,4	2,10	1,00	
ahedlo	7,5	-1,05	0,00	
ehedlo	8,8	2,15	1,00	
ehedlo	7,5	-0,07	0,42	
Ehedlo	7,5	-0,56	0,01	

Table 3: Expression profile data for gene HUP8001K17.

Based on this expression profile, the gene was further analyzed in zebrafish embryos. One corresponding zebrafish gene was identified for targeting. Two different morpholinos were prepared, sz143 and sz144, each targeted to the

zebrafish gene. Different amounts of morpholinos were administered as described below. The predetermined amount of each morpholino was administered to each fertilized egg. The embryos were allowed to develop. At 24 hpf secondary *in situ* hybridization screens with six different probes were conducted.

One screen was performed on embryos that received 1 ng of sz143 morpholino and 4 ng of sz144 morpholino. Four probes specifically selected to analyze axial and intersegmental vessel expression revealed the following: using the *fli-1* probe, 6% of the 17 embryos analyzed had medium intersegmental expression effects. Another 18% had high effects. The probe *flk-1*, VEGF receptor 2, indicated that 20% of the 15 morphants reviewed had medium and 13% had high effects. When analyzed through the probe *tie-1*, 63% of the 16 morphants observed had high effects. The probe *cdh5*, VE cadherin, indicated that 4% of the 24 morphants observed had medium effects, and another 4% had high effects. The probe *flt-4*, VEGF receptor 3, indicated that all 14 morphants observed were normal, and the probe *tie-2* showed all 18 observed morphants as normal.

The other screen was performed on embryos that received 1.5 ng of sz143 morpholino and 6 ng of sz144 morpholino. The probe *fli-1* indicated that 42% of the 12 morphants analyzed had high effects. The *flk-1* probe demonstrated that 23% of the 13 morphants observed had high effects. The *tie-1* probe revealed 54% of 13 morphants had high effects. The probe *cdh5* indicated that 15% of 27 morphants had medium effects and another 11% had high effects. The probe *flt-4* indicated that all 14 morphants observed were normal. And the probe *tie-2*, showed all 18 observed morphants as normal.

The following Table 4 summarizes the foregoing data.

	Morphants with 1 ng sz143, 4 ng sz144		Morphants with 1.5 ng sz143, 6 ng sz144	
Probe	Number analyzed	Results	Number analyzed	Results
<i>fli-1</i>	17	6%M, 18%H	12	42%H
<i>flk-1</i>	15	20%M, 13%H	13	23%H
<i>tie-1</i>	16	63%H	13	54%H
<i>cdh5</i>	24	4%M, 4%H	27	15%M, 11%H
<i>flt-4</i>	13	normal	14	normal
<i>tie-2</i>	19	normal	18	normal

Table 4: secondary *in situ* hybridization data

At 28 hpf embryos were observed morphologically. The wild type embryos, used as control, showed normal morphology as expected. As indicated previously, Figure 4 shows a wild type embryo at 28 hpf. The morphant embryos received a 1.5 ng dose of sz143 and a 6 ng dose of sz144, all did not exhibit normal morphology. A representative embryo is shown in Figure 11. Twenty embryos were observed, 50% of them showed a curly down body, indicated by the arrowhead in Figure 11, with yolk tube extension, indicated with a short arrow. Mild cell death was observed in 60% of the embryos, as shown by the long arrow in Figure 11. Finally, 50% of the embryos had yolk cell edema.

At 56 hpf embryos were again observed, for reference a wild type embryo is shown in Figure 6. A morphant at the corresponding stage is shown in Figure 12. Twenty (20) embryos were observed, 90% had a curly down body as shown by the long arrow in Figure 12, with reduced head as indicated by the short arrow. Pericardial edema, shown by the arrowhead, was observed in 90% of the embryos and reduced blood flow was also seen in 90% of the embryos.

Additional analyses were conducted on 48-56 hpf morphant embryos. A primary *in situ* hybridization screen with *cdh5* on 18 morphants which had received 1 ng sz143 and 3 ng sz144 revealed that 28% had reduced intersegmental expression, at a low effect level, with short and curly tails. The remaining 72% were normal. The same *in situ* hybridization screen was conducted using 11 morphants which had received 2 ng sz143 and 6 ng sz144. This revealed that 9% had reduced intersegmental expression, at a low effect level, with very short tails. The remaining 91% were normal.

Microangiography on 26 morphants which had received 1.5 ng of sz143 and 6 ng of sz144 was used to locate the presence of FITC-Dextran in various regions of the embryo. No FITC-Dextran was observed in the heart, but 31% of the embryos had FITC-Dextran in the head and heart. A total of 27% of the morphants had reduced intersegmental vasculature, and leaky vasculature was observed in 35% of the embryos. Only 42% of the embryos appeared normal. The combined percentages are greater than 100% since some embryos exhibited more than one non-normal feature. Figure 13 shows a representative of the 48-56 hpf embryos analyzed. The arrow points to an area of reduced intersegmental vasculature, and the arrowhead indicates a point of leaky vasculature. For reference, a wild type embryo at this time stage is shown in Figure 8. The experimental data reveal that the gene is expressed by scattered cells in many organs, but most clearly seen in the CNS.

Gene HUP8001K21

The gene having the sequence shown in SEQ ID NO:11 was identified as selectively expressed during angiogenesis based on microarray data, see Figure 14. Specific data are given below in Table 5. Using sequence and annotation databases the equivalent gene in mice (SEQ ID NO:12) and the human homolog (SEQ ID NO:14) was also deduced. Proteins encoded by these sequences are given at SEQ ID NO:s 13 and 15, respectively.

	intensity	log2 exp ratio	p-value	rank
ecdr	8,5	0,88		594
ec/lo	8,4	0,80		442
abeclo	8,5	0,71	1,00	
abecbec	8,8	-0,02	0,48	
ahedlo	8,0	1,15	1,00	
ebeclo	9,5	-0,03	0,47	
ehedlo	8,3	0,72	0,98	
eseclo	8,3	0,49	0,99	

Table 5: Expression profile data for gene HUP8001K21.

Based on this expression profile, the gene was further analyzed in zebrafish embryos. Two corresponding zebrafish genes were identified for targeting. Two morpholinos were prepared, sz257 and sz258, each targeted to one of the

zebrafish genes. Twelve (12) ng of sz257 morpholino and 12 ng of sz258 morpholino were administered to each fertilized egg. The embryos were allowed to develop. At 24 hpf a secondary *in situ* hybridization screen with six different probes was conducted.

Intersegmental expression was analyzed in the assay and results differed somewhat based on the probe used. The probe *fli-1* revealed that all of the 15 morphant embryos assayed were normal. The probe *flk-1* indicated that 13% of the 16 morphants reviewed had low effects and 6% had high effects. When analyzed through the probe *tie-1*, all 15 morphants observed were normal. The probe *cdh5* indicated that all 26 morphants observed were normal. The probe *flt-4* indicated that all 17 morphants observed were normal, the probe *tie-2* showed all 20 observed morphants as normal.

The following table, Table 6, summarizes this data.

Probe	Number analyzed	Results
<i>fli-1</i>	15	normal
<i>flk-1</i>	16	13%L, 6%H
<i>tie-1</i>	15	normal
<i>cdh5</i>	26	normal
<i>flt-4</i>	17	normal
<i>tie-2</i>	20	normal

Table 6: secondary *in situ* hybridization data

At 28 hpf embryos were observed morphologically. Figure 15 shows a representative morphant embryo at 28 hpf. As indicated by the arrow, yolk sac edema was observed in 47% of the 55 morphants analyzed. At 56 hpf a total of 53 embryos were observed, a representative morphant embryo is shown in Figure 16. As highlighted by the long arrow, expanded hindbrain was found in 34% of embryos. Yolk sac edema, shown by a short arrow, was also observed in 58% of embryos. An arrowhead points out the location checked for pericardial edema; it was not observed.

Additional analyses were conducted on 48-56 hpf morphant embryos. A primary *in situ* hybridization screen with *cdh5* on 20 morphants showed all as normal. Microangiography on 31 morphants was used to locate the presence of FITC-Dextran in various regions of the embryo, see Figure 17. Of the 31 embryos, 19% had FITC-Dextran in the heart but none had it in the heart and the head. Reduced intersegmental vasculature was seen as indicated by the arrow in Figure 17. High effects were observed in 19% of the embryos, medium effects in 13% and low

effects in 29%. No leaky vasculature was observed. Normal embryos accounted for 19% of the sample.

HUP8003D24

The gene having the sequence shown in SEQ ID NO:16 was identified as selectively expressed during angiogenesis based on microarray data, see Figure 18. Specific data are given below in Table 7. Using sequence and annotation databases the equivalent gene in mice (SEQ ID NO:17) and two human homologs (SEQ ID NO:s19 and 21) was also deduced. Proteins encoded by these sequences are given at SEQ ID NO:s 18, 20, and 22, respectively.

	intensity	log2 exp ratio	p-value	rank
ectf	9,1	0,48		2061
eclo	9,0	1,30		149
abeclo	8,1	3,14	1,00	
abecobec	8,7	2,26	1,00	
ahedlo	8,9	0,23	0,85	
ebeclo	9,1	0,51	0,90	
ehedlo	9,5	1,32	1,00	
eseclo	9,0	1,84	1,00	

Table 7: Expression profile data for gene HUP8003D24

Based on this expression profile, the gene was further analyzed in zebrafish embryos. Three corresponding zebrafish genes were identified for targeting. Two morpholinos were prepared, sz185 and sz186, which were

targeted to the three zebrafish genes. For the lower dose group, 3ng of sz185 morpholino and 6ng of sz186 morpholino were administered to each fertilized egg. For the double dose group, 6ng of sz185 morpholino and 12ng of sz186 morpholino were administered. The embryos were allowed to develop. At 24 hpf a secondary *in situ* hybridization screen with six different probes was conducted.

Intersegmental expression was analyzed in the assay and results differed somewhat based on the probe used. In the lower dose group, the probe *fli-1* revealed that 18% of the 11 morphant embryos assayed had medium effects, i.e., 36-70% loss of intersegmental expression, and 18% had high effects. The probe *flk-1* indicated that 36% of the 11 morphants reviewed had high effects. The probe *tie-1* indicated that 29% of the 14 morphants observed had high effects. The probe *cdh5* indicated 31% of the 16 morphants observed had high effects, and 31% had medium effects. The probe *flt-4* indicated that all 16 morphants observed were normal, and the probe *tie-2* indicated that all 15 morphants observed were normal.

In the higher dose group, the probe *fli-1* revealed that 33% of the 3 morphant embryos assayed had low effects and 33% had medium effects. The probe *flk-1* indicated that 100%, or both of the 2 morphants reviewed, had medium effects. The probe *cdh5* indicated 100%, all 7 of the morphants observed had high effects. The probe *flt-4* indicated that all 3 morphants observed were normal, and the probe *tie-2* indicated that all 7 morphants observed were normal.

The following Table 8 summarizes the foregoing data.

	Morphants with 3 ng sz185, 6 ng sz186		Morphants with 6 ng sz185, 12 ng sz186	
Probe	Number analyzed	Results	Number analyzed	Results
<i>fli-1</i>	11	18%M, 36%H	3	33%L, 33%M

<i>flk-1</i>	11	36%H	2	100%M
<i>tie-1</i>	14	29%H	n/a	no data
<i>cdh5</i>	16	31%M, 31%H	7	100%H
<i>flt-4</i>	16	normal	3	normal
<i>tie-2</i>	15	normal	7	normal

Table 8: secondary *in situ* hybridization data

At 28 hpf embryos were observed morphologically. Cell death was observed in 70% of the 66 embryos observed. Yolk sac edema was observed in 29% of the morphants. At 56 hpf a total of 66 embryos were observed for phenotypic characteristics. Yolk sac edema was observed in 42% of embryos, 35% showed reduced IS blood flow and 26% showed reduced blood flow.

Additional analyses were conducted on 48-56 hpf morphant embryos. A primary *in situ* hybridization screen with *cdh5* on 21 morphants receiving the lower doses noted above (3ng sz185, 6ng sz86) showed 52% as normal. Low effects of reduced intersegmental expression were seen in 43% of the embryos, and medium effects in 5%. Embryos receiving the double doses (6ng sz185, 12ng sz186), when viewed at the 48-56 hpf stage revealed 74% of the that the 23 embryos observed were normal. Low effects of reduced intersegmental expression were observed in 22% and medium effects in 4% of the embryos.

Microangiography on morphants given the lower dose of morpholinos (3ng sz185, 6ng sz186) was used to locate the presence of FITC-Dextran in various regions of the embryo, see Figure 19. Of the 33 embryos, none had FITC-Dextran in the heart, or the heart and head. Reduced intersegmental vasculature was seen as indicated by the arrow in Figure 19. High effects were observed in 6% of the embryos, medium effects in 15% and low effects in 36%. No leaky vasculature was observed. Normal embryos accounted for 43% of the sample.

The data reveal that the gene is expressed in many locations, such as vessels and epithelial structures in the kidneys as well as in large vessels, megakaryocytes, in heart valves and in the skin epithelium.

Gene HUP8004N1

The gene having the sequence shown in SEQ ID NO:23 was identified as selectively expressed during angiogenesis based on microarray data, see Figure 20. Specific data are given below in Table 9. Using sequence and annotation databases the equivalent gene in mice (SEQ ID NO:24) and the human homolog (SEQ ID NO:26) was also deduced. Proteins encoded by these sequences are given at SEQ ID NO:s 25 and 27, respectively.

	intensity	log2 exp ratio	p-value	rank
eecl	9,0	1,12		262
eclo	9,0	0,75		516
abeclo	8,0	0,44	0,79	
abecabec	8,6	-0,80	0,03	
ahedlo	9,0	-0,47	0,02	
abeclo	8,8	1,68	1,00	
ahedlo	9,3	1,18	1,00	
eseclo	9,0	1,22	1,00	

Table 9: Expression profile data for gene HUP8004N1

Based on this expression profile, the gene was further analyzed in zebrafish embryos. Two corresponding zebrafish genes were identified for targeting. Two morpholinos were prepared, sz223 and sz224, each targeted to one of the

zebrafish genes. Two dosing strategies were employed. The first dose group received 2ng of sz223 morpholino and 1ng of sz224 morpholino in each fertilized egg. The second dose group received 1ng of sz223 morpholino and 0.5ng of sz224 morpholino in each fertilized egg. The embryos were allowed to develop. At 24 hpf a secondary *in situ* hybridization screen with six different probes was conducted.

Intersegmental expression in embryos from the second dose group (1ng sz223, 0.5ng sz224) was analyzed in the assay and results differed somewhat based on the probe used. The probe *fli-1* revealed that 7% of the 15 morphant embryos assayed had low effects, and 7% had high effects. The probe *flk-1* indicated that 7% of the 14 morphants reviewed had high effects. The probe *tie-1* indicated that 7% of the 14 morphants observed had low effects, and 7% had high effects. The probe *cdh5* indicated that 8% of the 26 morphants observed had medium effects. The probe *flt-4* indicated that all 15 morphants observed were normal, and the probe *tie-2* indicated that all 15 morphants observed were normal.

The following table, Table 10, summarizes this data.

Probe	Number analyzed	Results
<i>fli-1</i>	15	7%L, 7%H
<i>flk-1</i>	14	7%H
<i>tie-1</i>	14	7%L, 7%H
<i>cdh5</i>	26	8%M
<i>flt-4</i>	15	normal
<i>tie-2</i>	15	normal

Table 10: secondary *in situ* hybridization data

At 28 hpf embryos were observed morphologically. Figure 21 shows a representative morphant embryo at 28 hpf. As indicated by the arrow, yolk sac edema was observed in 56% of the 59 morphants studied. At 56 hpf a total of 20 embryos were observed for phenotypic characteristics, a representative morphant embryo is shown in Figure 22. As indicated by the arrow, pericardial edema was observed in 35% of embryos, 65% had a blood pool in the yolk, also indicated by the arrow, and 30% showed reduced IS blood flow.

Additional analyses were conducted on 48-56 hpf morphant embryos from the second dose group. A primary *in situ* hybridization screen with *cdh5* on 22 morphants showed all as normal. Microangiography on 30 second dose group morphants was used to locate the presence of FITC-Dextran in various regions of the embryo, see Figure 23. Of the 30 embryos, 13% had FITC-Dextran in the heart, and 3% in the heart and head. Reduced intersegmental vasculature was seen as indicated

by the arrow in Figure 23. High effects were observed in 7% of the embryos and low effects in 20%. No leaky vasculature was observed. Normal embryos accounted for 57% of the sample.

The data reveal that the gene is expressed in specific endothelium. In kidneys, it is expressed by certain vessels and some other epithelial structures. There is also some expression in the liver.

Gene HUP8010A10

The gene having the sequence shown in SEQ ID NO:28 was identified as selectively expressed during angiogenesis based on microarray data, see Figure 24. Specific data are given below in Table 11. Using sequence and annotation databases the equivalent gene in mice (SEQ ID NO:29) and the human homolog (SEQ ID NO:31) was also deduced. Proteins encoded by these sequences are given at SEQ ID NO:s 30 and 32, respectively.

	intensity	log2 exp ratio	p-value	rank
ecor	8,8	0,98		424
eclo	8,7	0,36		1747
abeclo	8,4	0,26	0,63	
abecoboc	8,2	-2,20	0,00	
shedo	8,4	-0,06	0,38	
ebeclo	8,7	0,72	0,95	
shedo	9,4	0,14	0,67	
esedo	8,9	-0,37	0,03	

Table 11: Expression profile data for gene HUP8010A10

Based on this expression profile, the gene was further analyzed in zebrafish embryos. A corresponding zebrafish genes was identified for targeting. Two morpholinos were prepared, sz267 and sz268, each targeted to one of the

zebrafish genes. In a first dosage group, 4ng of sz267 morpholino and 2ng of sz268 morpholino were administered to each fertilized egg. In a second dosage group, 6ng of sz267 morpholino and 3ng of sz268 morpholino were administered. The embryos were allowed to develop. At 24 hpf a secondary *in situ* hybridization screen with six different probes was conducted.

Intersegmental expression was analyzed in the assay and results differed somewhat based on the probe used. In the first dose group (4ng sz267, 2ng sz268), the probe *fli-1* revealed that 13% of the 15 morphant embryos assayed had high effects. The probe *flk-1* indicated that 33% of the 15 morphants reviewed had low effects and 20% had high effects. The probe *tie-1* indicated that all 17 morphants observed were normal. The probe *cdh5* indicated that 8% of the 25 morphants observed had high effects. The probe *flt-4* indicated that all 13 morphants observed were normal, and the probe *tie-2* indicated that all 16 morphants observed were normal.

In the second dose group (6ng sz267, 3ng sz268), the probe *fli-1* revealed that 25% of the 16 morphant embryos assayed had low effects, and 19% had high effects. The probe *flk-1* indicated that 33% of the 6 morphants reviewed had low effects. The probe *tie-1* indicated that 67% of the 15 morphants observed had high effects. The probe *cdh5* indicated that 21% of the 24 morphants observed had low effects, 13% had medium effects, and 29% had high effects. The probe *flt-4* indicated that all 15 morphants observed were normal, and the probe *tie-2* indicated that all 15 morphants observed were normal.

The following Table 12 summarizes the foregoing data.

	Morphants with 4 ng sz267, 2 ng sz268		Morphants with 6 ng sz267, 3 ng sz268	
Probe	Number analyzed	Results	Number analyzed	Results
<i>fli-1</i>	15	13%H	16	25%L, 19%H
<i>flk-1</i>	15	33%L, 20%H	6	33%L
<i>tie-1</i>	17	normal	15	67%H
<i>cdh5</i>	25	8%H	24	21%L, 13%M, 29%H
<i>flt-4</i>	13	normal	15	normal
<i>tie-2</i>	16	normal	15	normal

Table 12: secondary *in situ* hybridization data

At 28 hpf embryos were observed morphologically. Figure 25 shows a representative morphant embryo at 28 hpf. Cell death in the head was observed in 47% of the 61 embryos observed, as indicated by the arrow in Figure 25. The arrowhead indicates expanded hindbrain, which was seen in 51% of embryos. Mild yolk sac edema was observed in 21% of the morphants. At 56 hpf a total of 59 embryos were observed for phenotypic characteristics, a representative morphant embryo is shown in Figure 26. The arrow indicates expanded hindbrain, which was seen in 44% of embryos. Mild yolk sac edema was observed in 29% of the morphants and is indicated by the arrowhead. Reduced IS blood flow was noted in 14% of the embryos, and reduced blood flow was found in 17% of the embryos.

Additional analyses were conducted on 48-56 hpf morphant embryos from the second dose group. A primary *in situ* hybridization screen with *cdh5* on 19 morphants showed 68% as normal. Low effects of reduced intersegmental expression were seen in 32% of the embryos. Microangiography on morphants was used to locate the presence of FITC-Dextran in various regions of the embryo, see Figure 27. Of the 32 embryos, none had FITC-Dextran in the heart, or the heart and head. Reduced intersegmental vasculature was seen as indicated by the arrow in Figure 27. High effects were observed in 6% of the embryos, medium effects in 3% and low effects in 34%. No leaky vasculature was observed. Normal embryos accounted for 56% of the sample.

Gene NOC8003L17

The gene having the sequence shown in SEQ ID NO:33 was identified as selectively expressed in blood vessels based on microarray data, see Figure 28. Specific data are given below in Table 13. Using sequence and annotation databases the equivalent gene in mice (SEQ ID NO:34) and the human homolog (SEQ ID NO:36) was also deduced. Proteins encoded by these sequences are given at SEQ ID NO:s 35 and 37, respectively.

	intensity	log2 exp ratio	p-value	rank
eccl	7,7	-0,06		6087
eclo	7,6	0,40		1547
abeclo	7,5	1,47	0,97	
abecbec	8,3	0,30	0,77	
ahedo	7,2	-0,04	0,41	
ehedo	8,3	1,87	1,00	
ehedo	7,8	0,60	0,99	
eseclo	7,5	-0,13	0,24	

Table 13: Expression profile data for gene NOC8003L17

Based on this expression profile, the gene was further analyzed in zebrafish embryos. One corresponding zebrafish gene was identified for targeting. Two morpholinos were prepared, sz180 and sz181, each targeted to the zebrafish

gene. In a first dose group, 12ng of sz180 and 1ng of sz181 were administered to each fertilized egg. In a second dose group, 12ng of sz180 and 2ng of sz181 were administered to each fertilized egg. The embryos were allowed to develop. At 24 hpf a secondary *in situ* hybridization screen with six different probes was conducted.

Intersegmental expression in embryos from the first dose group was analyzed in the assay and results differed somewhat based on the probe used. The probe *fli-1* revealed that 40 of the 15 morphant embryos assayed had high effects. The probe *flk-1* indicated that all 7 of the morphants reviewed were normal. The probe *tie-1* indicated that all 15 morphants observed were normal. The probe *cdh5* indicated that 15% of the 20 morphants observed had low effects, as well as 5% with medium effects and 30% with high effects. The probe *flt-4* indicated that all 11 morphants observed were normal, and the probe *tie-2* indicated that all 16 morphants observed were normal.

The following table, Table 14, summarizes this data.

Probe	Number analyzed	Results
<i>fli-1</i>	15	40%H
<i>flk-1</i>	7	normal
<i>tie-1</i>	15	normal
<i>cdh5</i>	20	15%L, 5%M, 30%H
<i>flt-4</i>	11	normal
<i>tie-2</i>	16	normal

Table 14: secondary *in situ* hybridization data

At 28 hpf embryos were observed morphologically. Figure 29 shows a representative morphant embryo. As indicated by the arrow, yolk sac edema was observed in 67% of the 48 morphants studied. Embryos observed at 56 hpf demonstrated normal morphology, a representative embryo is shown in Figure 30.

Additional analyses were conducted on 48-56 hpf morphant embryos. A primary *in situ* hybridization screen with *cdh5* on 14 morphants from the second dose group showed 79% as normal, the remaining 29% showing medium effects of reduced intersegmental expression. Microangiography on 29 first dose group morphants was used to locate the presence of FITC-Dextran in various regions of the embryo, see Figure 31. Of the 29 embryos, none had FITC-Dextran in the heart, 3% had FITC-Dextran in the heart and head. Reduced intersegmental vasculature was seen as indicated by the arrow in Figure 31. High effects were observed in 7% of the embryos, medium effects in 3% and low effects in 38%. No leaky vasculature was observed. Normal embryos accounted for 45% of the sample.

GeneNOC8009C9

The gene having the sequence shown in SEQ ID NO:38 was identified as selectively expressed during angiogenesis based on microarray data, see Figure 32. Specific data are given below in Table 15. Using sequence and annotation databases the equivalent gene in mice (SEQ ID NO:39) and the human homolog (SEQ ID NO:41) was also deduced. Proteins encoded by these sequences are given at SEQ ID NO:s 40 and 42, respectively.

	intensity	log2 exp ratio	p-value	rank
eccl	8,1	0,84		685
eclo	8,0	1,19		184
abeclo	7,4	1,57	1,00	
abecobec	8,1	1,44	1,00	
ahedlo	8,4	0,12	0,74	
ebeclo	8,0	1,52	1,00	
ehedlo	8,3	0,53	0,98	
eseclo	7,9	2,41	1,00	

Table 15: Expression profile data for gene NOC8009C9

Based on this expression profile, the gene was further analyzed in zebrafish embryos. One corresponding zebrafish genes was identified for targeting. Two morpholinos were prepared, sz241 and sz242, targeted to the zebrafish gene. Three (3)ng of sz241 morpholino and

1ng of sz242 morpholino were administered to each fertilized egg. The embryos were allowed to develop. At 24 hpf a secondary *in situ* hybridization screen with six different probes was conducted.

Intersegmental expression was analyzed in the assay and results differed somewhat based on the probe used. The probe *fli-1* revealed that 7% of the 15 morphant embryos assayed had medium effects. The probe *flk-1* indicated that all 15 morphants observed were normal. The probe *tie-1* indicated that 7% of the 15 morphants observed had high effects. The probe *cdh5* indicated that 15% of the 20 morphants observed had low effects. Medium effects were seen in 5% and high effects in 15%. The probe *flt-4* indicated that all 15 morphants observed were normal, and the probe *tie-2* indicated that all 16 morphants observed were normal.

The following table, Table 16, summarizes this data.

Probe	Number analyzed	Results
<i>fli-1</i>	15	7%M
<i>flk-1</i>	15	normal
<i>tie-1</i>	15	7%H
<i>cdh5</i>	20	15%L, 5%M, 15%H
<i>flt-4</i>	15	normal
<i>tie-2</i>	16	normal

Table 16: secondary *in situ* hybridization data

At 28 hpf embryos were observed morphologically. Figure 33 shows a representative morphant embryo at 28 hpf. Mild cell death was observed in 25% of the 53 embryos observed. At 56 hpf 52 embryos were observed for phenotypic characteristics, a representative morphant embryo is shown in Figure 34. As indicated by the arrow, pericardial edema was seen in 13% of embryos. The arrowhead points toward a region of yolk sac edema, seen in 25% of embryos.

Reduced IS blood flow was observed in 13% and 15% showed reduced axial blood flow.

Additional analyses were conducted on 48-56 hpf morphant embryos. A primary *in situ* hybridization screen with *cdh5* on 31 morphants showed all as normal. Microangiography on morphants was used to locate the presence of FITC-Dextran in various regions of the embryo, see Figure 35. Of the 29 embryos, 7% had FITC-Dextran in the heart, and 14% in the heart and head. Reduced intersegmental vasculature was seen as indicated by the arrows in Figure 35. High effects were observed in 3% of the embryos, medium effects in 3% and low effects in 21%. No leaky vasculature was observed. Normal embryos accounted for 52% of the sample. The data reveal that the gene is expressed in and around the heart and around organs, including some expression in select organs.

Gene NOC8009G23

The gene having the sequence shown in SEQ ID NO:43 was identified as selectively expressed during angiogenesis based on microarray data, see Figure 36. Specific data are given below in Table 17. Using sequence and annotation databases the equivalent gene in mice (SEQ ID NO:44) and the human homolog (SEQ ID NO:46) was also deduced. Proteins encoded by these sequences are given at SEQ ID NO:s 45 and 47, respectively.

	intensity	log2 exp ratio	p-value	rank
eccl	8,3	0,23		3262
ecfo	8,2	1,19		185
abeclo	7,2	2,94	1,00	
aberebec	8,1	2,09	1,00	
anacio	8,0	1,15	1,00	
ebacio	8,2	0,75	0,94	
ehacio	9,0	-0,02	0,47	
esacio	8,1	2,51	1,00	

Table 17: Expression profile data for gene NOC8009G23

Based on this expression profile, the gene was further analyzed in zebrafish embryos. One corresponding zebrafish gene was identified for targeting. Two morpholinos were prepared, sz149 and sz150, each targeted to the zebrafish

gene. In a first dose group, 1.5ng of sz149 morpholino and 1.5ng of sz150 morpholino were administered to fertilized eggs. In a second dose group, 2ng of sz149 morpholino and 2ng of sz150 morpholino were administered to fertilized eggs. In a third dose group, 3ng of sz149 morpholino and 3ng of sz150 morpholino were administered to fertilized eggs. The embryos were allowed to develop. At 24 hpf a secondary *in situ* hybridization screen with six different probes was conducted.

Intersegmental expression was analyzed in the assay and results differed somewhat based on the probe used. In studies with embryos from the second dose group, the probe *fli-1* revealed that 21% of the 14 morphant embryos assayed had high effects. The probe *flk-1* indicated that all 16 morphants reviewed were normal. The probe *tie-1* indicated that 36% of the 22 morphants observed had high effects. The probe *cdh5* indicated that 13% of the 15 morphants observed had low effects with breaks in axial expression. The probe *flt-4* indicated that all 16 morphants observed were normal, and the probe *tie-2* indicated that all 13 morphants observed were normal.

In studies from the second dose group, the probe *fli-1* revealed that 13% of the 15 morphant embryos assayed had medium effects, 27% had high effects. The probe

flk-1 indicated that 7% of the 15 morphants reviewed had low effects, 7% had medium effects and 20% had high effects. The probe *tie-1* indicated that 62% of the 13 morphants observed had high effects. The probe *cdh5* indicated that 25% of the 12 morphants observed had high effects, some with breaks in axial expression. The probe *flt-4* indicated that 13% of the 15 morphants observed had low effects in the axial vessels, including breaks in axial expression and severely malformed tails. The probe *tie-2* indicated that all 8 morphants observed were normal.

The following Table 18 summarizes the foregoing data.

	Morphants with 2 ng sz149, 2 ng sz150		Morphants with 3 ng sz149, 3 ng sz150	
Probe	Number analyzed	Results	Number analyzed	Results
<i>fli-1</i>	14	21%H	15	13%M, 27%H
<i>flk-1</i>	16	normal	15	7%L, 7%M, 20%H
<i>tie-1</i>	22	36%H	13	62%H
<i>cdh5</i>	15	13%L***	12	25%H***
<i>flt-4</i>	16	normal	15	13% low axial effects
<i>tie-2</i>	13	normal	8	normal

Table 18: secondary *in situ* hybridization data

At 28 hpf embryos were observed morphologically. Figure 37 shows a representative morphant embryo at 28 hpf. As indicated by the arrow, cell death was observed in 40% of the 20 embryos observed. As indicated by the arrowhead, yolk sac edema was observed in 55% of the morphants. Curly down body was seen in 40% of morphants. At 56 hpf a total of 20 embryos were observed for phenotypic characteristics, a representative morphant embryo is shown in Figure 38. As shown by the arrow, pericardial edema was observed in 55% of morphants. The arrowhead points toward yolk sac edema, observed in 55% of morphants. Curly down body was reported in 30% of embryos.

Additional analyses were conducted on 48-56 hpf morphant embryos. A primary *in situ* hybridization screen with *cdh5* on 22 morphants from the first dose group showed 90% as normal. Low effects of reduced intersegmental expression and curly down embryos were seen in 5% of the embryos, and high effects with very short tails were seen in 5% of embryos. A primary *in situ* hybridization screen with *cdh5* was also performed on 20 morphants from the third dose group, showing 80% as normal. Low effects of reduced intersegmental expression were seen in 5% of the embryos, and medium effects in 15% of embryos.

Microangiography on morphants was used to locate the presence of FITC-Dextran in various regions of the embryo, see Figure 39. Of the 25 embryos, none had FITC-Dextran in the heart, or the heart and head. Reduced intersegmental vasculature was seen in 24% of the embryos as indicated by the arrow in Figure 39. No leaky vasculature was observed. Normal embryos accounted for 76% of the sample, in example of normal intersegmental vessels is indicated by the arrowhead.

The gene having the sequence shown in SEQ ID NO:48 was identified as selectively expressed in blood vessels based on microarray data, see Figure 40. Specific data are given below in Table 19. Using sequence and annotation databases the equivalent gene in mice (SEQ ID NO:49) and the human homolog (SEQ ID NO:51) was also deduced. Proteins encoded by these sequences are given at SEQ ID NO:s 50 and 52, respectively.

	intensity	log2 exp ratio	p-value	rank
eccl	8,1	0,67		1246
eclo	8,0	1,37		123
abeclo	7,1	2,90	1,00	
abecabec	8,1	0,59	0,92	
ahedlo	7,6	0,19	0,85	
ebeclo	8,7	1,41	1,00	
ehedlo	8,4	1,89	1,00	
eseclo	7,7	1,28	1,00	

Table 19: Expression profile data for gene OJC8003C9

Based on this expression profile, the gene was further analyzed in zebrafish embryos. One corresponding zebrafish gene was identified for targeting. Two morpholinos were prepared, sz129

and sz130, each targeted to the zebrafish gene. In a first dose group, 3ng of sz129 morpholino and 4.5ng of sz130 morpholino were administered to each fertilized egg. In a second dose group, 4ng of sz129 morpholino and 6ng of sz130 morpholino were administered to each fertilized egg. In a third dose group, 6ng of sz129 morpholino and 8ng of sz130 morpholino were administered to each fertilized egg. In a fourth dose group, 6ng of sz129 morpholino and 9ng of sz130 morpholino were administered to each fertilized egg. The embryos were allowed to develop. At 24 hpf a secondary *in situ* hybridization screen with six different probes was conducted.

Intersegmental expression was analyzed in the assay and results differed somewhat based on the probe used. In embryos from the second dose group, the probe *fli-1* revealed that 20% of the 10 morphant embryos assayed had low effects, 10% had medium effects and 10% had high effects. The probe *flk-1* indicated that 11% of the 9 morphants reviewed had low effects, 33% had medium effects and 11% had high effects. The probe *tie-1* indicated that 22% of the 9 morphants observed had high effects. The probe *cdh5* indicated that 14% of the 7 morphants observed had medium effects and 14% had high effects. The probe *flt-4* indicated that all 9 morphants observed were normal, and the probe *tie-2* indicated that all 7 morphants observed were normal.

In embryos from the third dose group, the probe *fli-1* revealed that 10% of the 10 morphant embryos assayed had medium effects, and 50% had high effects. The probe *flk-1* indicated that 25% of the 12 morphants reviewed had medium effects and 25% had high effects. The probe *tie-1* indicated that 17% of the 6 morphants observed had low effects, and 50% had high effects. The probe *cdh5* indicated that 40% of 5 morphants observed had medium effects. The probe *flt-4* indicated that all 9 morphants observed were normal, and the probe *tie-2* indicated that all 6 morphants observed were normal.

The following Table 20 summarizes the foregoing data.

Morphants with 3 ng sz185, 6 ng sz186			Morphants with 6 ng sz185, 12 ng sz186	
Probe	Number	Results	Number	Results

	analyzed		analyzed	
<i>fli-1</i>	10	20%L, 10%M, 10%H	10	10%M, 50%H
<i>flk-1</i>	9	11%L, 33%M, 11%H	12	25%M, 25%H
<i>tie-1</i>	9	22%H	6	17%L, 50%H
<i>cdh5</i>	7	14%M, 14%H	5	40%M
<i>flt-4</i>	9	normal	9	normal
<i>tie-2</i>	7	normal	6	normal

Table 20: secondary *in situ* hybridization data

At 28 hpf embryos were observed morphologically. Figure 41 shows a representative morphant embryo at 28 hpf. As indicated by the arrow, curly down body was found in 35% of the 20 morphants observed. At 56 hpf a total of 20 embryos were observed for phenotypic characteristics, a representative morphant embryo is shown in Figure 42. As indicated by the long arrow, 60% of the embryos had cell death with an associated expanded hindbrain ventricle. Yolk sac edema was observed in 25% of embryos, as indicated by the short arrow. The arrowhead points out the lack of pericardial edema associated with the yolk sac edema.

Additional analyses were conducted on 48-56 hpf morphant embryos. A primary *in situ* hybridization screen with *cdh5* on 19 morphants from the first dose group showed all were normal. The primary *in situ* hybridization screen with *cdh5* on 10 morphants from the fourth dose group showed only 90% normal, the remaining 10% exhibiting low effects with curly tails. Microangiography on 19 morphants from the third dose group was used to locate the presence of FITC-Dextran in various regions of the embryo, see Figure 43. Of the 19 embryos, none had FITC-Dextran in the heart and head but 16% had it in the heart alone. Reduced intersegmental vasculature was seen in 37% of the embryos. No leaky vasculature was observed. Normal embryos accounted for 47% of the sample.

Gene OJC8009J7

The gene having the sequence shown in SEQ ID NO:53 was identified as selectively expressed in blood vessels based on microarray data, see Figure 44. Specific data are given below in Table 21. Using sequence and annotation databases the equivalent gene in mice (SEQ ID NO:54) and the human homolog (SEQ ID NO:56) was also deduced. Proteins encoded by these sequences are given at SEQ ID NO:s 55 and 57, respectively.

	intensity	log2 exp ratio	p-value	rank
<i>eccl</i>	8,5	0,62		1445
<i>eclo</i>	8,3	1,03		257
<i>abeclo</i>	8,3	2,37	1,00	
<i>abecbec</i>	9,2	0,38	0,84	
<i>ahedlo</i>	7,9	0,93	1,00	
<i>ebeclo</i>	8,8	1,53	1,00	
<i>ehedlo</i>	8,8	1,03	1,00	
<i>eseclo</i>	8,5	0,48	0,99	

Table 21: Expression profile data for gene OJC8009J7

Based on this expression profile, the gene was further analyzed in zebrafish embryos. One corresponding zebrafish gene was identified for targeting. Two morpholinos were prepared, sz175 and sz176, each targeted to the zebrafish

gene. Two (2) ng of sz175 morpholino and 12ng of sz176 morpholino were

administered to each fertilized egg. The embryos were allowed to develop. At 24 hpf a secondary *in situ* hybridization screen with six different probes was conducted.

Intersegmental expression was analyzed in the assay and results differed somewhat based on the probe used. The probe *fli-1* revealed that 7% of the 14 morphant embryos assayed had low effects, and 29% had high effects. The probe *flk-1* indicated that 25% of the 12 morphants reviewed had low effects and 8% had high effects. The probe *tie-1* indicated that 11% of the 9 morphants observed had medium effects and 11% had high effects. The probe *cdh5* indicated that 19% of the 16 morphants observed had low effects, 6% had medium effects, and 19% had high effects. The probe *flt-4* indicated that all 10 morphants observed were normal, and the probe *tie-2* indicated that all 6 morphants observed were normal.

The following table, Table 22, summarizes this data.

Probe	Number analyzed	Results
<i>fli-1</i>	14	7%L, 29%M
<i>flk-1</i>	12	25%L, 8%H
<i>tie-1</i>	9	11%M, 11%H
<i>cdh5</i>	16	19%L, 6%M, 19%H
<i>flt-4</i>	10	normal
<i>tie-2</i>	6	normal

Table 22: secondary *in situ* hybridization data

At 28 hpf embryos were observed morphologically. Figure 45 shows a representative morphant embryo at 28 hpf. As evidenced from the figure, particularly when viewed in light of the 28 hpf wild type embryo of Figure 4, the morphants exhibited normal morphology. At 56 hpf embryos again were observed for phenotypic characteristics, a representative morphant embryo is shown in Figure 46. Again, the normal morphology observed in the embryos can be easily understood when Figure 46 is viewed in light of the 56 hpf wild type embryo of Figure 6.

Additional analyses were conducted on 48-56 hpf morphant embryos. A primary *in situ* hybridization screen with *cdh5* on 17 morphants showed 88% as normal. Medium effects of reduced intersegmental expression were seen in the other 12% of embryos. Microangiography on morphants was used to locate the presence of FITC-Dextran in various regions of the embryo, see Figure 47. Of the 33 embryos, none had FITC-Dextran in the heart and head combined, but 4% had it in the heart alone. Reduced intersegmental vasculature was seen in 15% of embryos. No leaky vasculature was observed. Normal embryos accounted for 81% of the sample. The leaks observed came from blood vessels in the posterior head as indicated by the arrowhead.

Novel Applications Ascertained from *in vivo* Data

The present invention relates to the eleven gene targets, and proteins related thereto, which were originally identified as upregulated during vasculogenesis or angiogenesis through microarray evaluation and subsequently proven to play a critical role *in vivo* with zebrafish embryo experimentation. These genes and proteins can form the basis of novel methods and treatments directed to

angiogenesis-related conditions. For example, biological samples from a patient suspected of suffering from an angiogenesis-related condition can be screened to ascertain if genes or proteins of the present invention are expressed at the correct time, location, and intensity in the patient. Such screening methods form part of the claimed invention. If a gene and/or protein is identified as improperly expressed, therapies to correct the condition such as gene therapy or medicament can be initiated according to methods and procedures described herein or known in the art. With such specific data as is now possible using tools described herein, rapid diagnosis and specific, targeted treatment is possible.

One type of screening method envisioned relies on gene amplification for detecting patients with conditions related to vasculogenesis or angiogenesis. Such methods could employ PCR, in situ hybridisation, and/or Southern blotting techniques to elucidate the condition. Another type of screening method could be based on evaluations of gene expression, using known techniques such as quantitative PCR, microarrays, Northern blotting, or in situ hybridisation. Yet another type of screening method that could be used would measure or monitor protein expression and could be effected with techniques such as immunohistochemistry, Western blotting, ELISA, or FACS.

If it is determined, through methods of the present invention or other methods, that an angiogenesis-related condition could be improved through administration of compounds containing genes and/or proteins according to the invention, one or more of the genes and/or proteins could be administered together or sequentially by methods known in the art.

Isolated nucleic acid molecules or proteins of the present invention can be obtained, for example, by synthesis using standard direct peptide synthesizing techniques or recombinant methods. Proteins may be isolated or purified in a variety of ways known to those skilled in the art, such as electrophoretic purification or chromatographic techniques.

Administration of the compounds of the present invention can be effected by any method that enables delivery of the compounds to the site of desired action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion), and topical administration.

Gene therapy approaches may be used to introduce nucleotides of the present invention into a cell, group of cells, or organism. Both *in vivo* and *ex vivo* methods can be utilized. Vectors typically are used in this procedure. Non-virus or virus vectors could be employed, for example recombinant adenovirus or retrovirus. According to this use, the desired gene is introduced into a DNA virus or RNA virus, such as avirulent retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, poxvirus, poliovirus, Sindbis virus, Sendai virus, SV40, and immunodeficiency virus (HIV). The recombinant virus is then infected into the target cell(s). Multiple genes could be incorporated in a single vector, alternatively, they could be introduced to the target cell(s) in separate vectors simultaneously or sequentially. These methods are known in the art and are described in numerous patents and publications.

Another means to interfere with gene expression or protein production contemplated by the present invention is to employ small interfering RNA (siRNA). siRNA comprises a sense and antisense strand of RNA corresponding to the gene of interest, for example, SEQ ID NO:2. A siRNA molecule consists of approximately 19 nucleotides plus an overhang of approximately 2 nucleotides at the 3' end. Some preferred methods include between 19-23 nucleotides plus 3' overhang. The siRNA is introduced to the cell or cells of interest through known methods. Following introduction, the cell or cells destroy ssRNA having the same sequence. This results in a reduction or prevention in translation of a targeted gene and a corresponding reduction or prevention in protein production.

The amount of active compound administered can be determined after assessing the subject being treated, the severity of the disorder or condition, the rate of administration, and the disposition of the compound. Doses may be administered all at once, or spread out over a discrete time period.

Compounds of the present invention may be applied as a sole therapy or may involve one or more other active medicinal or pharmaceutical agent. Compositions may include carriers, adjuvants, buffers, or excipients as known in the art. If desired, the compositions may further contain ingredients such as flavorings, sweeteners, binders, dyes, lubricating agents, perfume, thickening agents, stabilizers, emulsifiers, dispersants, suspending agents, preservatives, and pH regulating agents. Compositions may be in any suitable form, for example, tablet, capsule, pill, powder, sustained release formulation, solution, suspension, emulsion, ointment or cream. The compositions may be sterile. Methods of preparing various pharmaceutical compositions with a specific amount of active compound are known or apparent to those skilled in this art. The pharmaceutical compositions of the present invention that have been described can be applied to all diseases that require vasculogenic or angiogenic therapy.

For example, one method for the treatment of an angiogenesis-related disorder involves a composition according to the present invention used to vascularize ischemic tissue. There are many ways to determine if a tissue is at risk of suffering ischemic damage from undesirable vascular occlusion. Such methods are well known in the art and include, for example, imaging techniques such as MRI to evaluate myocardial disease. After determining where and when to apply compositions of the present invention, the compositions can be administered to increase angiogenesis in tissue affected by or at risk of being affected by a vascular occlusion. This could be an effective means of preventing and/or attenuating ischemia in such tissue. Methods are known in the art to evaluate and measure the degree to which ischemia has been attenuated.

Further treatment methods according to the present invention include the use of any known technique that permits visualization, measurement, and/or evaluation of the functionality and degree of ischemia of the patient's heart. Such evaluations could be made prior to initiating treatment, during the course of treatment, after treatment has been completed, or at some or all stages. Examples of such techniques include echocardiography, cardiovascular nuclear imaging, magnetic resonance imaging, and contrast angiography.

Although the present invention takes a step forward in the understanding of vasculogenesis and angiogenesis, and treatments for conditions related to the same, there is still a need in the art to further understand these conditions. Therefore, the present invention further contemplates the creation and use of non-human transgenic animals which could be used for analysis and experimentation. Transgenic animals containing mutant, knock-out or modified genes corresponding to those disclosed herein are therefore also included in the invention. Transgenic animals are genetically modified animals into which recombinant, exogenous or cloned genetic material has been experimentally transferred. Such genetic material is often referred to as a transgene. The nucleic acid sequence of the transgene may be integrated either at a locus of a genome where that particular nucleic acid sequence is not otherwise normally found or at the normal locus for the transgene. The transgene may consist of nucleic acid sequences derived from the genome of the same species or of a different species than the species of the target animal.

Transgenic animals can be produced by a variety of different methods including transfection, electroporation, microinjection, gene targeting in embryonic stem cells and recombinant viral and retroviral infection as known in the art. The method of introduction of nucleic acid fragments into recombination competent mammalian cells can be by any method that favors co-transformation of multiple nucleic acid molecules. Detailed procedures for producing transgenic animals are available to one skilled in the art, for example, U.S. Pat. Nos. 5,489,743 and 5,602,307.

Transgenic technology can be used to produce animals which lack one or more of the eleven genes described above. Such knockout animals can be used, especially when their growth and development is measured against data from a wild type or control animal, to elucidate timing and function of the deleted gene(s). Further, these animals could also be engineered to exhibit angiogenesis-related disease states, thus furthering the understanding of the role of the particular gene(s) in the progression of the selected disease. This knowledge would be an advance in the state of the art and could lead to promising new therapies for the prevention, management, and cure of disease.

Further uses of transgenic animals according to the present invention include replacement of one or more of the above-identified gene(s) in the research organism with the human homolog of the gene. For example, a transgenic mouse whose gene corresponding to SEQ ID NO:7 has been replaced with the human homolog, SEQ ID NO:9. While it is accepted that research into effective drug therapies can be conducted in animal models, such a transgenic mouse could be a more effective screening tool into potential drug candidates for human use.

We Claim:

1. An isolated nucleic acid molecule according to any one of SEQ ID NO:s 2, 4, 7, 9, 12, 14, 17, 19, 21, 24, 26, 29, 31, 34, 36, 39, 41, 44, 46, 49, 51, 54, and 56 or a fragment or analogue thereof which has the ability to stimulate or inhibit at least one biological activity selected from the group consisting of vasculogenesis, angiogenesis, vascular permeability, endothelial cell proliferation, endothelial cell differentiation, endothelial cell migration, and endothelial cell survival, or an isolated nucleic acid molecule which hybridizes to one of the foregoing sequences under stringent conditions.
2. An isolated nucleic acid molecule which hybridizes to the complement of a nucleic acid molecule according to Claim 1 under stringent conditions.
3. An isolated siRNA molecule targeted to an isolated nucleic acid molecule according to Claims 1 or 2, wherein the isolated siRNA molecule is at least 19 base pairs long.
4. An expression vector comprising the nucleic acid according to Claims 1 or 2, optionally the nucleic acid may be operatively associated with a regulatory nucleic acid controlling the expression of the polypeptide encoded by said nucleic acid.
5. A host cell genetically engineered to contain a nucleic acid according to Claims 1 or 2.
6. A host cell transfected with an expression vector according to Claim 4.
7. A method of treating an angiogenesis-related condition in a cell, group of cells, or organism, comprising the step of administering an expression vector according to Claim 4 to the cell, group of cells, or organism.
8. An antibody with specific reactivity to a nucleic acid according to Claims 1 or 2, wherein the antibody may preferably be polyclonal or monoclonal and wherein the antibody may further comprise a detectable label such as a fluorescent label.
9. A transgenic, non-human animal which has been genetically engineered to contain a transgene comprising a nucleic acid according to Claims 1 or 2, preferably, the transgene may be expressed.
10. A pharmaceutical composition comprising a nucleic acid sequence according to Claims 1 or 2.
11. A method of affecting vasculogenesis or angiogenesis in a cell, group of cells, or organism, comprising the step of administering a pharmaceutical composition according to Claim 16 to the cell, group of cells, or organism, the affecting may preferably cause an increase or decrease, more preferably, the cell, group of cells, or organism has an angiogenesis-related disorder such as cancer, retinopathy, macular degeneration, corneal ulceration, stroke, ischemic heart disease, infertility, ulcers, sclerodoma, wound healing, ischemia, ischemic heart disease, myocardial infarction, myocardosis, angina pectoris, unstable angina, coronary arteriosclerosis,

arteriosclerosis obliterans, Berger's disease, arterial embolism, arterial thrombosis, cerebrovascular occlusion, cerebral infarction, cerebral thrombosis, cerebral embolism, rubeosis proliferative vitreoretinopathy, chronic inflammation, inflammatory bowel disease, psoriasis, sarcoidosis and rheumatoid arthritis.

12. An isolated polypeptide comprising a sequence of amino acids substantially corresponding to the amino acid sequence in any one of SEQ ID NO:s 3, 5, 8, 10, 13, 15, 18, 20, 22, 25, 27, 30, 32, 35, 37, 40, 42, 45, 47, 50, 52, 55, and 57 or a fragment or analogue thereof, said polypeptide having the ability to affect angiogenesis in a cell, a group of cells, or an organism.

13. A host cell genetically engineered to express a polypeptide according to Claim 12.

14. An antibody specifically reactive with a polypeptide according to Claim 12, wherein the antibody may preferably be polyclonal or monoclonal and wherein the antibody may further comprise a detectable label such as a fluorescent label.

15. A transgenic, non-human animal which has been genetically engineered to contain a transgene comprising a nucleic acid which encodes a polypeptide according to Claim 12, preferably, the transgene may be expressed.

16. A pharmaceutical composition comprising an isolated polypeptide according to Claim 12.

17. A method of affecting vasculogenesis or angiogenesis in a cell, group of cells, or organism, comprising the step of administering a pharmaceutical composition according to Claim 16 to the cell, group of cells, or organism, the affecting may preferably cause an increase or decrease, more preferably, the cell, group of cells, or organism has an angiogenesis-related disorder such as cancer, retinopathy, macular degeneration, corneal ulceration, stroke, ischemic heart disease, infertility, ulcers, sclerodoma, wound healing, ischemia, ischemic heart disease, myocardial infarction, myocardosis, angina pectoris, unstable angina, coronary arteriosclerosis, arteriosclerosis obliterans, Berger's disease, arterial embolism, arterial thrombosis, cerebrovascular occlusion, cerebral infarction, cerebral thrombosis, cerebral embolism, rubeosis proliferative vitreoretinopathy, chronic inflammation, inflammatory bowel disease, psoriasis, sarcoidosis and rheumatoid arthritis.

18. A method of detecting an angiogenesis-related transcript in a cell in a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence according to any one of SEQ ID NO:s 2, 4, 7, 9, 12, 14, 17, 19, 21, 24, 26, 29, 31, 34, 36, 39, 41, 44, 46, 49, 51, 54, and 56, wherein an angiogenesis-related transcript is detected where hybridization is detected, preferably the polynucleotide comprises a sequence according to any one of SEQ ID NO:s 2, 4, 7, 9, 12, 14, 17, 19, 21, 24, 26, 29, 31, 34, 36, 39, 41, 44, 46, 49, 51, 54, and 56, preferably the biological sample is a tissue sample or is comprised of isolated nucleic acids such as mRNA, preferably the nucleic acids are amplified prior to the step of contacting the biological sample with the polynucleotide, preferably the polynucleotide is immobilized on a solid surface.

19. A method of affecting at least one bioactivity selected from angiogenesis and vasculogenesis in a vertebrate organism, said method comprising the step of administering to said organism an effective angiogenesis or vasculogenesis affecting amount of a nucleotide or polypeptide according to Claims 1 or 12, wherein the organism is preferably a mammal such as mice, rats, rabbits, guinea pigs, cats, dogs, pigs, cows, monkeys, and humans, wherein vasculogenesis or angiogenesis is preferably enhanced, increased, inhibited, or decreased, wherein the organism preferably has an angiogenesis-related disorder such as cancer, retinopathy, macular degeneration, corneal ulceration, stroke, ischemic heart disease, infertility, ulcers, sclerodoma, wound healing, ischemia, ischemic heart disease, myocardial infarction, myocardosis, angina pectoris, unstable angina, coronary arteriosclerosis, arteriosclerosis obliterans, Berger's disease, arterial embolism, arterial thrombosis, cerebrovascular occlusion, cerebral infarction, cerebral thrombosis, cerebral embolism, rubeosis proliferative vitreoretinopathy, chronic inflammation, inflammatory bowel disease, psoriasis, sarcoidosis and rheumatoid arthritis.

20. A transgenic increased or decreased angiogenesis laboratory animal comprising one or more cells in which the expression of a sequence according to any one of SEQ ID NO:s 2, 4, 7, 9, 12, 14, 17, 19, 21, 24, 26, 29, 31, 34, 36, 39, 41, 44, 46, 49, 51, 54, and 56 is upregulated, downregulated, or absent.

FIG. 2

PRV03.12.05

Abstract

The present invention relates to polynucleotides and proteins associated with vasculogenesis- and angiogenesis-related disorders. The invention further relates to methods for the identification of compounds that modulate the expression of angiogenesis-related genes and gene products and to using such compounds as therapeutic agents in the treatment of angiogenesis-related disorders. The invention also relates to methods for the diagnostic evaluation, genetic testing and prognosis of angiogenesis-related disorders, and to methods and compositions for the treatment these disorders.

PRV03.12.05




Figure 1




Figure 2




Figure 3




Figure 4





Figure 5





Figure 9






Figure 10




Figure 11




Figure 12




Figure 13




Figure 14





Figure 15

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100






Figure 18




Figure 19




Figure 20



Figure 21

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161

一、二、三、四、五、六、七、八、九、十、十一、十二、十三、十四、十五、十六、十七、十八、十九、二十、二十一、二十二、二十三、二十四、二十五、二十六、二十七、二十八、二十九、三十、三十一、三十二、三十三、三十四、三十五、三十六、三十七、三十八、三十九、四十、四十一、四十二、四十三、四十四、四十五、四十六、四十七、四十八、四十九、五十、五十一、五十二、五十三、五十四、五十五、五十六、五十七、五十八、五十九、六十、六十一、六十二、六十三、六十四、六十五、六十六、六十七、六十八、六十九、七十、七十一、七十二、七十三、七十四、七十五、七十六、七十七、七十八、七十九、八十、八十一、八十二、八十三、八十四、八十五、八十六、八十七、八十八、八十九、九十、九十一、九十二、九十三、九十四、九十五、九十六、九十七、九十八、九十九、一百。






Figure 24




Figure 25




Figure 26




Figure 27




Figure 28






Figure 31




Figure 32




Figure 33




Figure 34

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100




Figure 35




Figure 36




Figure 37




Figure 38




Figure 39




Figure 40






Figure 43




Figure 44




Figure 45




Figure 46



Figure 47

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

SEQUENCE LISTING

<110> Hellström, Mats
Wallgard, Elisabet
Kalén, Mattias

<120> ANGIOGENESIS-AFFECTING POLYPEPTIDES, PROTEINS, AND
COMPOSITIONS, AND METHODS OF USE THEREOF

<130> 72861

<160> 57

<170> PatentIn version 3.2

<210> 1

<211> 692

<212> DNA

<213> Murinae gen. sp.

<400> 1

cggcggagac ccctgtgcgg tccggagggg ggcgcggccc cgactctgac ccgcgccggg
60

ggggtgggccc atggcggaga tcagcgacct ggaccggcag atcgagcagc tacggcgctg
120

cgagctgata aaagagagcg aagtcaaggc cctgtgcgcc aaggccagag aaatcttggt
180

agaagagagc aacgtgcaga ggggtggactc gccagtcaca gtatgcgggtg acatccatgg
240

acaattctat gacctcaagg agctgttcag agtaggtggc gatgtccctg agaccaacta
300

cctcttcatg ggagactttg tggaccgtgg tttctacagt gttgaaacct tcctcctcct
360

gctggctctt aagggttcgt atcctgacag aatcactttg atccggggca atcatgagag
420

tgcagagatt acccaggtct atgggttcta tgatgagtgc ttacggaaat atggttcagt
480

gactgtatgg cgctactgta ctgagatctt tgactacctc agcctgtctg ccattcattga
540

tggcaagatc ttctgtgtgc atggaaggtc tttccccttc catccagacc ttggaccaga
600

tccggacaat ttgaccgaaa gcaagaggta ccccatgat ggaccattg tgcgaccttc
660

ctgtggtctg accctgaaga cacaacaggc tg
692

<210> 2

<211> 1331

<212> DNA

<213> Murinae gen. sp.

<400> 2

gcggaggaa gtggggagtc gaagagactc agccggagtc tccgcggcgg agaccctgt
60

gcggtcggga gggggcggcg gcccgcactc tgaccgcgcg cgggggggtg ggccatggcg
120

gagatcagcg acctggaccg gcagatcgag cagctacggc gctgcgagct gatcaaagag
180

agcgaagtca aggccctgtg cgccaaggcc agagaaatct tggtagaaga gagcaacgtg
240

cagaggggtg actcgccagt cacagtatgc ggtgacatcc atggacaatt ctatgacctc
300

aaggagctgt tcagagtagg tggcgatgtc cctgagacca actacctctt catgggagac
360

tttgtggacc gtggtttcta cagtgttgaa accttccctc tctgtctggc tcttaaggtt
420

cgctatcctg acagaatcac ttgatccgg ggcaatcatg agagtcgcca gattaccag
480

gtctatgggt tctatgatga gtgcttacgg aaatatggtt cagtgactgt atggcgctac
540

tgtactgaga tctttgacta cctcagcctg tctgccatca ttgatggcaa gatcttctgt
600

gtgcatggag gtctttcccc ttccatccag accttggacc agatccggac aattgaccga
660

aagcaagagg taccocatga tggacccatg tgcgacctcc tgtggtctga cctgaagac
720

acaacaggct ggggagtgag ccccgcggg gcaggttacc tgtttggcag tgacgtggtc
780

gcccagttca atgcagccaa cgacattgat atgatctgcc gtgcccacca attagtgatg
840


gaaggctaca agtggcactt caatgagacc gtgcttactg tgtggtcagc gcctaattac
900

tgctaccgct gtggcaatgt ggcagccatc ttagaactgg atgagcacct ccagaaagat
960

ttcatcatct tcgaggctgc accccaagag acacgtggca tccctccaa aaagccagtg
1020

gccgactatt tctgtgact ccttggcccc agcccctctg gcccttggac cactgtgact
1080

gccctctgcc cagtcggagg ctgggtctga ggggctgcct ggctttgctt gcccagggt
1140



gcggacttgc tctggagagg tggagccttg gctcctggct tcctctcctt tctcccactt
1200

gatccatgaa gttttcagtc atttttttttt tcttttttcc ttttttttcc tttctttttt
1260

ctttttgttt ttgttttttag ataaaacatt ttgagaaaaa aagaaaaaaa ttctaataaa
1320

agaagaaaaa t
1331

<210> 3
<211> 307
<212> PRT
<213> Murinae gen. sp.

<400> 3

Met Ala Glu Ile Ser Asp Leu Asp Arg Gln Ile Glu Gln Leu Arg Arg
1 5 10 15

Cys Glu Leu Ile Lys Glu Ser Glu Val Lys Ala Leu Cys Ala Lys Ala
20 25 30

Arg Glu Ile Leu Val Glu Glu Ser Asn Val Gln Arg Val Asp Ser Pro
35 40 45

Val Thr Val Cys Gly Asp Ile His Gly Gln Phe Tyr Asp Leu Lys Glu
50 55 60

Leu Phe Arg Val Gly Gly Asp Val Pro Glu Thr Asn Tyr Leu Phe Met
65 70 75 80

Gly Asp Phe Val Asp Arg Gly Phe Tyr Ser Val Glu Thr Phe Leu Leu
85 90 95

Leu Leu Ala Leu Lys Val Arg Tyr Pro Asp Arg Ile Thr Leu Ile Arg
100 105 110

Gly Asn His Glu Ser Arg Gln Ile Thr Gln Val Tyr Gly Phe Tyr Asp
115 120 125

Glu Cys Leu Arg Lys Tyr Gly Ser Val Thr Val Trp Arg Tyr Cys Thr
130 135 140

Glu Ile Phe Asp Tyr Leu Ser Leu Ser Ala Ile Ile Asp Gly Lys Ile
145 150 155 160

Phe Cys Val His Gly Gly Leu Ser Pro Ser Ile Gln Thr Leu Asp Gln

165

170

175

Ile Arg Thr Ile Asp Arg Lys Gln Glu Val Pro His Asp Gly Pro Met
180 185 190

Cys Asp Leu Leu Trp Ser Asp Pro Glu Asp Thr Thr Gly Trp Gly Val
195 200 205

Ser Pro Arg Gly Ala Gly Tyr Leu Phe Gly Ser Asp Val Val Ala Gln
210 215 220

Phe Asn Ala Ala Asn Asp Ile Asp Met Ile Cys Arg Ala His Gln Leu
225 230 235 240

Val Met Glu Gly Tyr Lys Trp His Phe Asn Glu Thr Val Leu Thr Val
245 250 255

Trp Ser Ala Pro Asn Tyr Cys Tyr Arg Cys Gly Asn Val Ala Ala Ile
260 265 270

Leu Glu Leu Asp Glu His Leu Gln Lys Asp Phe Ile Ile Phe Glu Ala
275 280 285

Ala Pro Gln Glu Thr Arg Gly Ile Pro Ser Lys Lys Pro Val Ala Asp
290 295 300

Tyr Phe Leu
305

<210> 4
<211> 1339
<212> DNA
<213> Homo sapiens

<400> 4
ggcagggagc cggagagccg gaaccggagt cgcagcggcg gagaccctg tgcgggtgcg
60

agggggcggc ggccccgact ctgaccgcgc ccgggggtgg gccatggcgg agatcagcga
120

cctggaccgg cagatcgagc agctgcgtcg ctgcgagctc atcaaggaga gcgaagtcaa
180

ggccctgtgc gctaaggcca gagagatctt ggtagaggag agcaacgtgc agaggggtgga
240

ctcgccagtc acagtgtgcg gcgacatcca tggacaattc tatgacctca aagagctgtt
300

cagagtaggt ggcgacgtcc ctgagaccaa ctacctcttc atgggggact ttgtggaccg
360

tggtttctat agcgctgaaa cgttcctcct gctgctggca ctttaagggttc gctatcctga
420

tgcgcatcaca ctgatccggg gcaaccatga gagtcgccag atcacgcagg tctatggctt
480

ctacgatgag tgccctgcgca agtacggctc ggtgactgtg tggcgctact gcactgagat
540

ctttgactac ctcagcctgt cagccatcat cgatggcaag atcttctgcg tgcacggggg
600

cctctcccc tccatccaga cctggatca gattcggaca atcgaccgaa agcaagaggt
660

gcctcatgat gggcccatgt gtgacctcct ctggtctgac ccagaagaca ccacaggctg
720

ggcgctgagc ccccgaggag ccggtacct atttggcagt gacgtggtgg ccagttcaa
780

cgcagccaat gacattgaca tgatctgccg tgcccaccaa ctggtgatgg aaggttacia
840

gtggcacttc aatgagacgg tgctcactgt gtggtcggca cccaactact gctaccgctg
900

tgggaatgtg gcagccatct tggagctgga cgagcatctc cagaaagatt tcatcatctt
960

tgaggctgct ccccaagaga cacggggcat cccctccaag aagcccgtgg ccgactactt
1020

cctgtgaccc cgcccggccc ctgccccctc caacccttct ggccctcgca ccactgtgac
1080

tctgccatct tcctcagacg gaggtctggc gtgggggggg ctgtcctggc tctgctgtcc
1140

cccaagaggg tgcttcgagg gtgaggactt ctctggagag gcctggagac ctagctccat
1200


gttcctcctc ctctctcccc acttgaacca tgaagtttcc aataattttt ttttcttttt
1260

ttccttcttt tttctgtttg tttttagata aaaattttga gaaaaaaaat gaaaaaatc
1320

taataaaaaga agaaaaatg
1339

<210> 5
<211> 307
<212> PRT
<213> Homo sapiens

<400> 5



PROG 1205

Met Ala Glu Ile Ser Asp Leu Asp Arg Gln Ile Glu Gln Leu Arg Arg
1 5 10 15

Cys Glu Leu Ile Lys Glu Ser Glu Val Lys Ala Leu Cys Ala Lys Ala
20 25 30

Arg Glu Ile Leu Val Glu Glu Ser Asn Val Gln Arg Val Asp Ser Pro
35 40 45

Val Thr Val Cys Gly Asp Ile His Gly Gln Phe Tyr Asp Leu Lys Glu
50 55 60

Leu Phe Arg Val Gly Gly Asp Val Pro Glu Thr Asn Tyr Leu Phe Met
65 70 75 80

Gly Asp Phe Val Asp Arg Gly Phe Tyr Ser Val Glu Thr Phe Leu Leu
85 90 95

Leu Leu Ala Leu Lys Val Arg Tyr Pro Asp Arg Ile Thr Leu Ile Arg
100 105 110

Gly Asn His Glu Ser Arg Gln Ile Thr Gln Val Tyr Gly Phe Tyr Asp
115 120 125

Glu Cys Leu Arg Lys Tyr Gly Ser Val Thr Val Trp Arg Tyr Cys Thr
130 135 140

Glu Ile Phe Asp Tyr Leu Ser Leu Ser Ala Ile Ile Asp Gly Lys Ile
145 150 155 160

Phe Cys Val His Gly Gly Leu Ser Pro Ser Ile Gln Thr Leu Asp Gln
165 170 175

Ile Arg Thr Ile Asp Arg Lys Gln Glu Val Pro His Asp Gly Pro Met
180 185 190

Cys Asp Leu Leu Trp Ser Asp Pro Glu Asp Thr Thr Gly Trp Gly Val
195 200 205

Ser Pro Arg Gly Ala Gly Tyr Leu Phe Gly Ser Asp Val Val Ala Gln
210 215 220

Phe Asn Ala Ala Asn Asp Ile Asp Met Ile Cys Arg Ala His Gln Leu
225 230 235 240

PROB-1203

Val Met Glu Gly Tyr Lys Trp His Phe Asn Glu Thr Val Leu Thr Val
 245 250 255

Trp Ser Ala Pro Asn Tyr Cys Tyr Arg Cys Gly Asn Val Ala Ala Ile
 260 265 270

Leu Glu Leu Asp Glu His Leu Gln Lys Asp Phe Ile Ile Phe Glu Ala
 275 280 285

Ala Pro Gln Glu Thr Arg Gly Ile Pro Ser Lys Lys Pro Val Ala Asp
 290 295 300

Tyr Phe Leu
 305

<210> 6
 <211> 646
 <212> DNA
 <213> Murinae gen. sp.

<400> 6
 tcctttccta gtctgtcttc agatgaaacc tattctctgc ttgtacaaga accagtagcc
 60

gtcctcaagg ccaacagcgt tggggagcgt tacgagggtt agagacgttt agccagtttag
 120

tttaccaaga ctctttcggg actttcacca tcaatgaatc cagtatagct gattctccaa
 180

gattccctca tagaggaatt ttaattgata catctagaca cttcctgcct gtgaagacaa
 240

ttttaaaaac tctggatgcc atggctttta ataagtttaa tgttcttcac tggcacatag
 300

tggacgacca gtctttccct tatcagagta ccacttttcc tgagctaagc aataagggaa
 360

gctactcttt gtctcatgtc tatacaccaa acgatgtccg gatgggtgctg gagtaagccc
 420

ggctccgagg gattcgagtc ataccagaat ttgatacccc tggccatata cagtcttggg
 480

gcaaaggaca gaaaaacctt ctaactccat gttacaatca aaaaactaaa actcaagtgt
 540

ttgggcctgt agacccaact gtaaacacaa cgtatgcatt ctttaacaca tttttcaaag
 600

aatcagcag tgtgtttcca gatcagttca tccacttggg aggaga
 646

<210> 7

<211> 1805
<212> DNA
<213> Murinae gen. sp.

<400> 7
ggatgctttc ttcccagcga cccagactgg aagggttggtc caaagactgc ctagccagac
60
tcgcggagca gtcattgccg agtccccgcg tagcgcccc gggtctgtgc tgctgcaggc
120
gctggtgtcg ctagtgtcgc tggccctagt ggccccggcc cgactgcaac ctgcgctatg
180
gcccttcccc cgctcgggtgc agatgttccc gcggctgttg tacatctccg cggaggactt
240
cagcatcgac cacagtccca attccacagc gggcccttcc tgctcgtgc tacaggaggc
300
gtttcggcga tattacaact atgtttttgg tttctacaag agacatcatg gccctgctag
360
atttcgagct gagccacagt tgcagaagct cctggtctcc attaccctcg agtcagagtg
420
cgagtccttc cctagtctgt cttcagatga aacctattct ctgcttgtag aagaaccagt
480
agccgtcctc aaggccaaca gcgtttgggg agcggttaga ggtttagaga cgtttagcca
540
gttagtttac caagactctt tcgggacttt caccatcaat gaatccagta tagctgattc
600
tccaagattc cctcatagag gaattttaat tgatacatct agacacttcc tgctgtgaa
660
gacaatttta aaaactctgg atgccatggc ttttaataag tttaatgttc ttcactggca
720
catagtggac gaccagtctt tcccttatca gaggaccact tttcctgagc taagcaataa
780
gggaagctac tctttgtctc atgtctatac accaaacgat gtccggatgg tgctggagta
840
cgcccggtc cgagggattc gaggcatacc agaatttgat acccctggcc atacacagtc
900
ttggggcaaa ggacagaaaa accttctaac tccatgttac aatcaaaaaa ctaaaactca
960
agtgtttggg cctgtagacc caactgtaaa cacaacgtat gcattcttta acacattttt
1020
caaagaaatc agcagtgtgt ttccagatca gttcatccac ttggggaggag atgaagtaga
1080
atttcaatgt tgggcatcaa atccaaacat ccaaggtttc atgaagagaa agggcttttg
1140

cagcgatttt agaagactag aatcctttta tattaanaag attttggaat ttatttcac
1200

cttaaagaag aactccattg tttggcaaga agtttttgat gataaggagg agcttcagcc
1260

gggcacagta gtcgaagtgt ggaagagtga gcattattca tatgagctaa agcaagtcac
1320

aggctctggc ttccctgcca tctttctgc tcttggtac ttagacctga tcagctatgg
1380

gcaagactgg aaaaactact acaaagttga gcccttaat tttgaaggct ctgagaagca
1440

gaaacaactt gttattgggt gagaagcttg cctgtgggga gaatttgagg atgcaactaa
1500

ccttactcca agattatggc ctgagcaag cgctgttggg gagagactct ggagccctaa
1560

aactgtcact gacctagaaa atgcctacaa acgactggcc gtgcaccgct gcagaatggg
1620

cagccgtgga atagctgcac aacctctcta tactggatac tgtaactatg agaataaaat
1680

atagaagtga cagacgtcta cagcattcca gctatgatca tgttgattct gaaatcatgt
1740

aaattaagat ttgttaggct gttttttttt taaataaacc atctttttat tgattgaatc
1800

tttct
1805

<210> 8
<211> 536
<212> PRT
<213> Murinae gen. sp.

<400> 8

Met Pro Gln Ser Pro Arg Ser Ala Pro Gly Leu Leu Leu Leu Gln Ala
1 5 10 15

Leu Val Ser Leu Val Ser Leu Ala Leu Val Ala Pro Ala Arg Leu Gln
20 25 30

Pro Ala Leu Trp Pro Phe Pro Arg Ser Val Gln Met Phe Pro Arg Leu
35 40 45

Leu Tyr Ile Ser Ala Glu Asp Phe Ser Ile Asp His Ser Pro Asn Ser
50 55 60

PROTEIN

Thr Ala Gly Pro Ser Cys Ser Leu Leu Gln Glu Ala Phe Arg Arg Tyr
65 70 75 80

Tyr Asn Tyr Val Phe Gly Phe Tyr Lys Arg His His Gly Pro Ala Arg
85 90 95

Phe Arg Ala Glu Pro Gln Leu Gln Lys Leu Leu Val Ser Ile Thr Leu
100 105 110

Glu Ser Glu Cys Glu Ser Phe Pro Ser Leu Ser Ser Asp Glu Thr Tyr
115 120 125

Ser Leu Leu Val Gln Glu Pro Val Ala Val Leu Lys Ala Asn Ser Val
130 135 140

Trp Gly Ala Leu Arg Gly Leu Glu Thr Phe Ser Gln Leu Val Tyr Gln
145 150 155 160

Asp Ser Phe Gly Thr Phe Thr Ile Asn Glu Ser Ser Ile Ala Asp Ser
165 170 175

Pro Arg Phe Pro His Arg Gly Ile Leu Ile Asp Thr Ser Arg His Phe
180 185 190

Leu Pro Val Lys Thr Ile Leu Lys Thr Leu Asp Ala Met Ala Phe Asn
195 200 205

Lys Phe Asn Val Leu His Trp His Ile Val Asp Asp Gln Ser Phe Pro
210 215 220

Tyr Gln Ser Thr Thr Phe Pro Glu Leu Ser Asn Lys Gly Ser Tyr Ser
225 230 235 240

Leu Ser His Val Tyr Thr Pro Asn Asp Val Arg Met Val Leu Glu Tyr
245 250 255

Ala Arg Leu Arg Gly Ile Arg Val Ile Pro Glu Phe Asp Thr Pro Gly
260 265 270

His Thr Gln Ser Trp Gly Lys Gly Gln Lys Asn Leu Leu Thr Pro Cys
275 280 285

Tyr Asn Gln Lys Thr Lys Thr Gln Val Phe Gly Pro Val Asp Pro Thr
290 295 300

Val Asn Thr Thr Tyr Ala Phe Phe Asn Thr Phe Phe Lys Glu Ile Ser

305
Ser Val Phe Pro Asp Gln Phe Ile His Leu Gly Gly Asp Glu Val Glu
325 330 335

Phe Gln Cys Trp Ala Ser Asn Pro Asn Ile Gln Gly Phe Met Lys Arg
340 345 350

Lys Gly Phe Gly Ser Asp Phe Arg Arg Leu Glu Ser Phe Tyr Ile Lys
355 360 365

Lys Ile Leu Glu Ile Ile Ser Ser Leu Lys Lys Asn Ser Ile Val Trp
370 375 380

Gln Glu Val Phe Asp Asp Lys Val Glu Leu Gln Pro Gly Thr Val Val
385 390 395 400

Glu Val Trp Lys Ser Glu His Tyr Ser Tyr Glu Leu Lys Gln Val Thr
405 410 415

Gly Ser Gly Phe Pro Ala Ile Leu Ser Ala Pro Trp Tyr Leu Asp Leu
420 425 430

Ile Ser Tyr Gly Gln Asp Trp Lys Asn Tyr Tyr Lys Val Glu Pro Leu
435 440 445

Asn Phe Glu Gly Ser Glu Lys Gln Lys Gln Leu Val Ile Gly Gly Glu
450 455 460

Ala Cys Leu Trp Gly Glu Phe Val Asp Ala Thr Asn Leu Thr Pro Arg
465 470 475 480

Leu Trp Pro Arg Ala Ser Ala Val Gly Glu Arg Leu Trp Ser Pro Lys
485 490 495

Thr Val Thr Asp Leu Glu Asn Ala Tyr Lys Arg Leu Ala Val His Arg
500 505 510

Cys Arg Met Val Ser Arg Gly Ile Ala Ala Gln Pro Leu Tyr Thr Gly
515 520 525

Tyr Cys Asn Tyr Glu Asn Lys Ile
530 535

<210> 9
<211> 1746

<212> DNA
<213> Homo sapiens

<400> 9

ctgatccggg ccgggcggga agtcgggtcc cgaggctccg gctcggcaga ccgggcggaa
60

agcagccgag cggccatgga gctgtgcggg ctggggctgc cccggccgcc catgctgctg
120

gcgctgctgt tggcgacact gctggcggcg atgttggcgc tgctgactca ggtggcgcctg
180

gtggtgcagg tggcggaggc ggctcgggcc ccgagcgtct cggccaagcc ggggcggcgc
240

ctgtggcccc tgccgctctt ggtgaagatg accccgaacc tgctgcatct cggcccggag
300

aacttctaca tcagccacag cccaattcc acggcgggcc cctcctgcac cctgctggag
360

gaagcgtttc gacgatatca tggctatatt tttggtttct acaagtggca tcatgaacct
420

gctgaattcc aggctaaaac ccaggttcag caacttcttg totcaatcac ccttcagtca
480

gagtgtgatg ctttcccca catatcttca gatgagtctt atactttact tgtgaaagaa
540

ccagtggctg tccttaaggc caacagagtt tggggagcat tacgagggtt agagacctt
600

agccagttag tttatcaaga ttcttatgga actttcacca tcaatgaatc caccattatt
660

gattctccaa ggttttctca cagaggaatt ttgattgata catccagaca ttatctgcc
720

gttaagatta ttcttaaaac tctggatgcc atggctttta ataagtttaa tgttcttcac
780

tggcacatag ttgatgacca gtctttccca tatcagagca tcacttttcc tgagttaagc
840

aataaaggaa gctattcttt gtctcatggt tatacaccaa atgatgtccg tatggtgatt
900

gaatatgcca gattacgagg aattcgagtc ctgccagaat ttgatcccc tgggcataca
960

ctatcttggg gaaaaggcca gaaagacctc ctgactccat gttacagtag acaaaacaag
1020

ttggactctt ttggacctat aaaccctact ctgaatacaa catacagctt ccttactaca
1080

tttttcaaag aaattagtga ggtgtttcca gatcaattca ttcatttggg aggagatgaa
1140

gtggaattta aatgttggga atcaaatacca aaaattcaag atttcatgag gcaaaaaggc
1200

tttggcacag attttaagaa actagaatct ttctacattc aaaaggtttt ggatattatt
1260

gcaaccataa acaagggatc cattgtctgg caggaggttt ttgatgataa agcaaagctt
1320

gcgccgggca caatagttga agtatggaaa gacagcgcat atcctgagga actcagtaga
1380

gtcacagcat ctggcttccc tgtaatcctt tctgctcctt ggtacttaga ttgatttagc
1440

tatggacaag attggaggaa atactataaa gtggaacctc ttgattttgg cggtactcag
1500

aaacagaaac aacttttcat tgggtggagaa gcttgtctat ggggagaata tgtggatgca
1560

actaacctca ctccaagatt atggcctcgg gcaagtgcctg ttggtgagag actctggagt
1620

tccaaagatg tcagagatat ggatgacgcc tatgacagac tgacaaggca ccgctgcagg
1680

atggtcgaac gtggaatagc tgcacaacct ctttatgctg gatattgtaa ccatgagaac
1740

atgtaa
1746

<210> 10
<211> 556
<212> PRT
<213> Homo sapiens

<400> 10

Met Glu Leu Cys Gly Leu Gly Leu Pro Arg Pro Pro Met Leu Leu Ala
1 5 10 15

Leu Leu Leu Ala Thr Leu Leu Ala Ala Met Leu Ala Leu Leu Thr Gln
20 25 30

Val Ala Leu Val Val Gln Val Ala Glu Ala Ala Arg Ala Pro Ser Val
35 40 45

Ser Ala Lys Pro Gly Pro Ala Leu Trp Pro Leu Pro Leu Leu Val Lys
50 55 60

Met Thr Pro Asn Leu Leu His Leu Ala Pro Glu Asn Phe Tyr Ile Ser
65 70 75 80

His Ser Pro Asn Ser Thr Ala Gly Pro Ser Cys Thr Leu Leu Glu Glu
85 90 95

Ala Phe Arg Arg Tyr His Gly Tyr Ile Phe Gly Phe Tyr Lys Trp His
100 105 110

His Glu Pro Ala Glu Phe Gln Ala Lys Thr Gln Val Gln Gln Leu Leu
115 120 125

Val Ser Ile Thr Leu Gln Ser Glu Cys Asp Ala Phe Pro Asn Ile Ser
130 135 140

Ser Asp Glu Ser Tyr Thr Leu Leu Val Lys Glu Pro Val Ala Val Leu
145 150 155 160

Lys Ala Asn Arg Val Trp Gly Ala Leu Arg Gly Leu Glu Thr Phe Ser
165 170 175

Gln Leu Val Tyr Gln Asp Ser Tyr Gly Thr Phe Thr Ile Asn Glu Ser
180 185 190

Thr Ile Ile Asp Ser Pro Arg Phe Ser His Arg Gly Ile Leu Ile Asp
195 200 205

Thr Ser Arg His Tyr Leu Pro Val Lys Ile Ile Leu Lys Thr Leu Asp
210 215 220

Ala Met Ala Phe Asn Lys Phe Asn Val Leu His Trp His Ile Val Asp
225 230 235 240

Asp Gln Ser Phe Pro Tyr Gln Ser Ile Thr Phe Pro Glu Leu Ser Asn
245 250 255

Lys Gly Ser Tyr Ser Leu Ser His Val Tyr Thr Pro Asn Asp Val Arg
260 265 270

Met Val Ile Glu Tyr Ala Arg Leu Arg Gly Ile Arg Val Leu Pro Glu
275 280 285

Phe Asp Thr Pro Gly His Thr Leu Ser Trp Gly Lys Gly Gln Lys Asp
290 295 300

Leu Leu Thr Pro Cys Tyr Ser Arg Gln Asn Lys Leu Asp Ser Phe Gly
305 310 315 320

Pro Ile Asn Pro Thr Leu Asn Thr Thr Tyr Ser Phe Leu Thr Thr Phe

325

330

335

Phe Lys Glu Ile Ser Glu Val Phe Pro Asp Gln Phe Ile His Leu Gly
340 345 350

Gly Asp Glu Val Glu Phe Lys Cys Trp Glu Ser Asn Pro Lys Ile Gln
355 360 365

Asp Phe Met Arg Gln Lys Gly Phe Gly Thr Asp Phe Lys Lys Leu Glu
370 375 380

Ser Phe Tyr Ile Gln Lys Val Leu Asp Ile Ile Ala Thr Ile Asn Lys
385 390 395 400

Gly Ser Ile Val Trp Gln Glu Val Phe Asp Asp Lys Ala Lys Leu Ala
405 410 415

Pro Gly Thr Ile Val Glu Val Trp Lys Asp Ser Ala Tyr Pro Glu Glu
420 425 430

Leu Ser Arg Val Thr Ala Ser Gly Phe Pro Val Ile Leu Ser Ala Pro
435 440 445

Trp Tyr Leu Asp Leu Ile Ser Tyr Gly Gln Asp Trp Arg Lys Tyr Tyr
450 455 460

Lys Val Glu Pro Leu Asp Phe Gly Gly Thr Gln Lys Gln Lys Gln Leu
465 470 475 480

Phe Ile Gly Gly Glu Ala Cys Leu Trp Gly Glu Tyr Val Asp Ala Thr
485 490 495

Asn Leu Thr Pro Arg Leu Trp Pro Arg Ala Ser Ala Val Gly Glu Arg
500 505 510

Leu Trp Ser Ser Lys Asp Val Arg Asp Met Asp Asp Ala Tyr Asp Arg
515 520 525

Leu Thr Arg His Arg Cys Arg Met Val Glu Arg Gly Ile Ala Ala Gln
530 535 540

Pro Leu Tyr Ala Gly Tyr Cys Asn His Glu Asn Met
545 550 555

<210> 11
<211> 676

<212> DNA
<213> Murinae gen. sp.

<220>
<221> misc_feature
<222> (604)..(604)
<223> n is a, c, g, or t

<400> 11
ggagctggtg ggccggagcg gcggcgccgc catgtccgac agcgagaagc tcaacctgga
60

ctccatcatc gggcgctgc tggaagtga gggctcacgg cctgggaaga acgtgcagct
120

gacagagaac gagatccgtg gtctgtgctt caaatcccgg gagattttcc tgagccagcc
180

cattcttctg gagcttgagg cgcctctcaa gatctgtggt gacatccatg gccagtacta
240

tgaccttcta cggctgtttg agtatggtgg cttccctcca gagagcaact acctcttctt
300

gggggattat gtagatcggg gcaagcagtc tttggagacc atctgcctgt tgctggccta
360

taagatcaga taccgggaga atttctttct acttcgtggg aacctgaggt gtgccagcat
420

caaccgcatt tatggcttct atgatgaatg caagagaaga tacaacatca aactgtggaa
480

gacgttcact gactgcttca actgcctgcc cattgcagcc attgtggatg agaagatctt
540

ctgctgccac gggggcctgt ctccagactt gcaatccatg gagcagatta ggcgtattat
600

gcgngccaca gacgtgcctg accagggcct actgtgtgat ctctgtggt ctgaccctga
660

caagaaatag cctcca
676

<210> 12
<211> 1369
<212> DNA
<213> Murinae gen. sp.

<400> 12
ggaggcagga gagggcccgg agctggtggg ccggagcggc ggccgcccca tgtccgacag
60

cgagaagctc aacctggact ccatcatcgg gcgcctgctg gaagtgcagg gctcacggcc
120

tgggaagaac gtgcagctga cagagaacga gatccgtggt ctgtgcctca aatcccggga
180

gattttcctg agccagccca ttcttctgga gcttgaggcg cccctcaaga tctgtggtga
240

catccatggc cagtactatg accttctacg gctgtttgag tatggtggct tccctccaga
300

gagcaactac ctcttcttgg gggattatgt agatcggggc aagcagtctt tggagaccat
360

ctgcctgttg ctggcctata agatcagata cccggagaat ttctttctac ttcgtgggaa
420

ccatgagtgt gccagcatca accgcattta tggcttctat gatgaatgca agagaagata
480

caacatcaaa ctgtggaaga cgttcaactga ctgcttcaac tgccctgocca ttgcagccat
540

tgtggatgag aagatcttct gctgccacgg gggcctgtct ccagacttgc aatccatgga
600

gcagattagg cgtattatgc ggcccacaga cgtgcctgac cagggcctac tgtgtgatct
660

cctgtggtct gaccctgaca aggatgttca aggctggggc gagaatgacc gtggtgtctc
720

ctttaccttt ggggctgagg tggtagccaa gttcctgcac aagcatgatt tggacctcat
780

ctgcagagca catcaggttg tagaagatgg ctatgagttc tttgccaaga gacagttggt
840

gacactcttc tcagctccca actactgtgg agagtttgac aatgctgggt ccatgatgag
900

tgtggatgag accctcatgt gttccttcca gatcctcaag cccgctgata agaataaggg
960

caagtatggg cagttcagcg gcctgaaccc cggaggccgg cccatcactc caccgccaa
1020

ttctgccaaa gccaaagaaat agcctccatg tgctgccott ctgcccaga tcgtttgtac
1080

agaaatcatg ctgccatggg tcacactggc ctctcaggcc caccgctcac ggggaacaca
1140

cagcgttaag tgtctttcct ttatttttta aagaatcaat agcagcatct aatctcccag
1200

ggctccctcc caccagcacc tgtggtggct gcaagtggaa tcctggggcc aaggctgcag
1260

ctcagggcaa tggcagacca gattgtgggt ctccagcctt gcattggctgg cagccagatc
1320

ctggggcaac ccatctggtc tcttgaataa aggtcaaagc tggattctc
1369

<210> 13
 <211> 330
 <212> PRT
 <213> Murinae gen. sp.

<400> 13

Met Ser Asp Ser Glu Lys Leu Asn Leu Asp Ser Ile Ile Gly Arg Leu
 1 5 10 15

Leu Glu Val Gln Gly Ser Arg Pro Gly Lys Asn Val Gln Leu Thr Glu
 20 25 30

Asn Glu Ile Arg Gly Leu Cys Leu Lys Ser Arg Glu Ile Phe Leu Ser
 35 40 45

Gln Pro Ile Leu Leu Glu Leu Glu Ala Pro Leu Lys Ile Cys Gly Asp
 50 55 60

Ile His Gly Gln Tyr Tyr Asp Leu Leu Arg Leu Phe Glu Tyr Gly Gly
 65 70 75 80

Phe Pro Pro Glu Ser Asn Tyr Leu Phe Leu Gly Asp Tyr Val Asp Arg
 85 90 95

Gly Lys Gln Ser Leu Glu Thr Ile Cys Leu Leu Leu Ala Tyr Lys Ile
 100 105 110

Arg Tyr Pro Glu Asn Phe Phe Leu Leu Arg Gly Asn His Glu Cys Ala
 115 120 125

Ser Ile Asn Arg Ile Tyr Gly Phe Tyr Asp Glu Cys Lys Arg Arg Tyr
 130 135 140

Asn Ile Lys Leu Trp Lys Thr Phe Thr Asp Cys Phe Asn Cys Leu Pro
 145 150 155 160

Ile Ala Ala Ile Val Asp Glu Lys Ile Phe Cys Cys His Gly Gly Leu
 165 170 175

Ser Pro Asp Leu Gln Ser Met Glu Gln Ile Arg Arg Ile Met Arg Pro
 180 185 190

Thr Asp Val Pro Asp Gln Gly Leu Leu Cys Asp Leu Leu Trp Ser Asp
 195 200 205

Pro Asp Lys Asp Val Gln Gly Trp Gly Glu Asn Asp Arg Gly Val Ser

210

215

220

Phe Thr Phe Gly Ala Glu Val Val Ala Lys Phe Leu His Lys His Asp
225 230 235 240

Leu Asp Leu Ile Cys Arg Ala His Gln Val Val Glu Asp Gly Tyr Glu
245 250 255

Phe Phe Ala Lys Arg Gln Leu Val Thr Leu Phe Ser Ala Pro Asn Tyr
260 265 270

Cys Gly Glu Phe Asp Asn Ala Gly Ala Met Met Ser Val Asp Glu Thr
275 280 285

Leu Met Cys Ser Phe Gln Ile Leu Lys Pro Ala Asp Lys Asn Lys Gly
290 295 300

Lys Tyr Gly Gln Phe Ser Gly Leu Asn Pro Gly Gly Arg Pro Ile Thr
305 310 315 320

Pro Pro Arg Asn Ser Ala Lys Ala Lys Lys
325 330

<210> 14

<211> 993

<212> DNA

<213> Homo sapiens

<400> 14

atgtccgaca gcgagaagct caacctggac tcgatcatcg ggcgcctgct ggaagtgcag
60

ggctcgcggc ctggcaagaa tgtacagctg acagagaacg agatccgcgg tctgtgcctg
120

aatccccggg agatttttct gagccagccc attcttctgg agctggaggc acccctcaag
180

atctgcggtg acatacacgg ccagtactac gaccttctgc gactatttga gtatggcggg
240

ttccctcccg agagcaacta cctctttctg ggggactatg tggacagggg caagcagtc
300

ttggagacca tctgcctgct gctggcctat aagatcaagt accccgagaa cttcttctg
360

ctccgtggga accacgagtg tgccagcatc aaccgcatct atggtttcta cgatgagtgc
420

aagagacgct acaacatcaa actgtggaaa accttcactg actgcttcaa ctgcctgccc
480

atcgcgccca tagtggacga aaagatcttc tgctgccacg gaggcctgtc cccggacctg
540

cagtctatgg agcagattcg gcggatcatg cggcccacag atgtgcctga ccagggcctg
600

ctgtgtgacc tgctgtggtc tgaccctgac aaggacgtgc agggctgggg cgagaacgac
660

cgtggcgtct cttttacctt tggagccgag gtgggtggcca agttcctcca caagcacgac
720

ttggacctca tctgccgagc acaccaggtg gtagaagacg gctacgagtt ctttgccaag
780

cggcagctgg tgacactttt ctcagctccc aactactgtg gcgagtttga caatgctggc
840

gccatgatga gtgtggacga gaccctcatg tgctcttttc agatcctcaa gcccgccgac
900

aagaacaagg ggaagtacgg gcagttcagt ggctgaacc ctggaggccg acccatcacc
960

ccaccccgca attccgccaa agccaagaaa tag
993

<210> 15
<211> 330
<212> PRT
<213> Homo sapiens

<400> 15

Met	Ser	Asp	Ser	Glu	Lys	Leu	Asn	Leu	Asp	Ser	Ile	Ile	Gly	Arg	Leu
1				5					10					15	

Leu	Glu	Val	Gln	Gly	Ser	Arg	Pro	Gly	Lys	Asn	Val	Gln	Leu	Thr	Glu
			20					25					30		

Asn	Glu	Ile	Arg	Gly	Leu	Cys	Leu	Lys	Ser	Arg	Glu	Ile	Phe	Leu	Ser
		35					40					45			

Gln	Pro	Ile	Leu	Leu	Glu	Leu	Glu	Ala	Pro	Leu	Lys	Ile	Cys	Gly	Asp
	50					55					60				

Ile	His	Gly	Gln	Tyr	Tyr	Asp	Leu	Leu	Arg	Leu	Phe	Glu	Tyr	Gly	Gly
65					70					75				80	

Phe	Pro	Pro	Glu	Ser	Asn	Tyr	Leu	Phe	Leu	Gly	Asp	Tyr	Val	Asp	Arg
				85					90					95	

Gly	Lys	Gln	Ser	Leu	Glu	Thr	Ile	Cys	Leu	Leu	Leu	Ala	Tyr	Lys	Ile
			100					105					110		

Lys Tyr Pro Glu Asn Phe Phe Leu Leu Arg Gly Asn His Glu Cys Ala
115 120 125

Ser Ile Asn Arg Ile Tyr Gly Phe Tyr Asp Glu Cys Lys Arg Arg Tyr
130 135 140

Asn Ile Lys Leu Trp Lys Thr Phe Thr Asp Cys Phe Asn Cys Leu Pro
145 150 155 160

Ile Ala Ala Ile Val Asp Glu Lys Ile Phe Cys Cys His Gly Gly Leu
165 170 175

Ser Pro Asp Leu Gln Ser Met Glu Gln Ile Arg Arg Ile Met Arg Pro
180 185 190

Thr Asp Val Pro Asp Gln Gly Leu Leu Cys Asp Leu Leu Trp Ser Asp
195 200 205

Pro Asp Lys Asp Val Gln Gly Trp Gly Glu Asn Asp Arg Gly Val Ser
210 215 220

Phe Thr Phe Gly Ala Glu Val Val Ala Lys Phe Leu His Lys His Asp
225 230 235 240

Leu Asp Leu Ile Cys Arg Ala His Gln Val Val Glu Asp Gly Tyr Glu
245 250 255

Phe Phe Ala Lys Arg Gln Leu Val Thr Leu Phe Ser Ala Pro Asn Tyr
260 265 270

Cys Gly Glu Phe Asp Asn Ala Gly Ala Met Met Ser Val Asp Glu Thr
275 280 285

Leu Met Cys Ser Phe Gln Ile Leu Lys Pro Ala Asp Lys Asn Lys Gly
290 295 300

Lys Tyr Gly Gln Phe Ser Gly Leu Asn Pro Gly Gly Arg Pro Ile Thr
305 310 315 320

Pro Pro Arg Asn Ser Ala Lys Ala Lys Lys
325 330

<210> 16
<211> 702
<212> DNA

<213> Murinae gen. sp.

<400> 16

ggcatgacag gcagtgagca ggtgatgagc cagggttggtg atctcttttag tgagggaata
60

ggctgctgga gatatggctg tgggtctacaa ggaggctggg gaactagcaa ggagatgctc
120

tctcagctat cacagcctta cagcaaagcc actatctctt tggattttga aattttctct
180

gccatgccta tgactatttt aaaattgggc aaagtatatc catttcagag gggctttttc
240

tgtactgaca acagcgtgaa gtaccogtac catgacagta ccatcccgtc ccgtatactc
300

gccatactgg ggcttggctt acccattttc tctatgagta tggagaatct ctgtctgttt
360

actttaatgt cttgcattcg aattcctttg tcggcaatcc ctacatagcc accatttaca
420

aagccgtcgg agccttttgt tcggagtctc agctagtcag tccttgaactg acatcgctaa
480

gtatactata ggcagtttgc ggccgcactt cttggctatc tgtaaccag actggtcaaa
540

aatcaactgc agtgatggct atattgagga ctacatatgt caagggaatg aagagaaagt
600

caaggagggc aggttgtctt tctactcggg acactcttca ttctctatgt actgcatgct
660

gtttgtcgca ctttatcttc aagccaggat gaaggagac tg
702

<210> 17

<211> 1432

<212> DNA

<213> Murinae gen. sp.

<400> 17

catccttaga gctcgcccg gctgttgag agggcacagg gcagcggagg gcgattggcc
60

gcgacgagcc agcactgaga gagcaggcgc ctgaggcgac agatcggcgg ccactcgggtg
120

gcagggcggc ccaatccaaa ctgccttggc ccctgctccc gtcagtctaa gaggctcgca
180

gtcgtttggg gcggccgcca tcccaggggc ggggctctgg gaattgggta tctggaccgc
240

cgcggtctgt tcctcccgcc actcgcacca ggtgggtgaca ccatccagcc ggtgaccatg
300

ttcgacaaga cgcggtgcc gtacgtggcc ctcgatgtga tttgcgtgtt gctggctgga
360

ttgccttttg caattcttac ttcaaggcat acccccttcc agogaggaat attctgtaat
420

gatgactcca tcaagtaccc ttacaaggaa gacaccatac cttatgcctt attaggtgga
480

atagtcattc cattctgtat tatcgttatg agtattggag aatctctgtc tgtttacttt
540

aatgtcttgc attcgaattc ctttgtcggc aatccctaca tagccaccat ttacaaagcc
600

gtcggagcct ttttgttcgg agtctcagct agtcagtcct tgactgacat cgctaagtat
660

actataggca gtttgcggcc gcacttcttg gctatctgta acccagactg gtcaaaaatc
720

aactgcagtg atggctatat tgaggactac atatgtcaag ggaatgaaga gaaagtcaag
780

gagggcaggt tgtctttcta ctggggacac tcttcattct ctatgtactg catgctgttt
840

gtcgcacttt atcttcaagc caggatgaag ggagactggg caagactctt acgacccatg
900

ctccagtttg ggetcattgc tttttccata tatgtgggcc tttctcgagt gtctgactac
960

aaacaccact ggagtgcagt cacagttgga ctcatteagg gagctgctat ggctatactg
1020

gttgctttgt atgtatccga tttcttcaag gacacacatt cttacaaaga gagaaaggaa
1080

gaggatccac acacgactct ccatgaaacc gccagttcac ggaactactg ggcgctggcc
1140

cgcttcaaag gcaacagctg gaggctaaag gcagggggat gcgtattact tcctgctgta
1200

cagaccattc tataaaggac tgctgctatc tatacctcct ggatgcccat tttatgtgtg
1260

tacagttact tctaacacaa tgagtaacag ttcaattaaa gaaaatgaag cctgtcacta
1320

aaacactgtc ccacctgtac atttttattg aaagacgcta tgtacaaatg tgtatgttac
1380

atgccttctc agaatgatgt tgacttaaata ataataaaaa gcttgtgaac ca
1432

<210> 18
<211> 378
<212> PRT

<213> Murinae gen. sp.

<400> 18

Glu Ser Arg Arg Leu Arg Arg Gln Ile Gly Gly His Ser Val Ala Gly
1 5 10 15

Arg Pro Asn Pro Asn Cys Pro Gly Pro Cys Ser Arg Gln Ser Lys Arg
20 25 30

Leu Ala Val Ala Trp Gly Gly Arg His Pro Glu Gly Gly Ala Leu Gly
35 40 45

Ile Gly Tyr Leu Asp Arg Arg Gly Leu Phe Leu Pro Pro Leu Ala Pro
50 55 60

Gly Gly Asp Thr Ile Gln Pro Val Thr Met Phe Asp Lys Thr Arg Leu
65 70 75 80

Pro Tyr Val Ala Leu Asp Val Ile Cys Val Leu Leu Ala Gly Leu Pro
85 90 95

Phe Ala Ile Leu Thr Ser Arg His Thr Pro Phe Gln Arg Gly Ile Phe
100 105 110

Cys Asn Asp Asp Ser Ile Lys Tyr Pro Tyr Lys Glu Asp Thr Ile Pro
115 120 125

Tyr Ala Leu Leu Gly Gly Ile Val Ile Pro Phe Cys Ile Ile Val Met
130 135 140

Ser Ile Gly Glu Ser Leu Ser Val Tyr Phe Asn Val Leu His Ser Asn
145 150 155 160

Ser Phe Val Gly Asn Pro Tyr Ile Ala Thr Ile Tyr Lys Ala Val Gly
165 170 175

Ala Phe Leu Phe Gly Val Ser Ala Ser Gln Ser Leu Thr Asp Ile Ala
180 185 190

Lys Tyr Thr Ile Gly Ser Leu Arg Pro His Phe Leu Ala Ile Cys Asn
195 200 205

Pro Asp Trp Ser Lys Ile Asn Cys Ser Asp Gly Tyr Ile Glu Asp Tyr
210 215 220

Ile Cys Gln Gly Asn Glu Glu Lys Val Lys Glu Gly Arg Leu Ser Phe

225 230 235 240
Tyr Ser Gly His Ser Ser Phe Ser Met Tyr Cys Met Leu Phe Val Ala
245 250 255
Leu Tyr Leu Gln Ala Arg Met Lys Gly Asp Trp Ala Arg Leu Leu Arg
260 265 270
Pro Met Leu Gln Phe Gly Leu Ile Ala Phe Ser Ile Tyr Val Gly Leu
275 280 285
Ser Arg Val Ser Asp Tyr Lys His His Trp Ser Asp Val Thr Val Gly
290 295 300
Leu Ile Gln Gly Ala Ala Met Ala Ile Leu Val Ala Leu Tyr Val Ser
305 310 315 320
Asp Phe Phe Lys Asp Thr His Ser Tyr Lys Glu Arg Lys Glu Glu Asp
325 330 335
Pro His Thr Thr Leu His Glu Thr Ala Ser Ser Arg Asn Tyr Trp Ala
340 345 350
Leu Ala Arg Phe Lys Gly Asn Ser Trp Arg Leu Lys Ala Gly Gly Cys
355 360 365
Val Leu Leu Pro Ala Val Gln Thr Ile Leu
370 375
<210> 19
<211> 1626
<212> DNA
<213> Homo sapiens
<400> 19
tcagcgggag gggctggacc ccgcgttcct cctccctgcc ggtcccccata cttaaagcga
60
gagtctggac gccccgcctg tgggagagag cgccgggata cggacgggga gcaaccgggg
120
caggccgtgc cggctgagga ggtcctgagg ctacagagct gccgcggctg gcacacgagc
180
gcctcggcac taaccgagtg ttcgcggggg ctgtgagggg agggccccgg gcgccattgc
240
tggcgggtggg agcgcgcgcc ggtctcagcc cgccctcggc tgctctctc ctccggctgg
300

gaggggcccgt agtcgggggc cgtcgccagc cccggcccgg gctcgagaat caagggcctc
360

ggccgcccgtc ccgcagctca gtccatcgcc ctggccgggc agcccgggca gagaccatgt
420

ttgacaagac ggggctgccg tacgtggccc tcgatgtgct ctgcgtgttg ctggcttcca
480

tgcctatggc tgttctaaaa ttgggcccac tatatccatt tcagagaggc tttttctgta
540

aagacaacag catcaactat ccgtaccatg acagtaccgt cacatccact gtcctcatcc
600

tagtgggggt tggcttgccc atttcctcta ttattcttgg agaaaccctg tctgtttact
660

gtaacctttt gcactcaaatt tcctttatca ggaataacta catagccact atttacaag
720

ccattggaac ctttttattt ggtgcagctg ctagtcagtc cctgactgac attgccaagt
780

attcaatagg cagactgcgg cctcacttct tggatgtttg tgatccagat tgggtcaaaaa
840

tcaactgcag cgatgggttac attgaatact acatatgtcg aggggaatgca gaaagagtta
900

aggaaggcag gttgtccttc tattcaggcc actcttcgtt ttocatgtac tgcattgctg
960

ttgtggcact ttatcttcaa gccaggatga agggagactg ggcaagactc ttacgcccc
1020

cactgcaatt tgggtcttgtt gccgtatcca tttatgtggg cctttctcga gtttctgatt
1080

ataaacacca ctggagcgat gtgttgactg gactcattca gggagctctg gttgcaatat
1140

tagttgctgt atatgtatcg gatttcttca aagaaagaac ttctttttaa gaaagaaaag
1200


aggaggactc tcatacaact ctgcatgaaa caccaacaac tgggaatcac tatccgagca
1260

atcaccagcc ttgaaaggca gcagggtgcc caggtgaagc tggcctgttt tctaaaggaa
1320

aatgattgcc acaaggcaag aggatgcac tttcttctctg gtgtacaagc ctttaagac
1380

ttctgctgct gctatgcctc ttggatgcac actttgtgtg tacatagtta cttttaactc
1440

agtggttatc taatagctct aaactcatta aaaaaactcc aagccttcca ccaaaacagt
1500



gccccacotg tatacatttt tattaaaaaa atgtaatgct tatgtataaa catgtatgta
1560

atatgctttc tatgaatgat gtttgattta aatataatac atattaaaat gtatgggaga
1620

accaa
1626

```
<210> 20
<211> 378
<212> PRT
<213> Homo sapiens
```

<400> 20

Gly Gly Pro Glu Ala Thr Glu Leu Pro Arg Leu Ala His Glu Arg Leu
1 5 10 15

Gly Thr Asn Arg Val Phe Ala Gly Ala Val Arg Gly Gly Pro Arg Ala
20 25 30

Pro Leu Leu Ala Val Gly Ala Pro Pro Gly Leu Ser Pro Pro Ser Ala
35 40 45

Ala Leu Leu Leu Arg Leu Gly Gly Ala Val Ala Arg Gly Arg Arg Gln
50 55 60

Pro Arg Pro Gly Leu Glu Asn Gln Gly Pro Arg Pro Pro Ser Arg Ser
65 70 75 80

Ser Val His Arg Pro Cys Arg Ala Ala Arg Ala Glu Thr Met Phe Asp
85 90 95

Lys Thr Arg Leu Pro Tyr Val Ala Leu Asp Val Leu Cys Val Leu Leu
100 105 110

Ala Ser Met Pro Met Ala Val Leu Lys Leu Gly Gln Ile Tyr Pro Phe
115 120 125

Gln Arg Gly Phe Phe Cys Lys Asp Asn Ser Ile Asn Tyr Pro Tyr His
130 135 140

Asp Ser Thr Val Thr Ser Thr Val Leu Ile Leu Val Gly Val Gly Leu
145 150 155 160

Pro Ile Ser Ser Ile Ile Leu Gly Glu Thr Leu Ser Val Tyr Cys Asn
165 170 175

Leu Leu His Ser Asn Ser Phe Ile Arg Asn Asn Tyr Ile Ala Thr Ile
180 185 190

Tyr Lys Ala Ile Gly Thr Phe Leu Phe Gly Ala Ala Ala Ser Gln Ser
195 200 205

Leu Thr Asp Ile Ala Lys Tyr Ser Ile Gly Arg Leu Arg Pro His Phe
210 215 220

Leu Asp Val Cys Asp Pro Asp Trp Ser Lys Ile Asn Cys Ser Asp Gly
225 230 235 240

Tyr Ile Glu Tyr Tyr Ile Cys Arg Gly Asn Ala Glu Arg Val Lys Glu
245 250 255

Gly Arg Leu Ser Phe Tyr Ser Gly His Ser Ser Phe Ser Met Tyr Cys
260 265 270

Met Leu Phe Val Ala Leu Tyr Leu Gln Ala Arg Met Lys Gly Asp Trp
275 280 285

Ala Arg Leu Leu Arg Pro Thr Leu Gln Phe Gly Leu Val Ala Val Ser
290 295 300

Ile Tyr Val Gly Leu Ser Arg Val Ser Asp Tyr Lys His His Trp Ser
305 310 315 320

Asp Val Leu Thr Gly Leu Ile Gln Gly Ala Leu Val Ala Ile Leu Val
325 330 335

Ala Val Tyr Val Ser Asp Phe Phe Lys Glu Arg Thr Ser Phe Lys Glu
340 345 350

Arg Lys Glu Glu Asp Ser His Thr Thr Leu His Glu Thr Pro Thr Thr
355 360 365

Gly Asn His Tyr Pro Ser Asn His Gln Pro
370 375

<210> 21
<211> 816
<212> DNA
<213> Homo sapiens

<400> 21
atttattccc ttttgctagc tggattgcct tttgcaattc ttacttcaag gcataccccc
60

ttccaacgag gagtattctg taatgatgag tccatcaagt acccttacaagaagacacc
120

ataccttatg cgttattagg tggaataatc attccattca gtattatcgt tattattctt
180

ggagaaaccc tgtctgttta ctgtaacctt ttgcactcaa attcctttat caggaataac
240

tacatagcca ctatttacaagaagcattgga acccttttat ttggtgcagc tgctagtcag
300

tccctgactg acattgcca gtattcaata ggcagactgc ggcctcactt cttggatggt
360

tgtgatccag attggtcaaa aatcaactgc agcgatgggt acattgaata ctacatatgt
420

cgagggaatg cagaaagagt taaggaaggc aggttgtcct tctattcagg ccactcttcg
480

ttttccatgt actgcatgct gtttgtggca ctttatcttc aagccaggat gaaggagac
540

tgggcaagac tcttacgccc cacactgcaa ttggtcttg ttgccgtatc catttatgtg
600

ggcctttctc gaggtttctga ttataaacac cactggagcg atgtgttgac tggactcatt
660

caggagctc tgggtgcaat attagttgct gtatatgtat cggatttctt caaagaaaga
720

acttctttta aagaaagaaa agaggaggac tctcatacaa ctctgcatga aacaccaaca
780

actgggaatc actatccgag caatcaccag ccttga
816

<210> 22
<211> 271
<212> PRT
<213> Homo sapiens

<400> 22

Ile Tyr Ser Leu Leu Leu Ala Gly Leu Pro Phe Ala Ile Leu Thr Ser
1 5 10 15

Arg His Thr Pro Phe Gln Arg Gly Val Phe Cys Asn Asp Glu Ser Ile
20 25 30

Lys Tyr Pro Tyr Lys Glu Asp Thr Ile Pro Tyr Ala Leu Leu Gly Gly
35 40 45

Ile Ile Ile Pro Phe Ser Ile Ile Val Ile Ile Leu Gly Glu Thr Leu
50 55 60

Ser Val Tyr Cys Asn Leu Leu His Ser Asn Ser Phe Ile Arg Asn Asn
65 70 75 80

Tyr Ile Ala Thr Ile Tyr Lys Ala Ile Gly Thr Phe Leu Phe Gly Ala
85 90 95

Ala Ala Ser Gln Ser Leu Thr Asp Ile Ala Lys Tyr Ser Ile Gly Arg
100 105 110

Leu Arg Pro His Phe Leu Asp Val Cys Asp Pro Asp Trp Ser Lys Ile
115 120 125

Asn Cys Ser Asp Gly Tyr Ile Glu Tyr Tyr Ile Cys Arg Gly Asn Ala
130 135 140

Glu Arg Val Lys Glu Gly Arg Leu Ser Phe Tyr Ser Gly His Ser Ser
145 150 155 160

Phe Ser Met Tyr Cys Met Leu Phe Val Ala Leu Tyr Leu Gln Ala Arg
165 170 175

Met Lys Gly Asp Trp Ala Arg Leu Leu Arg Pro Thr Leu Gln Phe Gly
180 185 190

Leu Val Ala Val Ser Ile Tyr Val Gly Leu Ser Arg Val Ser Asp Tyr
195 200 205

Lys His His Trp Ser Asp Val Leu Thr Gly Leu Ile Gln Gly Ala Leu
210 215 220

Val Ala Ile Leu Val Ala Val Tyr Val Ser Asp Phe Phe Lys Glu Arg
225 230 235 240

Thr Ser Phe Lys Glu Arg Lys Glu Glu Asp Ser His Thr Thr Leu His
245 250 255

Glu Thr Pro Thr Thr Gly Asn His Tyr Pro Ser Asn His Gln Pro
260 265 270

<210> 23
<211> 840
<212> DNA
<213> Murinae gen. sp.

<220>

<221> misc_feature
<222> (474)..(474)
<223> n is a, c, g, or t

<400> 23
ccgaagtaag ttgccagtt ttctgtotta tactgagggt cgccgggtca tgggtgccage
60

ctgactgaga agaggacgct cccgggaaac gaatgaggaa ccacctctc ctgctgttca
120

agtacagggg cctgggtgcg aaagggaaga aaagcaaaag acgaaaatgg ctaaatttaa
180

gatcogtcca gccactgocct ctgactgcag tgacatcctg cgactgatca aggaactggc
240

taaatatgaa tacatggaag atcaagtcatt tttaactgag aaagatctcc aagaggatgg
300

ctttggagaa caccctttct accactgcct ggttgacagaa gtgcctaaag agcactggac
360

ccctgaagga catagcattg ttgggttcgc catgtactat ttacctatg acccatggat
420

tggcaagttg ctgtatcttg aagacttctt cgtgatgagt gattacagag gctntggat
480

aggatcagaa attttgaaga atctaagcca ggttgccatg aagtgtcgct gcagcagtat
540

gcacttcttg gtagcagaat ggaatgaacc atctatcaac ttctacaaaa gaagaggtgc
600

ttcggatctg tccagtgaag agggatggga ggctcttcaa gattgacaag agtacttgct
660

aaaaatggca gcagaggagt gaggcgtgcc ggtgtagaac atgacaacct ccattgtgct
720

ttagaataat tctcagcttc ccttgcttct tatcttctgg ttaggtgaa ataatagagc
780

gagccaccat tccaaagctt tattaccagt gacgtgttgc atgtttgaaa tcggtctggt
840

<210> 24
<211> 1052
<212> DNA
<213> Murinae gen. sp.

<400> 24
gctgcgcagt ttccccgaag taagtttgcc agttttctgt cttatactga ggttcgccgg
60

gtcatgggtgc cagcctgact gagaagagga cgctccccgg aaacgaatga ggaaccacct
120

PRJ03.12.03

cctcctgctg ttcaagtaca ggggcctggt ggcgcaaaggg aagaaaagca aaagacgaaa
180

atggctaaat ttaagatccg tccagccact gcctctgact gcagtgcacat cctgcgactg
240

atcaaggaac tggctaaata tgaatacatg gaagatcaag tcattttaac tgagaaagat
300

ctccaagagg atggcttttg agaacacccc ttctaccact gcctggttgc agaagtgcct
360

aaagagcact ggacccctga aggacatagc attgttgggt tcgccatgta ctattttacc
420

tatgacccat ggattggcaa gttgctgtat cttgaagact tcttcgtgat gagtgattac
480

agaggctttg gtataggatc agaaattttg aagaatctaa gccaggttgc catgaagtgt
540

cgctgcagca gtatgcactt cttggtagca gaatggaatg aaccatctat caacttctac
600

aaaagaagag gtgcttcgga tctgtccagt gaagagggat ggaggctctt caagattgac
660

aaagagtact tgctaaaaat ggcagcagag gagtgaggcg tgccggtgta gacaatgaca
720

acctccattg tgcttttagaa taattctcag ctcccttgc tttctatctt gtgtgtagtg
780

aaataataga ggcagcaccc attccaaagc tttattacca gtgacgttgt tgcattgttg
840

aaattcggtc tgttttaaagt ggcagtcatt tatgtggttt ggaggcagaa ttcttgaaca
900

tcttttgatg aagaacaagg tggtagatc ttactatata agaaaaacaa aacttcattc
960

ttgtgagtca tttaaagtgt tacaatgtac aactgggtac ttagagtttc tgttttgatt
1020

cttttttttt taaataaaact actctttgat tt
1052

<210> 25
<211> 171
<212> PRT
<213> Murinae gen. sp.

<400> 25

Met	Ala	Lys	Phe	Lys	Ile	Arg	Pro	Ala	Thr	Ala	Ser	Asp	Cys	Ser	Asp
1				5					10					15	

Ile Leu Arg Leu Ile Lys Glu Leu Ala Lys Tyr Glu Tyr Met Glu Asp

PROTEIN DATA

20

25

30

Gln Val Ile Leu Thr Glu Lys Asp Leu Gln Glu Asp Gly Phe Gly Glu
35 40 45

His Pro Phe Tyr His Cys Leu Val Ala Glu Val Pro Lys Glu His Trp
50 55 60

Thr Pro Glu Gly His Ser Ile Val Gly Phe Ala Met Tyr Tyr Phe Thr
65 70 75 80

Tyr Asp Pro Trp Ile Gly Lys Leu Leu Tyr Leu Glu Asp Phe Phe Val
85 90 95

Met Ser Asp Tyr Arg Gly Phe Gly Ile Gly Ser Glu Ile Leu Lys Asn
100 105 110

Leu Ser Gln Val Ala Met Lys Cys Arg Cys Ser Ser Met His Phe Leu
115 120 125

Val Ala Glu Trp Asn Glu Pro Ser Ile Asn Phe Tyr Lys Arg Arg Gly
130 135 140

Ala Ser Asp Leu Ser Ser Glu Glu Gly Trp Arg Leu Phe Lys Ile Asp
145 150 155 160

Lys Glu Tyr Leu Leu Lys Met Ala Ala Glu Glu
165 170

<210> 26
<211> 1111
<212> DNA
<213> Homo sapiens

<400> 26
gcgagctct tagtcgctgg cgcactggtg tttatccgtc actcgccgag gttccttggg
60

tcatggtgcc agcctgactg agaagaggac gctcccggga gacgaatgag gaaccacctc
120

ctcctactgt tcaagtacag gggcctgggtc cgcaaaggga agaaaagcaa aagacgaaaa
180

tggctaaatt cgtgatccgc ccagccactg ccgcccactg cagtgcacata ctgcggctga
240

tcaaggagct ggctaaatat gaatacatgg aagaacaagt aatcttaact gaaaaagatc
300

tgctagaaga tggtttttga gagcaccct tttaccaactg cctgggttgca gaagtgccga
360

aagagcactg gactccggaa ggtaaccctt cgccttttcc agaagccaga gagaccaaca
420

ttgttggttt tgccatgtac tattttacct atgaccctg gattggcaag ttattgtatc
480

ttgaggactt ctctgtgatg agtgattata gaggtacgat tgagctttgg cataggatca
540

gaaattctga agaattctaag ccaggttgca atgaggtgtc gctggcagca tgcacttctt
600

gggcagaatg gaatgaacca tccatcaact tctataaaag aagaggtgct tctgatctgt
660

ccagtgaaga gggttggaga ctgttcaaga tcgacaagga gtacttgcta aaaatggcaa
720

cagaggagtg aggagtgtg ctgtagatga caacctccat tctatttttag aataaattcc
780

caacttctct tgctttctat gctgtttgta gtgaaataat agaattgagca cccattccaa
840

agctttatta ccagtggcgt tgttgcatgt ttgaaatgag gtctgtttta agtggcaatc
900

tcagatgcag tttggagagt cagatcttct tcttgaata tctttcgata aacaacaagg
960

tggtgtgatc ttaatatatt tgaaaaaac ttcattctcg tgagtcattt aaatgtgtac
1020

aatgtacaca ctggtactta gagtttctgt ttgattcttt ttttaataaac tactctttga
1080

tttaattcta aaaaaaaaaa aaaaaaagac a
1111

<210> 27

<211> 190

<212> PRT

<213> Homo sapiens

<400> 27

Glu Pro Pro Pro Pro Thr Val Gln Val Gln Gly Pro Gly Pro Gln Arg
1 5 10 15

Glu Glu Lys Gln Lys Thr Lys Met Ala Lys Phe Val Ile Arg Pro Ala
20 25 30

Thr Ala Ala Asp Cys Ser Asp Ile Leu Arg Leu Ile Lys Glu Leu Ala
35 40 45

PR03 12-05

Lys Tyr Glu Tyr Met Glu Glu Gln Val Ile Leu Thr Glu Lys Asp Leu
50 55 60

Leu Glu Asp Gly Phe Gly Glu His Pro Phe Tyr His Cys Leu Val Ala
65 70 75 80

Glu Val Pro Lys Glu His Trp Thr Pro Glu Gly Asn Pro Ser Pro Phe
85 90 95

Pro Glu Ala Arg Glu Thr Asn Ile Val Gly Phe Ala Met Tyr Tyr Phe
100 105 110

Thr Tyr Asp Pro Trp Ile Gly Lys Leu Leu Tyr Leu Glu Asp Phe Phe
115 120 125

Val Met Ser Asp Tyr Arg Gly Thr Ile Glu Leu Trp His Arg Ile Arg
130 135 140

Asn Ser Glu Glu Ser Lys Pro Gly Cys Asn Glu Val Ser Leu Ala Ala
145 150 155 160

Cys Thr Ser Trp Ala Glu Trp Asn Glu Pro Ser Ile Asn Phe Tyr Lys
165 170 175

Arg Arg Gly Ala Ser Asp Leu Ser Ser Glu Glu Gly Trp Arg
180 185 190

<210> 28
<211> 745
<212> DNA
<213> Murinae gen. sp.

<400> 28
aatctatgga gcagattcgg cgaattatga gaccaactga tgtaccagat caaggtcttc
60

tttgtgatct ttgggtggtct gaccccgatg aaagatgtct taggctgggg tgaaaatgac
120

agaggagtgt ccttcacatt tgggtgcagaa gtggttgcaa aatttctcca taagcatgat
180

tcggatctta tatgtagagc ccatcaggtg gttgaagatg gctatgagtt tttcgcaaag
240

aggcagttag tcactctggt gttctgcgag cccaactact gtggcgagtt tgacaatgca
300

ggcgccatga tgagtgtgga tgagaccctc atgtgttcct tccagatttt aaagcctgca
360

gagaaaaaga agcccaacgc cagagacct gtcacaccac cacggggtat gatcacaag
420

caagcaaaga aatagatgtc acttgacact gcctgggttg gacttgtaac atagcgttca
480

taaccttctt ttttaaactg tgatgtgctg gtcagcttgc ccaggtagac ctgtctgtcg
540

ggcctcctc catttgatta ctgctggcac ttgctggtta tagcagcaag ccaagcactt
600

cattctcaag agagcatttg gttctgaacc tctgttccct ttgtggacag ctctgatgat
660

ggtgttaagc tgtacacctt gccaggttat cctgtctgag gagaaagtgt acaattgatc
720

tttttttagt ttagtataag tcatg
745

<210> 29

<211> 2127

<212> DNA

<213> Murinae gen. sp.

<400> 29

gctgctgcgg gagggtcggc gccgggaagg cgatggcgga tatcgacaaa ctcaacatcg
60

acagcatcat ccaacggctg ctggaagtga gaggggtccaa gccaggcaag aatgtccagc
120

tccaggagaa cgagatccga ggactctgcc tgaagtctcg ggagatcttc ctgagtcagc
180

ctatcctttt agaacttgaa gcaccactca agatatgtgg tgacatccac gggcagtact
240

atgatttgct ccgtctgttt gaatacgggtg gctttcctcc agagagcaac tatttgtttc
300

tcggggacta tgtggacagg ggcaagcagt ccctggagac aatctgcctc ttgctggcct
360

acaaaatcaa gtatccggag aacttcttcc ttctcagagg gaaccacgag tgcgccagca
420

tcaataggat ctacggattt tatgatgagt gtaaaagaag atacaacatt aagctgtgga
480

aaacgttcac agactgtttt aactgcttgc cgatagcagc catcgtggac gagaagatat
540

tctgctgtca tggagggtta tcaccagatc ttcaatctat ggagcagatt cggcgaatta
600

tgagaccaac tgatgtacca gatcaaggtc ttctttgtga tcttttgtgg tctgaccccg
660

ataaagatgt cttaggctgg ggtgaaaatg acagaggagt gtccttcaca tttggtgcag
720

aagtggttgc aaaatttctc cataagcatg atttggatct tataatgtaga gcccatcagg
780

tggttgaaga tggctatgag ttttttgcaa agaggcagtt agtcactctg ttttctgcac
840

ccaactactg tggcgagttt gacaatgcag gcgccatgat gagtgtggat gagaccctca
900

tgtgttcctt ccagatttta aagcctgcag agaaaaagaa gcccaacgcc acgagacctg
960

tcacaccacc acgggggatg atcacaaagc aagcaaagaa atagatgtca cttgacactg
1020

cctgggttggg acttgtaaca tagcggtcat aaccttcctt tttaaactgt gatgtgctgg
1080

tcagcttgcc caggtagacc tgtctgtcgg gccctcctcc atttgattac tgctggcact
1140

tgctggttat agcagcaagc caagcacttc attctcaaga gagcattttg ttttgaacct
1200

ctgttccctt tgtggacagc tctgatgatg gtgttaagct gtacaccctg gcaggttatc
1260

ctgtctgagg agaaagtgtg caattgatct ttttttaatt tagtataagt catgaataat
1320

gtaaatgcct gttttcttta ggatataaag agagccttag agtgcggtgag tctctacatg
1380

taattgtcat aaatgcattc tgttgataca aaccactgtg aacaattttt tttccagttt
1440

gtttgaaagg gactgctttc cctcattgtc ttgtcatgta caaactagtg tctgcagctg
1500

tggcagcagg agtgacctgc ctgccgccag ccctgccag actatctgaa gcacactcct
1560

tcccactgca catttaataa tgattaaagc cattcttttc aatgtctgtg attccttcct
1620

aaagccaaag tttctgttgg actgtatggc acgccctggg gatgaggtgg ccagggcatc
1680

gaggctgcgt gcacaggccg cctccctccg tggggcctca gaagcaggtt attttaacta
1740

gcaatagtgg tatagtgtg agtaagctat taatgatgga agttaatgac actttgtaca
1800

gttcccatat agtctattca ctgagtgatc tttttacagt tggatcaggc ctgaaccctg
1860

ccattcagaa agcttcaa at tatagaaaca acactgtcct atacgagtga ccgataatgc
1920

tttctttggc tacattcttt attctgcggt gacattgagg cttataaatc aaaaggaact
1980

aacttgccgt ccaccggttt atacagaact cacagtatct atgacttttt taaactacga
2040

cctgttaa at gaatctgttt gcacagatgc ccgtgtacaa tgccatgtgc tgagaatggt
2100

ttcagactta ttaa atgcaa gcttggt
2127

<210> 30

<211> 323

<212> PRT

<213> Murinae gen. sp.

<400> 30

Met Ala Asp Ile Asp Lys Leu Asn Ile Asp Ser Ile Ile Gln Arg Leu
1 5 10 15

Leu Glu Val Arg Gly Ser Lys Pro Gly Lys Asn Val Gln Leu Gln Glu
20 25 30

Asn Glu Ile Arg Gly Leu Cys Leu Lys Ser Arg Glu Ile Phe Leu Ser
35 40 45

Gln Pro Ile Leu Leu Glu Leu Glu Ala Pro Leu Lys Ile Cys Gly Asp
50 55 60

Ile His Gly Gln Tyr Tyr Asp Leu Leu Arg Leu Phe Glu Tyr Gly Gly
65 70 75 80

Phe Pro Pro Glu Ser Asn Tyr Leu Phe Leu Gly Asp Tyr Val Asp Arg
85 90 95

Gly Lys Gln Ser Leu Glu Thr Ile Cys Leu Leu Leu Ala Tyr Lys Ile
100 105 110

Lys Tyr Pro Glu Asn Phe Phe Leu Leu Arg Gly Asn His Glu Cys Ala
115 120 125

Ser Ile Asn Arg Ile Tyr Gly Phe Tyr Asp Glu Cys Lys Arg Arg Tyr
130 135 140

Asn Ile Lys Leu Trp Lys Thr Phe Thr Asp Cys Phe Asn Cys Leu Pro
145 150 155 160

Ile Ala Ala Ile Val Asp Glu Lys Ile Phe Cys Cys His Gly Gly Leu
165 170 175

Ser Pro Asp Leu Gln Ser Met Glu Gln Ile Arg Arg Ile Met Arg Pro
180 185 190

Thr Asp Val Pro Asp Gln Gly Leu Leu Cys Asp Leu Leu Trp Ser Asp
195 200 205

Pro Asp Lys Asp Val Leu Gly Trp Gly Glu Asn Asp Arg Gly Val Ser
210 215 220

Phe Thr Phe Gly Ala Glu Val Val Ala Lys Phe Leu His Lys His Asp
225 230 235 240

Leu Asp Leu Ile Cys Arg Ala His Gln Val Val Glu Asp Gly Tyr Glu
245 250 255

Phe Phe Ala Lys Arg Gln Leu Val Thr Leu Phe Ser Ala Pro Asn Tyr
260 265 270

Cys Gly Glu Phe Asp Asn Ala Gly Ala Met Met Ser Val Asp Glu Thr
275 280 285

Leu Met Cys Ser Phe Gln Ile Leu Lys Pro Ala Glu Lys Lys Lys Pro
290 295 300

Asn Ala Thr Arg Pro Val Thr Pro Pro Arg Gly Met Ile Thr Lys Gln
305 310 315 320

Ala Lys Lys

<210> 31

<211> 993

<212> DNA

<213> Homo sapiens

<400> 31

atgtccgaca gogagaagct caacctggac togatcatcg ggcgcctgct ggaagtgcag
60

ggctcgcggc ctggcaagaa tgtacagctg acagagaacg agatccgcgg tctgtgcctg
120

aaatcccggg agatttttct gagccagccc attcttctgg agctggaggc accoctcaag
180

atctgoggtg acatacacgg ccagtactac gaccttctgc gactatttga gtatggcggt
240

ttccctcccg agagcaacta cctctttctg ggggactatg tggacagggg caagcagtc
300

ttggagacca tctgcctgct gctggcctat aagatcaagt accccgagaa cttcttcctg
360

ctccgtggga accacgagtg tgccagcatc aaccgcatct atggtttcta cgatgagtgc
420

aagagacgct acaacatcaa actgtggaaa accttcactg actgcttcaa ctgcctgcc
480

atcgcgcca tagtggacga aaagatcttc tgctgccacg gaggcctgtc cccggacctg
540

cagtctatgg agcagattcg gcggatcatg cggcccacag atgtgcctga ccagggcctg
600

ctgtgtgacc tgctgtggtc tgaccctgac aaggacgtgc agggctgggg cgagaacgac
660

cgtggcgtct cttttacctt tggagccgag gtgggtggcca agttcctcca caagcacgac
720

ttggacctca tctgccgagc acaccaggtg gtagaagacg gctacgagtt ctttgccaag
780

cggcagctgg tgacactttt ctcagctccc aactactgtg gcgagtttga caatgctggc
840

gccatgatga gtgtggacga gaccctcatg tgctctttcc agatcctcaa gcccgccgac
900

aagaacaagg ggaagtacgg gcagttcagt ggcctgaacc ctggaggccg acccatcacc
960

ccaccccgca attccgcca agccaagaaa tag
993

<210> 32

<211> 330

<212> PRT

<213> Homo sapiens

<400> 32

Met Ser Asp Ser Glu Lys Leu Asn Leu Asp Ser Ile Ile Gly Arg Leu
1 5 10 15

Leu Glu Val Gln Gly Ser Arg Pro Gly Lys Asn Val Gln Leu Thr Glu
20 25 30

Asn Glu Ile Arg Gly Leu Cys Leu Lys Ser Arg Glu Ile Phe Leu Ser
35 40 45

Gln Pro Ile Leu Leu Glu Leu Glu Ala Pro Leu Lys Ile Cys Gly Asp
50 55 60

Ile His Gly Gln Tyr Tyr Asp Leu Leu Arg Leu Phe Glu Tyr Gly Gly
65 70 75 80

Phe Pro Pro Glu Ser Asn Tyr Leu Phe Leu Gly Asp Tyr Val Asp Arg
85 90 95

Gly Lys Gln Ser Leu Glu Thr Ile Cys Leu Leu Leu Ala Tyr Lys Ile
100 105 110

Lys Tyr Pro Glu Asn Phe Phe Leu Leu Arg Gly Asn His Glu Cys Ala
115 120 125

Ser Ile Asn Arg Ile Tyr Gly Phe Tyr Asp Glu Cys Lys Arg Arg Tyr
130 135 140

Asn Ile Lys Leu Trp Lys Thr Phe Thr Asp Cys Phe Asn Cys Leu Pro
145 150 155 160

Ile Ala Ala Ile Val Asp Glu Lys Ile Phe Cys Cys His Gly Gly Leu
165 170 175

Ser Pro Asp Leu Gln Ser Met Glu Gln Ile Arg Arg Ile Met Arg Pro
180 185 190

Thr Asp Val Pro Asp Gln Gly Leu Leu Cys Asp Leu Leu Trp Ser Asp
195 200 205

Pro Asp Lys Asp Val Gln Gly Trp Gly Glu Asn Asp Arg Gly Val Ser
210 215 220

Phe Thr Phe Gly Ala Glu Val Val Ala Lys Phe Leu His Lys His Asp
225 230 235 240

Leu Asp Leu Ile Cys Arg Ala His Gln Val Val Glu Asp Gly Tyr Glu
245 250 255

Phe Phe Ala Lys Arg Gln Leu Val Thr Leu Phe Ser Ala Pro Asn Tyr
260 265 270

Cys Gly Glu Phe Asp Asn Ala Gly Ala Met Met Ser Val Asp Glu Thr
275 280 285

Leu Met Cys Ser Phe Gln Ile Leu Lys Pro Ala Asp Lys Asn Lys Gly
290 295 300

Lys Tyr Gly Gln Phe Ser Gly Leu Asn Pro Gly Gly Arg Pro Ile Thr
305 310 315 320

Pro Pro Arg Asn Ser Ala Lys Ala Lys Lys
325 330

<210> 33
<211> 747
<212> DNA
<213> Murinae gen. sp.

<220>
<221> misc_feature
<222> (298)..(298)
<223> n is a, c, g, or t

<400> 33
cgacaagtca tgctgctcgc tatgaataag gttgaaggag acaacattag cggcggttgc
60

ttcgttggcc tgtatgacct ggacgcctct cgctacttgc tcttctgcc tctgtgctc
120

tgcgtatttg ttgagctggg agagtagccc agtggtagag cggccacctg gaatacttga
180

ggacctgggg ttgtctccca gcactgcaaa aggaaaattc actgttacag tcttccttgc
240

acttaaacca gctttgtcta ttgttttttt ggtttggctt tgttactttt gttgctgntt
300

atTTTTgttg ttgttgtttg tttgtttgag acagggtttt tttgctagcc ctgactgtcc
360

tgaaactccc tctgtagacc aggctggcct caaacttaca gagatccgcc tgcctcagcc
420

tcccaagtgc tgggaataat ggtgtggtca ccaccgccc gccttttgtc tattttttaa
480

cttgaaagaa acaacagccc agatttcaaa aataatataa tgcacttata cctaaaaaaa
540

caaccaggag tgcccagtta ataacatttt ttaaattgtg ggatgggaag ggcattagag
600

gagtcttcct tctattgaag attcattaaa gtatttaaga tatgcccttt cactctttat
660

ataaatccaa gatttttctt tgctgaagta tttaaaactt ttgtaccttt atatgtagat
720

atgaatttga aaatatgctt atgtgta
747

<210> 34
<211> 2021
<212> DNA
<213> Murinae gen. sp.

<400> 34
gggcaagaaa cttcaacaga agtccacacc tcccagaag catccgtcaa agagggacga
60

gcagaccgag caaacactcc cagcgccaaa gatcgggact gtggggaatc tgcagggccc
120

agttccaagc tctctgggaa ccggaacggc agggaaagcc gagcgggcgg cctgaaggag
180

agaagcaatg gatcagaggg ggctccaagt gaaggaaggg taagtccaaa gagcagcgtt
240

cctgagactg gcctgataga ctgcagcact tcacaggccg ccagttctcc agaaccaacc
300

agcctcaagg gctccacatc tctgcctgtt cactcagctt ccagagctag gaaagagcag
360

ggtgctggca gccattccga cgcttgaaga aaactgtctc gttccccag aagcacatgt
420

atgttacact ggagatgacc aactgatttg tcttataaag gccactgttg agctgggaga
480

gtagcccagt ggtacagcgc ccacctggaa tacttgagga cctgggggttg tctcccagca
540

ctgcaaaaagg aaaattcact gttacagtct tccttgcact taaaccagct ttgtctattg
600

tttttttggg ttggctttta tttttgttgc tgttattttt gttgttgttt gtttgttttt
660

ttgtttgttt gtttgagaca gggtttcttt gctagccctg actgtcctga aactccctct
720

gtagaccagg ctggcctcaa acttacagag atctgcctgc ctcagcctcc cgagtgettg
780

gaataatggg gtgggtcacca ctgcccagcc ttttgtctgt ttttaaactt gaaagaaaca
840

acagcccaga tttcaaaaat aatataatgc atttatacct aaaaaaccaa ccaggagtgc
900

ccagttaata acacttttta aatgtgggga tgggaagggc attagaggag tcttccttct
960

attgaagatt cattaaagta ttttaagata tgctctttca ctcttttatat aaatccaaga
1020

Arg Gly His Ser Leu Phe Thr Cys Glu Pro Ile Thr Val Pro Arg Cys
20 25 30

Met Lys Met Thr Tyr Asn Met Thr Phe Phe Pro Asn Leu Met Gly His
35 40 45

Tyr Asp Gln Gly Ile Ala Ala Val Glu Met Gly His Phe Leu His Leu
50 55 60

Ala Asn Leu Glu Cys Ser Pro Asn Ile Glu Met Phe Leu Cys Gln Ala
65 70 75 80

Phe Ile Pro Thr Cys Thr Glu Gln Ile His Val Val Leu Pro Cys Arg
85 90 95

Lys Leu Cys Glu Lys Ile Val Ser Asp Cys Lys Lys Leu Met Asp Thr
100 105 110

Phe Gly Ile Arg Trp Pro Glu Glu Leu Glu Cys Asn Arg Leu Pro His
115 120 125

Cys Asp Asp Thr Val Pro Val Thr Ser His Pro His Thr Glu Leu Ser
130 135 140

Gly Pro Gln Lys Lys Ser Asp Gln Val Pro Arg Asp Ile Gly Phe Trp
145 150 155 160

Cys Pro Lys His Leu Arg Thr Ser Gly Asp Gln Gly Tyr Arg Phe Leu
165 170 175

Gly Ile Glu Gln Cys Ala Pro Pro Cys Pro Asn Met Tyr Phe Lys Ser
180 185 190

Asp Glu Leu Asp Phe Ala Lys Ser Phe Ile Gly Ile Val Ser Ile Phe
195 200 205

Cys Leu Cys Ala Thr Leu Phe Thr Phe Leu Thr Phe Leu Ile Asp Val
210 215 220

Arg Arg Phe Arg Tyr Pro Glu Arg Pro Ile Ile Tyr Tyr Ser Val Cys
225 230 235 240

Tyr Ser Ile Val Ser Leu Met Tyr Phe Val Gly Phe Leu Leu Gly Asn
245 250 255

Ser Thr Ala Cys Asn Lys Ala Asp Glu Lys Leu Glu Leu Gly Asp Thr
260 265 270

Val Val Leu Gly Ser Lys Asn Lys Ala Cys Ser Val Val Phe Met Phe
275 280 285

Leu Tyr Phe Phe Thr Met Ala Gly Thr Val Trp Trp Val Ile Leu Thr
290 295 300

Ile Thr Trp Phe Leu Ala Ala Gly Arg Lys Trp Ser Cys Glu Ala Ile
305 310 315 320

Glu Gln Lys Ala Val Trp Phe His Ala Val Ala Trp Gly Ala Pro Gly
325 330 335

Phe Leu Thr Val Met Leu Leu Ala Met Asn Lys Val Glu Gly Asp Asn
340 345 350

Ile Ser Gly Val Cys Phe Val Gly Leu Tyr Asp Leu Asp Ala Ser Arg
355 360 365

Tyr Phe Val Leu Leu Pro Leu Cys Leu Cys Val Phe Val Gly Leu Ser
370 375 380

Leu Leu Leu Ala Gly Ile Ile Ser Leu Asn His Val Arg Gln Val Ile
385 390 395 400

Gln His Asp Gly Arg Asn Gln Glu Lys Leu Lys Lys Phe Met Ile Arg
405 410 415

Ile Gly Val Phe Ser Gly Leu Tyr Leu Val Pro Leu Val Thr Leu Leu
420 425 430

Gly Cys Tyr Val Tyr Glu Leu Val Asn Arg Ile Thr Trp Glu Met Thr
435 440 445

Trp Phe Ser Asp His Cys His Gln Tyr Arg Ile Pro Cys Pro Tyr Gln
450 455 460

Ala Asn Pro Lys Ala Arg Pro Glu Leu Ala Leu Phe Met Ile Lys Tyr
465 470 475 480

Leu Met Thr Leu Ile Val Gly Ile Ser Ala Val Phe Trp Val Gly Ser
485 490 495

PR03-1203

Lys Lys Thr Cys Thr Glu Trp Ala Gly Phe Phe Lys Arg Asn Arg Lys
500 505 510

Arg Asp Pro Ile Ser Glu Ser Arg Arg Val Leu Gln Glu Ser Cys Glu
515 520 525

Phe Phe Leu Lys His Asn Ser Lys Val Lys His Lys Lys Lys His Gly
530 535 540

Ala Pro Gly Pro His Arg Leu Lys Val Ile Ser Lys Ser Met Gly Thr
545 550 555 560

Ser Thr Gly Ala Thr Thr Asn His Gly Thr Ser Ala Met Ala Ile Ala
565 570 575

Asp His Asp Tyr Leu Gly Gln Glu Thr Ser Thr Glu Val His Thr Ser
580 585 590

Pro Glu Ala Ser Val Lys Glu Gly Arg Ala Asp Arg Ala Asn Thr Pro
595 600 605

Ser Ala Lys Asp Arg Asp Cys Gly Glu Ser Ala Gly Pro Ser Ser Lys
610 615 620

Leu Ser Gly Asn Arg Asn Gly Arg Glu Ser Arg Ala Gly Gly Leu Lys
625 630 635 640

Glu Arg Ser Asn Gly Ser Glu Gly Ala Pro Ser Glu Gly Arg Val Ser
645 650 655

Pro Lys Ser Ser Val Pro Glu Thr Gly Leu Ile Asp Cys Ser Thr Ser
660 665 670

Gln Ala Ala Ser Ser Pro Glu Pro Thr Ser Leu Lys Gly Ser Thr Ser
675 680 685

Leu Pro Val His Ser Ala Ser Arg Ala Arg Lys Glu Gln Gly Ala Gly
690 695 700

Ser His Ser Asp Ala
705

<210> 36
<211> 2039
<212> DNA
<213> Homo sapiens

<400> 36

aggagacaac attagtggag ttgctttgt tggcctttat gacctggatg cttctcgcta
60

ctttgtactc ttgcoactgt gcctttgtgt gtttgttggg ctctctcttc ttttagctgg
120

cattatttcc ttaaactcatg ttcgacaagt catacaacat gatggccgga accaagaaaa
180

actaaagaaa tttatgattc gaattggagt cttcagcggc ttgtatcttg tgccattagt
240

gacacttctc ggatgttacg tctatgagca agtgaacagg attacctggg agataacttg
300

ggtctctgat cattgtcgtc agtaccatat cccatgtcct tatcaggcaa aagcaaaagc
360

tcgaccagaa ttggctttat ttatgataaa atacctgatg acattaattg ttggcatctc
420

tgctgtcttc tgggttggaa gcaaaaagac atgcacagaa tgggctgggt tttttaaacg
480

aatcgcaag agagatccaa tcagtgaag tcgaagagta ctacaggaat catgtgagtt
540

tttcttaaag cacaattcta aagttaaaca caaaaagaag cactataaac caagttcaca
600

caagctgaag gtcatttcca aatccatggg aaccagcaca ggagctacag caaatcatgg
660

cacttctgca gtagcaatta ctagccatga ttacctagga caagaaactt tgacagaaat
720

ccaaacctca ccagaaacat caatgagaga ggtgaaagcg gacggagcta gcacccccag
780

gttaagagaa caggactgtg gtgaacctgc ctgccagca gcatccatct ccagactctc
840

tggggaacag gtcgacggga agggccaggc aggcagtgt tctgaaagtg cgcggagtga
900

aggaaggatt agtccaaaga gtgatattac tgacactggc ctggcacaga gcaacaattt
960

gcagggtccc agttcttcag aaccaagcag cctcaaaggt tccacatctc tgcttgttca
1020

cccggtttca ggagtgagaa aagagcaggg aggtggttgt cattcagata cttgaagaac
1080

atcttctctc gttactcaga agcaaatttg tgttacactg gaagtgacct atgcactggt
1140

ttgtaagaat cactgttaca ttcttctttt gcaacttaaag ttgcattgcc tactgttata
1200

ctggaaaaaa tagagttcaa gaataatatg actcatttca cacaaagggtt aatgacaaca
1260

atataoctga aaacagaaaa tgtgcagggtt aataatattt ttttaatagt gtgggaggac
1320

agagtttagag gaatcttcct tttctattta tgaagattct actcttggtta agagtatttt
1380

aagatgtact atgctatttt acttttttga tataaaatca agatatttct ttgctgaagt
1440

atttaaactct tatccttgta tttttttata catatttgaa aataagctta tatgtatttg
1500

aacttttttg aaatcctatt caagtatttt tatcatgcta ttgtgatatt ttagcacttt
1560

ggtagctttt acactgaatt tctaagaaaa ttgtaaaata gtcttctttt atactgtaaa
1620

aaaagatata ccaaaaagtc ttataatagg aatttaactt taaaaacca cttattgata
1680

ccttaccatc taaaatgtgt gatttttata gtctcgtttt aggaatttca cagatctaaa
1740

ttatgtaact gaaataagggt gcttactcaa agagtgtcca ctattgattg tattatgctg
1800

ctcactgac cttctgcata tttaaaataa aatgtcctaa aggggttagta gacaaaatgt
1860

tagtcttttg tatattaggc caagtgcaat tgacttccct tttttaatgt ttcatgacca
1920

cccattgatt gtattataac cacttacagt tgcttatatt ttttgtttta acttttgttt
1980

tttaacattt agaattattac attttgtatt atacagtacc tttctcagac attttgtag
2039

<210> 37
<211> 706
<212> PRT
<213> Homo sapiens

<400> 37

Met	Glu	Met	Phe	Thr	Phe	Leu	Leu	Thr	Cys	Ile	Phe	Leu	Pro	Leu	Leu
1				5					10					15	

Arg	Gly	His	Ser	Leu	Phe	Thr	Cys	Glu	Pro	Ile	Thr	Val	Pro	Arg	Cys
			20					25					30		

Met	Lys	Met	Ala	Tyr	Asn	Met	Thr	Phe	Phe	Pro	Asn	Leu	Met	Gly	His
		35					40					45			

Tyr Asp Gln Ser Ile Ala Ala Val Glu Met Glu His Phe Leu Pro Leu
50 55 60

Ala Asn Leu Glu Cys Ser Pro Asn Ile Glu Thr Phe Leu Cys Lys Ala
65 70 75 80

Phe Val Pro Thr Cys Ile Glu Gln Ile His Val Val Pro Pro Cys Arg
85 90 95

Lys Leu Cys Glu Lys Val Tyr Ser Asp Cys Lys Lys Leu Ile Asp Thr
100 105 110

Phe Gly Ile Arg Trp Pro Glu Glu Leu Glu Cys Asp Arg Leu Gln Tyr
115 120 125

Cys Asp Glu Thr Val Pro Val Thr Phe Asp Pro His Thr Glu Phe Leu
130 135 140

Gly Pro Gln Lys Lys Thr Glu Gln Val Gln Arg Asp Ile Gly Phe Trp
145 150 155 160

Cys Pro Arg His Leu Lys Thr Ser Gly Gly Gln Gly Tyr Lys Phe Leu
165 170 175

Gly Ile Asp Gln Cys Ala Pro Pro Cys Pro Asn Met Tyr Phe Lys Ser
180 185 190

Asp Glu Leu Glu Phe Ala Lys Ser Phe Ile Gly Thr Val Ser Ile Phe
195 200 205

Cys Leu Cys Ala Thr Leu Phe Thr Phe Leu Thr Phe Leu Ile Asp Val
210 215 220

Arg Arg Phe Arg Tyr Pro Glu Arg Pro Ile Ile Tyr Tyr Ser Val Cys
225 230 235 240

Tyr Ser Ile Val Ser Leu Met Tyr Phe Ile Gly Phe Leu Leu Gly Asp
245 250 255

Ser Thr Ala Cys Asn Lys Ala Asp Glu Lys Leu Glu Leu Gly Asp Thr
260 265 270

Val Val Leu Gly Ser Gln Asn Lys Ala Cys Thr Val Leu Phe Met Leu
275 280 285

Leu Tyr Phe Phe Thr Met Ala Gly Thr Val Trp Trp Val Ile Leu Thr
290 295 300

Ile Thr Trp Phe Leu Ala Ala Gly Arg Lys Trp Ser Cys Glu Ala Ile
305 310 315 320

Glu Gln Lys Ala Val Trp Phe His Ala Val Ala Trp Gly Thr Pro Gly
325 330 335

Phe Leu Thr Val Met Leu Leu Ala Met Asn Lys Val Glu Gly Asp Asn
340 345 350

Ile Ser Gly Val Cys Phe Val Gly Leu Tyr Asp Leu Asp Ala Ser Arg
355 360 365

Tyr Phe Val Leu Leu Pro Leu Cys Leu Cys Val Phe Val Gly Leu Ser
370 375 380

Leu Leu Leu Ala Gly Ile Ile Ser Leu Asn His Val Arg Gln Val Ile
385 390 395 400

Gln His Asp Gly Arg Asn Gln Glu Lys Leu Lys Lys Phe Met Ile Arg
405 410 415

Ile Gly Val Phe Ser Gly Leu Tyr Leu Val Pro Leu Val Thr Leu Leu
420 425 430

Gly Cys Tyr Val Tyr Glu Gln Val Asn Arg Ile Thr Trp Glu Ile Thr
435 440 445

Trp Val Ser Asp His Cys Arg Gln Tyr His Ile Pro Cys Pro Tyr Gln
450 455 460

Ala Lys Ala Lys Ala Arg Pro Glu Leu Ala Leu Phe Met Ile Lys Tyr
465 470 475 480

Leu Met Thr Leu Ile Val Gly Ile Ser Ala Val Phe Trp Val Gly Ser
485 490 495

Lys Lys Thr Cys Thr Glu Trp Ala Gly Phe Phe Lys Arg Asn Arg Lys
500 505 510

Arg Asp Pro Ile Ser Glu Ser Arg Arg Val Leu Gln Glu Ser Cys Glu
515 520 525

Phe Phe Leu Lys His Asn Ser Lys Val Lys His Lys Lys Lys His Tyr

530

535

540

Lys Pro Ser Ser His Lys Leu Lys Val Ile Ser Lys Ser Met Gly Thr
545 550 555 560

Ser Thr Gly Ala Thr Ala Asn His Gly Thr Ser Ala Val Ala Ile Thr
565 570 575

Ser His Asp Tyr Leu Gly Gln Glu Thr Leu Thr Glu Ile Gln Thr Ser
580 585 590

Pro Glu Thr Ser Met Arg Glu Val Lys Ala Asp Gly Ala Ser Thr Pro
595 600 605

Arg Leu Arg Glu Gln Asp Cys Gly Glu Pro Ala Ser Pro Ala Ala Ser
610 615 620

Ile Ser Arg Leu Ser Gly Glu Gln Val Asp Gly Lys Gly Gln Ala Gly
625 630 635 640

Ser Val Ser Glu Ser Ala Arg Ser Glu Gly Arg Ile Ser Pro Lys Ser
645 650 655

Asp Ile Thr Asp Thr Gly Leu Ala Gln Ser Asn Asn Leu Gln Val Pro
660 665 670

Ser Ser Ser Glu Pro Ser Ser Leu Lys Gly Ser Thr Ser Leu Leu Val
675 680 685

His Pro Val Ser Gly Val Arg Lys Glu Gln Gly Gly Gly Cys His Ser
690 695 700

Asp Thr
705

<210> 38

<211> 773

<212> DNA

<213> Murinae gen. sp.

<400> 38

ctgaggtgct agcaccagcc tggttgtctc tggcgggcct gaagcaagca tggatcaaga
60

ggctgtgggc aacgttgtgc tcttggccct tgtcacctc atcagcgtgg tccagaatgc
120

gttctttgcc cacaaggtgg agcatgaaag caaggcgc atatgggagaa gcttccagag
180

gaccgggact cttgcctttg agcgggtcta cactgccaac cagaactgcg tagatgcgta
240

ccccactttc cttgtggtac tctggactgc aggactactt tgcagccaag tccctgcage
300

cttcgcgga ctgatgtacc tgtttgtgag gcaaaaatac tttgtcggct atctgggaga
360

gagaactcag agcaccctg gctacatctt cggcaagcgg atcatcctgt tctgttctt
420

catgtccttc gccgggatac tcaaccatta cctcatcttc ttcttcggaa gcgactttga
480

gaactacatc agaacggtaa gcacgacgat ctccccgctg cttctcatcc cctgattgct
540

ggagacagag aaggacgctc accagatcaa tagagacgca tcataacgca acgccgcgaa
600

ggcttctgct cctcttcaag ctgtagatgc tgtcaatctt gctgccctcg gggctctgtg
660

gcatcogtta actttgcttt tccgggaaga aaaatgtctt gtgctaagct ccaccctcg
720

aatgcggcgg tgggccagga tttatgtcta catccagcct atacttctcc tgg
773

<210> 39

<211> 852

<212> DNA

<213> Murinae gen. sp.

<400> 39

ggaaggctga ggtgctagca ccagcctggt tgtctctggc gggcctgaag caagcatgga
60

tcaagaggct gtgggcaacg ttgtgctcct ggcccttgtc accctcatca gcgtggtcca
120

gaatgtgttt ttgcccact atgtggagca tgaaagcaat gcgcataatg ggagaagctt
180


ccagaggacc gggactcttg cctttgagcg ggtctacact gcccaaccaga actgcgtaga
240

tgcgtacccc actttccttg tggtagcttg gactgcagga ctactttgca gccaaagtccc
300

tgccgccttc gccggactga tgtacctgtt tgtgaggcaa aaatactttg tcggctatct
360

gggagagaga actcagagca cccctggcta catcttcggc aagcggatca tctgttctt
420

gttctctatg tcttcgcgcg ggatactcaa ccattacctc atcttcttct tcggaagcga
480



ctttgagaac tacatcagaa cggtaagcac gacgatctcc ccgctgcttc tcatcccctg
540

attgctggag acagagaagg acgctcacca gatcaataga gacgcatcat aacgcaacgc
600

cgcgaaggct tctgctcctc ttcaagctgt agatgctgtc aatcttgctg coctcggggc
660

tctgtggcat ccgttaactt tgcttttccg ggaagaaaaa tgtcttgtgc tagctccacc
720

cctcgaatgc ggcggtggcc caggatttat tgtctacatc cagcctatac ttctcctggc
780

ttatcctgct ttctgaagat gtcttgtaat cagacacgtg ttttcctaaa ataaagggta
840

tagacaaaat tt
852

<210> 40
<211> 161
<212> PRT
<213> Murinae gen. sp.

<400> 40

Met Asp Gln Glu Ala Val Gly Asn Val Val Leu Leu Ala Leu Val Thr
1 5 10 15

Leu Ile Ser Val Val Gln Asn Val Phe Phe Ala His Tyr Val Glu His
20 25 30

Glu Ser Asn Ala His Asn Gly Arg Ser Phe Gln Arg Thr Gly Thr Leu
35 40 45

Ala Phe Glu Arg Val Tyr Thr Ala Asn Gln Asn Cys Val Asp Ala Tyr
50 55 60

Pro Thr Phe Leu Val Val Leu Trp Thr Ala Gly Leu Leu Cys Ser Gln
65 70 75 80

Val Pro Ala Ala Phe Ala Gly Leu Met Tyr Leu Phe Val Arg Gln Lys
85 90 95

Tyr Phe Val Gly Tyr Leu Gly Glu Arg Thr Gln Ser Thr Pro Gly Tyr
100 105 110

Ile Phe Gly Lys Arg Ile Ile Leu Phe Leu Phe Leu Met Ser Phe Ala
115 120 125

Gly Ile Leu Asn His Tyr Leu Ile Phe Phe Phe Gly Ser Asp Phe Glu
130 135 140

Asn Tyr Ile Arg Thr Val Ser Thr Thr Ile Ser Pro Leu Leu Leu Ile
145 150 155 160

Pro

<210> 41
<211> 873
<212> DNA
<213> Homo sapiens

<400> 41
acttcccctt cctgtacagg gcaggttgtg cagctggagg cagagcagtc ctctctgggg
60

agcctgaagc aaacatggat caagaaactg taggcaatgt tgtcctgttg gccatcgtca
120

ccctcatcag cgtgggtccag aatggattct ttgcccataa agtggagcac gaaagcagga
180

cccagaatgg gaggagcttc cagaggaccg gaacacttgc ctttgagcgg gtctacactg
240

ccaaccagaa ctgtgtagat gcgtacccca ctttcctcgc tgtgctctgg tctgcggggc
300

tactttgcag ccaagttcct gctgcgtttg ctggactgat gtacttgttt gtgaggcaaa
360

agtactttgt cggttaccta ggagagagaa cgcagagcac cctgggctac atatttggga
420

aacgcatcat actcttcctg ttctcatgt ccgttgctgg catattcaac tattacctca
480

tcttcttttt cggaagtgc tttgaaaact acataaagac gatctccacc accatctccc
540

ctctacttct cattccctaa ctctctgctg aatatggggt tgggtgttctc atctaataa
600

tacctacaag tcatacataat tcagctcttg agagcattct gctcttcttt agatggctgt
660

aaatctattg gccatctggg cttcacagct tgagttaacc ttgcttttcc gggaacaaaa
720

tgatgtcatg tcagctccgc cccttgaaca tgaccgtggc cccaaatttg ctattcccat
780

gcattttggt tgtttcttca cttatcctgt tctctgaaga tgttttgtga ccaggtttgt
840

PRJN3-12-05

gtttttcttaa aataaaatgc agagacatgt ttt
873

<210> 42
<211> 161
<212> PRT
<213> Homo sapiens

<400> 42

Met Asp Gln Glu Thr Val Gly Asn Val Val Leu Leu Ala Ile Val Thr
1 5 10 15

Leu Ile Ser Val Val Gln Asn Gly Phe Phe Ala His Lys Val Glu His
20 25 30

Glu Ser Arg Thr Gln Asn Gly Arg Ser Phe Gln Arg Thr Gly Thr Leu
35 40 45

Ala Phe Glu Arg Val Tyr Thr Ala Asn Gln Asn Cys Val Asp Ala Tyr
50 55 60

Pro Thr Phe Leu Ala Val Leu Trp Ser Ala Gly Leu Leu Cys Ser Gln
65 70 75 80

Val Pro Ala Ala Phe Ala Gly Leu Met Tyr Leu Phe Val Arg Gln Lys
85 90 95

Tyr Phe Val Gly Tyr Leu Gly Glu Arg Thr Gln Ser Thr Pro Gly Tyr
100 105 110

Ile Phe Gly Lys Arg Ile Ile Leu Phe Leu Phe Leu Met Ser Val Ala
115 120 125

Gly Ile Phe Asn Tyr Tyr Leu Ile Phe Phe Phe Gly Ser Asp Phe Glu
130 135 140

Asn Tyr Ile Lys Thr Ile Ser Thr Thr Ile Ser Pro Leu Leu Leu Ile
145 150 155 160

Pro

<210> 43
<211> 803
<212> DNA
<213> Murinae gen. sp.

<400> 43

PRJ03.12.03

ttcagcttta tgggttggct tccttgactg cattttctgt cagttaacta aactccagac
60

tcatggattt tctcgaccag aaaatcagac tattttcctg aataatctac tagaaacttt
120

tacggaacac atttcatgtt tcctttgaag agttaagaga agaaagtatt tgtaagaaca
180

ggaaaagaaa caaataacttt gcaaataaac tggctgctgc tgtgaccaca tctgaatagc
240

aaaggcgatc gatcaagcgc tgcggacaaa aggcctcctg taagctgcac tgcctgacaa
300

tggtaagctc caatggctcc cagtgccctt atgacgactc ctttaagtac actctgtacg
360

ggtgcatgtt cagcatggctc ttcgtgcttg ggctgatatc caactgtgtt gcgatataca
420

ttttcatctg tgcctcaaaa gtgagaaatg aaactacaac gtacatgatt aacctggcaa
480

tgtcagattt acttttcgtc tttactttgc catttcggat tttttacttt gcaacacgga
540

attggccatt tggagatcta ctctgtaaga tttcagtaat gctgttttac accaatatgt
600

atgggaagca ttctgttctt aacctgtatc agtgtagatc gattttctggc aattgtctac
660

ccattttaagt caaagacttt aagaaacgaa acgaaaatgc aaagaatcgt ttgcattgcc
720

tgtgtggttc acagtgatgg gaggaagtgc gctgcagttt tctttcagtc gacccactct
780

caggggaaca atactcagaa gct
803

<210> 44

<211> 1849

<212> DNA

<213> Murinae gen. sp.

<400> 44

agagacagcc catctcacia tacagctggc aacctccgaa aggcctctcc attcagcaag
60

cgcgaaacatg cttaggaatt tatctgggat cccttaaacg actgcctatc gccgtccgga
120

atcaatgtag aaatacaaag tttgagaata aaaagaagga agaagtaccc gaggacgacg
180

ggcggacgga cgcacggcga gtgtttgtga ctgaagtaaa gctgggtttgg accctggcgg
240

ctgaagcaca agtttccacg cggactgggc tggcccgact tggaacagtt tttccttaca
300

ctttcagctt tatgggttgg cttccttgac tgcattttct gtcagttaac taaactccag
360

actcatggat tttctcgacc agaaaatcag actattttcc tgaataatct actagaaact
420

tttacggaac acatttcatg tttcctttga agagttaaga gaagaaagta tttgtaagaa
480

caggaaaaga aacaaatact ttgcaaataa actggctgct gctgtgacca catctgaata
540

gcaaaggcga tcgatcaagc gctgcggaca aaaggcctcc tgtaagctgc actgcctgac
600

aatggtaagc tccaatggct cccagtgcct ttatgacgac tcctttaagt acactctgta
660

cgggtgcatg ttcagcatgg tcttcgtgct tgggctgata tccaactgtg ttgcgatata
720

cattttcatc tgtgccttca aagtgagaaa tgaaactaca acgtacatga ttaacctggc
780

aatgtcagat ttacttttctg tctttacttt gccatttcgg attttttact ttgcaacacg
840

gaattggcca tttggagatc tactctgtaa gatttcagta atgctgtttt acaccaatat
900

gtatggaagc attctgttct taacctgtat cagtgtagat cgatttctgg caattgtcta
960

cccattttaag tcaaagactt taagaacgaa acgaaatgca aagatcgttt gcattgctgt
1020

gtggttcaca gtgatgggag gaagtgcgcc tgcagttttc tttcagtcca cccacttcca
1080

ggggaacaat acctcagaag cctgctttga gaactttcca ggggccacat ggaaaactta
1140

tctctccagg attgtgattt tcattgaaat agtgggcttt tttatccctc tcattttgaa
1200

cgtaacttgt tctagtatgg tgctaagaac tttaaataaa cctgtttacat taagtagaag
1260

caaatgaac aaaactaagg ttttaaaaat gatttttgtc cacttgggtca tcttctgttt
1320

ctgttttgtg ccctacaaca tcaacctcat tttgtactcg ctcatgagga cacagacctt
1380

tgtaactgc tctgtgggtg cggcagtggg gaccatgtac ccgatcactc totgcategc
1440

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996

tgtttccaac tgctgctttg accctattgt ttactacttc acctcagaca caattcagaa
1500

ctcaataaaa atgaaaaact ggctcggttag aagaagtgc tccaggttct ctgaagttca
1560

gggcactgag aattttatcc aacacaacct acagacctta aaaaataaga tatttgataa
1620

tgaatctgca atataagctg cctgactaag ccactgggac tgctccgtgt tcaactgtga
1680

aaactgtgtt cttgggaact atctctccgg ctccaacaga aaatattttt aaaggaagtt
1740

tgtgtctgat gtgttaaaca ttaaaatata ttctattctt gtatgcacgc cattttactt
1800

tcttgaacca ctttaacgtg ttttttcctc attaaaaaaa aaaaactcc
1849

<210> 45

<211> 316

<212> PRT

<213> Murinae gen. sp.

<400> 45

Asp Asp Ser Phe Lys Tyr Thr Leu Tyr Gly Cys Met Phe Ser Met Val
1 5 10 15

Phe Val Leu Gly Leu Ile Ser Asn Cys Val Ala Ile Tyr Ile Phe Ile
20 25 30

Cys Ala Leu Lys Val Arg Asn Glu Thr Thr Thr Tyr Met Ile Asn Leu
35 40 45

Ala Met Ser Asp Leu Leu Phe Val Phe Thr Leu Pro Phe Arg Ile Phe
50 55 60

Tyr Phe Ala Thr Arg Asn Trp Pro Phe Gly Asp Leu Leu Cys Lys Ile
65 70 75 80

Ser Val Met Leu Phe Tyr Thr Asn Met Tyr Gly Ser Ile Leu Phe Leu
85 90 95

Thr Cys Ile Ser Val Asp Arg Phe Leu Ala Ile Val Tyr Pro Phe Lys
100 105 110

Ser Lys Thr Leu Arg Thr Lys Arg Asn Ala Lys Ile Val Cys Ile Ala
115 120 125

PRJ03-12-05

Val Trp Phe Thr Val Met Gly Gly Ser Ala Pro Ala Val Phe Phe Gln
130 135 140

Ser Thr His Ser Gln Gly Asn Asn Thr Ser Glu Ala Cys Phe Glu Asn
145 150 155 160

Phe Pro Ala Ala Thr Trp Lys Thr Tyr Leu Ser Arg Ile Val Ile Phe
165 170 175

Ile Glu Ile Val Gly Phe Phe Ile Pro Leu Ile Leu Asn Val Thr Cys
180 185 190

Ser Ser Met Val Leu Arg Thr Leu Asn Lys Pro Val Thr Leu Ser Arg
195 200 205

Ser Lys Met Asn Lys Thr Lys Val Leu Lys Met Ile Phe Val His Leu
210 215 220

Val Ile Phe Cys Phe Cys Phe Val Pro Tyr Asn Ile Asn Leu Ile Leu
225 230 235 240

Tyr Ser Leu Met Arg Thr Gln Thr Phe Val Asn Cys Ser Val Val Ala
245 250 255

Ala Val Arg Thr Met Tyr Pro Ile Thr Leu Cys Ile Ala Val Ser Asn
260 265 270

Cys Cys Phe Asp Pro Ile Val Tyr Tyr Phe Thr Ser Asp Thr Ile Gln
275 280 285

Asn Ser Ile Lys Met Lys Asn Trp Ser Val Arg Arg Ser Asp Ser Arg
290 295 300

Phe Ser Glu Val Gln Gly Thr Glu Asn Phe Ile Gln
305 310 315

<210> 46
<211> 1035
<212> DNA
<213> Homo sapiens

<400> 46
atggtaagcg ttaacagctc ccaactgcttc tataatgact cctttaagta cactttgtat
60
gggtgcatgt tcagcatggt gtttgtgctt gggttaatat ccaattgtgt tgccatatac
120

Tyr Thr Leu Tyr Gly Cys Met Phe Ser Met Val Phe Val Leu Gly Leu

20

25

30

Ile Ser Asn Cys Val Ala Ile Tyr Ile Phe Ile Cys Val Leu Lys Val
35 40 45

Arg Asn Glu Thr Thr Thr Tyr Met Ile Asn Leu Ala Met Ser Asp Leu
50 55 60

Leu Phe Val Phe Thr Leu Pro Phe Arg Ile Phe Tyr Phe Thr Thr Arg
65 70 75 80

Asn Trp Pro Phe Gly Asp Leu Leu Cys Lys Ile Ser Val Met Leu Phe
85 90 95

Tyr Thr Asn Met Tyr Gly Ser Ile Leu Phe Leu Thr Cys Ile Ser Val
100 105 110

Asp Arg Phe Leu Ala Ile Val Tyr Pro Phe Lys Ser Lys Thr Leu Arg
115 120 125

Thr Lys Arg Asn Ala Lys Ile Val Cys Thr Gly Val Trp Leu Thr Val
130 135 140

Ile Gly Gly Ser Ala Pro Ala Val Phe Val Gln Ser Thr His Ser Gln
145 150 155 160

Gly Asn Asn Ala Ser Glu Ala Cys Phe Glu Asn Phe Pro Glu Ala Thr
165 170 175

Trp Lys Thr Tyr Leu Ser Arg Ile Val Ile Phe Ile Glu Ile Val Gly
180 185 190

Phe Phe Ile Pro Leu Ile Leu Asn Val Thr Cys Ser Ser Met Val Leu
195 200 205

Lys Thr Leu Thr Lys Pro Val Thr Leu Ser Arg Ser Lys Ile Asn Lys
210 215 220

Thr Lys Val Leu Lys Met Ile Phe Val His Leu Ile Ile Phe Cys Phe
225 230 235 240

Cys Phe Val Pro Tyr Asn Ile Asn Leu Ile Leu Tyr Ser Leu Val Arg
245 250 255

Thr Gln Thr Phe Val Asn Cys Ser Val Val Ala Ala Val Arg Thr Met
260 265 270

Tyr Pro Ile Thr Leu Cys Ile Ala Val Ser Asn Cys Cys Phe Asp Pro
275 280 285

Ile Val Tyr Tyr Phe Thr Ser Asp Thr Ile Gln Asn Ser Ile Lys Met
290 295 300

Lys Asn Trp Ser Val Arg Arg Ser Asp Phe Arg Phe Ser Glu Val His
305 310 315 320

Gly Ala Glu Asn Phe Ile Gln His Asn Leu Gln Thr Leu Lys Ser Lys
325 330 335

Ile Phe Asp Asn Glu Ser Ala Ala
340

<210> 48

<211> 814

<212> DNA

<213> Murinae gen. sp.

<400> 48

gagcgcgcgt aagatggcac taccattttc tgtcaacctt cggggtgcgt aatggcctct
60

ggccaggcct agcacatgta cctcacagac caactggcaa gcagccttca gggagctcga
120

tccccaaaca gccagtcacc acctctgtcc cctcttccact gttggctcgtc agactgcctg
180

agtggacagc aggctggctg cgttgtatct tcaacttcctt cctctgactg gcttgctctt
240

gtctctcagt ctttcatccc aggcagctgc ctgaggtagg tgaggaggat ggtgagccag
300

gcaggtctac aataaaggca gctctgtccg gctccttctg gctcgtgagt gtcaccggcc
360

tggaagactg agggaatggc tccccctctt cctccccgtc tttccccagt tccttccta
420

tggtggccca tgtgccagg gagttggaag catcaggagg accctcttag tgtggggaag
480

gaagtcagag accattgaca cagtgaagag gcaggatcat gtgttggaag cctgttagca
540

ggaccaaggt gactottggg agagactctt gtggacacag gccgtggtgg cttgtcagac
600

cttaaagggt ccaggccac cctgccagg atccctggtc tgctttctcc aggacacact
660

gggacactgc tgagtaatga gcagcttatt acacacaatg ggaagagggg cagagagggc
720

tgtgtcgggt gagtctcggc tgggactgaa gtttgccata agtagtggtt gtacatccag
780

gagcctggct acctgtcttt accccttgaa ggac
814

<210> 49
<211> 1164
<212> DNA
<213> Murinae gen. sp.

<400> 49
ggtcgctatt tcttggtgcg tgacatcacc gagaagatgg acatactggg caccttgaag
60

agctgtgggg ctcccaactt ccggcaggtg cggggaggcc tccctgtgtt tggcatggga
120

cagcccagcc tcttgggggt caggagggtc ctgcagaaac tccagacgga cggactcaag
180

gagtgcatta tcttctgctg gcgggaggag cctgtggtgt tcttgccgcg tgaggaggac
240

tttgtgtctt acacacctcg agacaaggag agccttcctg agaacctcag ggaccctagt
300

ccaggggtca aggctgagaa tctggagctg gccatccaga aagagatcca tgactttgcc
360

caattgagag ataatgtgta ccacgtatac cacaacacag aggacctgcg cggggagccg
420

cacaccgtgg ccatccgagg tgaggatggc gtgtgctgta ccgaggaggt gtttaagcgg
480

ccgctcttcc tgcagcccac ctacagatac caccgcctcc ccttgccaga gcaaggggcc
540

cccctggaag ccagtttga tgcctttgtc agcgttcttc gggagacccc cagccttctg
600


ccactcagag ataaccacgg gcctctgcct gccctcctgt tcagctgcca gtcaggtgta
660

ggcagaacca acctaggcat ggtcctggga accctcgtca tgttccacca cagtaggacc
720

acctcccagc tagaggcagc ctccccgttg gccaaacccc tgcccatgga gcagtttcag
780

gtgatccagg gcttcatctg taagggtgcca cagggaaga aaatgggtgga ggaggtggat
840

cgagcgatca gtgcctgtgc agagttgcat gacctgaagg aggaggtcct aaaaaaccag
900



aggaggctgg aaagcttcag gccagagagc cggggacagg aatgtggtag tcagcaagct
960

gtccagcaga gggcgctgtg gagcctggag ctgtacttct atctgctcct atttaactac
1020

tatctgcatg agcagtaccc cctggccttt gccctcagtt tcagtcgatg gctgtgtacc
1080

catcctgagc tgtaccgtct gctgggtggag ctgaattcag tggggccctt ggtccctggg
1140

gacctcatcg ccaagggctc cctg
1164

<210> 50

<211> 388

<212> PRT

<213> Murinae gen. sp.

<400> 50

Gly Arg Tyr Phe Leu Val Arg Asp Ile Thr Glu Lys Met Asp Ile Leu
1 5 10 15

Gly Thr Leu Lys Ser Cys Gly Ala Pro Asn Phe Arg Gln Val Arg Gly
20 25 30

Gly Leu Pro Val Phe Gly Met Gly Gln Pro Ser Leu Leu Gly Phe Arg
35 40 45

Arg Val Leu Gln Lys Leu Gln Thr Asp Gly Leu Lys Glu Cys Ile Ile
50 55 60

Phe Cys Val Arg Glu Glu Pro Val Val Phe Leu Arg Ala Glu Glu Asp
65 70 75 80

Phe Val Ser Tyr Thr Pro Arg Asp Lys Glu Ser Leu His Glu Asn Leu
85 90 95

Arg Asp Pro Ser Pro Gly Val Lys Ala Glu Asn Leu Glu Leu Ala Ile
100 105 110

Gln Lys Glu Ile His Asp Phe Ala Gln Leu Arg Asp Asn Val Tyr His
115 120 125

Val Tyr His Asn Thr Glu Asp Leu Arg Gly Glu Pro His Thr Val Ala
130 135 140

Ile Arg Gly Glu Asp Gly Val Cys Val Thr Glu Glu Val Phe Lys Arg
145 150 155 160

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200

Pro Leu Phe Leu Gln Pro Thr Tyr Arg Tyr His Arg Leu Pro Leu Pro
165 170 175

Glu Gln Gly Ala Pro Leu Glu Ala Gln Phe Asp Ala Phe Val Ser Val
180 185 190

Leu Arg Glu Thr Pro Ser Leu Leu Pro Leu Arg Asp Asn His Gly Pro
195 200 205

Leu Pro Ala Leu Leu Phe Ser Cys Gln Ser Gly Val Gly Arg Thr Asn
210 215 220

Leu Gly Met Val Leu Gly Thr Leu Val Met Phe His His Ser Arg Thr
225 230 235 240

Thr Ser Gln Leu Glu Ala Ala Ser Pro Leu Ala Lys Pro Leu Pro Met
245 250 255

Glu Gln Phe Gln Val Ile Gln Gly Phe Ile Cys Lys Val Pro Gln Gly
260 265 270

Lys Lys Met Val Glu Glu Val Asp Arg Ala Ile Ser Ala Cys Ala Glu
275 280 285

Leu His Asp Leu Lys Glu Glu Val Leu Lys Asn Gln Arg Arg Leu Glu
290 295 300

Ser Phe Arg Pro Glu Ser Arg Gly Gln Glu Cys Gly Ser Gln Gln Ala
305 310 315 320

Val Gln Gln Arg Ala Leu Trp Ser Leu Glu Leu Tyr Phe Tyr Leu Leu
325 330 335

Leu Phe Asn Tyr Tyr Leu His Glu Gln Tyr Pro Leu Ala Phe Ala Leu
340 345 350

Ser Phe Ser Arg Trp Leu Cys Thr His Pro Glu Leu Tyr Arg Leu Leu
355 360 365

Val Glu Leu Asn Ser Val Gly Pro Leu Val Pro Gly Asp Leu Ile Ala
370 375 380

Lys Gly Ser Leu
385

PM001203

<210> 51
<211> 4303
<212> DNA
<213> Homo sapiens

<400> 51
ggctgctggc agactatggg tacaacggcc agcacagccc agcagacggt ctgggcaggc
60

accccatattg agggcctaca gggcagtggc acgatggaca gtcggcactc cgtcagcatc
120

cactccttcc agagcactag cttgcataac agcaaggcca agtccatcat cccaacaag
180

gtggcccctg ttgtgatcac gtacaactgc aaggaggagt tccagatcca tgatgagctg
240

ctcaaggctc attacacgtt gggccggctc tcggacaaca cccctgagca ctacctggtg
300

caaggccgct acttcctggt gcgggatgtc actgagaaga tggatgtgct gggcaccgtg
360

ggaagctgtg gggcccccaa ctcccgccag gtgcagggtg ggctcactgt gtcggcctg
420

ggacagccca gcctctcagg gttcaggcgg gtcctccaga aactccagaa ggacggacat
480

agggagtgtg tcattctctg tgtgcgggag gaacctgtgc ttttctgcg tgcagatgag
540

gactttgtgt cctacacacc tcgagacaag cagaaccttc atgagaacct ccagggcctt
600

ggacccgggg tccgggtgga gagcctggag ctggccatcc ggaaagagat ccacgacttt
660

gcccagctga gcgagaacac ataccatgtg taccataaca ccgaggacct gtgggggggag
720

cccatgctg tggccatcca tggtagaggac gacttgcctg tgacggagga ggtgtacaag
780

cggccctctt tctgcagcc cacctacagg taccacgcc tgcccctgcc cgagcaaggg
840

agtcccctgg agggccagtt ggacgccttt gtcagtgttc tcggggagac cccagcctg
900

ctgcagctcc gtgatgccca cgggcctccc ccagccctcg tcttcagctg ccagatgggc
960

gtgggcagga ccaacctggg catggtcctg ggcacctca tctgtcttca ccgcagtggg
1020

accacctccc agccagaggc tgccccacg caggccaagc cctgcctat ggagcagttc
1080

caggtgatcc agagctttct ccgcatggtg ccccagggaa ggaggatggt ggaagaggtg
1140

gacagagcca tcactgcctg tgccgagttg catgacctga aagaagtggc cttggaaaac
1200

cagaagaagt tagaaggat ccgaccggag agcccagccc aggggaagcgg cagccgacac
1260

agcgtctggc agagggcgct gtggagcctg gagcgatact tctacctgat cctgtttaac
1320

tactaccttc atgagcagta cccgctggcc ttgcccctca gtttcagccg ctggctgtgt
1380

gcccaccctg agctgtaccg cctgcccgtg acgtgagct cagcaggccc tgtggctccg
1440

agggacctca tcgccagggg ctccctacgg gaggaagatc tggctctccc ggacgcgctc
1500

agcaatgtca gagagatgga tgtggccaac ttccggcggg tgccccgcat gccatctac
1560

ggcacggccc agcccagcgc caaggccctg gggagcatcc tggcctacct gacggacgcc
1620

aagaggaggc tgcggaaggc tgtctgggtg agccttcggg aggaggccgt gttggagtgt
1680

gacgggcaca cctacagcct gcgggtggcct gggccccctg tggctcctga ccagctggag
1740

accctggagg ccagctgaa ggcccatcta agcgagcctc ccccaggcaa ggagggcccc
1800

ctgacctaca ggttccagac ctgccttacc atgcaggagg tcttcagcca gcaccgcagg
1860

gcctgtcctg gcctcaccta ccaccgcata cccatgccgg acttctgtgc ccccagagag
1920

gaggactttg accagctgct ggaggccctg cgggcccgcc tctccaagga cccaggcact
1980

ggcttcgtgt tcagctgcct cagcggccag ggccgtacca caactgcgat ggtggtggct
2040

gtcctggcct tctggcacat ccaaggcttc cccgaggtgg gtgaggagga gctcgtgagt
2100

gtgcctgatg ccaagttcac taagggtgaa ttccaggtag taatgaaggc ggtgcagctg
2160

ctacccgatg ggcaccgtgt gaagaaggag gtggacgcag cgctggacac tgtcagcgag
2220

accatgacgc ccattgacta ccacctgcgg gagatcatca tctgcaccta ccgccaggcg
2280

aaggcagcga aagaggcgca agaaatgcgg aggctgcagc tggggagcct gcagtacttg
2340

gagcgctatg tctgcctgat tctcttcaac gcgtacctcc acctggagaa ggccgactcc
2400

tggcagaggc ccttcagcac ctggatgcag gaggtggcat cgaaggctgg catctacgag
2460

atccttaacg agctgggctt ccccgagctg gagagcgggg aggaccagcc cttctccagg
2520

ctgcgctacc ggtggcagga gcagagctgc agcctcgagc cctctgcccc cgaggacttg
2580

ctgtaggggg ccttactccc tgtccccca cccacagggc cccacgcagg cctgggggtg
2640

ctgaggtgct cttggctggg agcggccctg aggggtgctg gccttgaaat gattcccca
2700

cttctggag agactgagcg gagttgggag cctttttaga aagaactttt tataggacag
2760

ggagacagca cagccatccc ttgcaaacca ccaaggtgtg tggctgacct ccaggaggga
2820

gcactcactg gagtgctcac aaggtgcaca ctgctgtgtg taccttgagc acaggccggc
2880

gttcagcctc caaggggctc actccccag ttgcaaaca ctgtggatct ctctgtcctc
2940

ttctccctc tctcagattg gcctggcagc cctggcaca gagcagacc ggccactggt
3000

agctccccac ttcttactc ctgctgctct gccattgccg ctccccttgt tgcctcccaa
3060

gcactgccct cgggcgtctg gcagcctgag gtgggtggag gggacagtgt tctggataga
3120

tctattatgt gaaaggcagc ttcacccagt tttctggact ctcatgcccc catctccgac
3180

ctgggagact tcaggaatga caacctaccc agcctgggtg ggctggcagg atggtggagg
3240

tttctcaagg agctggagac ttcagggagc cctctcatg gggaggaaag agcttccagg
3300

gggcgaacgc agcacagagg aagaggcctg ctccacttgt ctgggaacct gggcaggagg
3360

cacagaggaa gccaaaggct ggagctgcag gtccccggc atctctctct gtcccggcag
3420

cccaggatgg cctgggtgcc ccacctgctg cagcaggagc cccaaggagt gctagctgag
3480

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

ggtggttgct ggggtggtcc tcatggacag tgaggtgtgc aagggtgcac tgaggggtggt
3540

gggaggggat cacctgggtt ccaggccatc cttgctgagc atctttgagc ctgccttccg
3600

gtgggagcag aaaaggccag accctgctga gttagaggct gctgggatcc actgtttcca
3660

cacagcggga aggctgctgg gaacagggtg cagagaagtg ccatgtttgc gttgagcctt
3720

gcagctcttc cagctgggga ctggtgcttg ctgaaacca ggagctgaac agtgaggagg
3780

ctgtccacct tgcttggtc actgggacca ggaaagcctg tctttgggta ggctcgtgta
3840

cttctgcagg aaaaaaaaaa aaggatgtgt cattgggtcat gatatttgaa aaggggagga
3900

ggccgaagtt gttcccatct atccagtatt ggaaaatatt tgacccctt ggctgaatto
3960

ttttgcagaa ctactgtgtg tctgttctact accttttcag gtttattggt tttatttttg
4020

catgaattaa gacgttttaa tttctttgca gacaagggtc agatgaggag tcagagatgg
4080

gaatgaatgg ggagggatcc tttgtgttct catggttggc tctgactttc agctgtgttg
4140

ggaccactgg ctgatcacat cacctctctg cctcagtttc cccatctgta aaatgggaga
4200

ataatacttg cctacctacc tcacaggggt gttgtgagga ttcatttggtg attttttttt
4260

ttttgtaca gagcttttaa gcattaaaaa cagctaaatg tga
4303

<210> 52
<211> 861
<212> PRT
<213> Homo sapiens

<400> 52

Gly Cys Trp Gln Thr Met Gly Thr Thr Ala Ser Thr Ala Gln Gln Thr
1 5 10 15

Val Ser Ala Gly Thr Pro Phe Glu Gly Leu Gln Gly Ser Gly Thr Met
20 25 30

Asp Ser Arg His Ser Val Ser Ile His Ser Phe Gln Ser Thr Ser Leu
35 40 45

His	Asn	Ser	Lys	Ala	Lys	Ser	Ile	Ile	Pro	Asn	Lys	Val	Ala	Pro	Val
50						55					60				
Val	Ile	Thr	Tyr	Asn	Cys	Lys	Glu	Glu	Phe	Gln	Ile	His	Asp	Glu	Leu
65					70					75					80
Leu	Lys	Ala	His	Tyr	Thr	Leu	Gly	Arg	Leu	Ser	Asp	Asn	Thr	Pro	Glu
				85					90					95	
His	Tyr	Leu	Val	Gln	Gly	Arg	Tyr	Phe	Leu	Val	Arg	Asp	Val	Thr	Glu
			100					105					110		
Lys	Met	Asp	Val	Leu	Gly	Thr	Val	Gly	Ser	Cys	Gly	Ala	Pro	Asn	Phe
		115					120					125			
Arg	Gln	Val	Gln	Gly	Gly	Leu	Thr	Val	Phe	Gly	Met	Gly	Gln	Pro	Ser
						135					140				
Leu	Ser	Gly	Phe	Arg	Arg	Val	Leu	Gln	Lys	Leu	Gln	Lys	Asp	Gly	His
145					150					155					160
Arg	Glu	Cys	Val	Ile	Phe	Cys	Val	Arg	Glu	Glu	Pro	Val	Leu	Phe	Leu
				165					170					175	
Arg	Ala	Asp	Glu	Asp	Phe	Val	Ser	Tyr	Thr	Pro	Arg	Asp	Lys	Gln	Asn
			180					185					190		
Leu	His	Glu	Asn	Leu	Gln	Gly	Leu	Gly	Pro	Gly	Val	Arg	Val	Glu	Ser
		195					200					205			
Leu	Glu	Leu	Ala	Ile	Arg	Lys	Glu	Ile	His	Asp	Phe	Ala	Gln	Leu	Ser
		210				215					220				
Glu	Asn	Thr	Tyr	His	Val	Tyr	His	Asn	Thr	Glu	Asp	Leu	Trp	Gly	Glu
225					230					235					240
Pro	His	Ala	Val	Ala	Ile	His	Gly	Glu	Asp	Asp	Leu	His	Val	Thr	Glu
				245					250					255	
Glu	Val	Tyr	Lys	Arg	Pro	Leu	Phe	Leu	Gln	Pro	Thr	Tyr	Arg	Tyr	His
			260					265					270		
Arg	Leu	Pro	Leu	Pro	Glu	Gln	Gly	Ser	Pro	Leu	Glu	Ala	Gln	Leu	Asp
		275					280					285			

PROO-1205

Ala Phe Val Ser Val Leu Arg Glu Thr Pro Ser Leu Leu Gln Leu Arg
290 295 300

Asp Ala His Gly Pro Pro Pro Ala Leu Val Phe Ser Cys Gln Met Gly
305 310 315 320

Val Gly Arg Thr Asn Leu Gly Met Val Leu Gly Thr Leu Ile Leu Leu
325 330 335

His Arg Ser Gly Thr Thr Ser Gln Pro Glu Ala Ala Pro Thr Gln Ala
340 345 350

Lys Pro Leu Pro Met Glu Gln Phe Gln Val Ile Gln Ser Phe Leu Arg
355 360 365

Met Val Pro Gln Gly Arg Arg Met Val Glu Glu Val Asp Arg Ala Ile
370 375 380

Thr Ala Cys Ala Glu Leu His Asp Leu Lys Glu Val Val Leu Glu Asn
385 390 395 400

Gln Lys Lys Leu Glu Gly Ile Arg Pro Glu Ser Pro Ala Gln Gly Ser
405 410 415

Gly Ser Arg His Ser Val Trp Gln Arg Ala Leu Trp Ser Leu Glu Arg
420 425 430

Tyr Phe Tyr Leu Ile Leu Phe Asn Tyr Tyr Leu His Glu Gln Tyr Pro
435 440 445

Leu Ala Phe Ala Leu Ser Phe Ser Arg Trp Leu Cys Ala His Pro Glu
450 455 460

Leu Tyr Arg Leu Pro Val Thr Leu Ser Ser Ala Gly Pro Val Ala Pro
465 470 475 480

Arg Asp Leu Ile Ala Arg Gly Ser Leu Arg Glu Asp Asp Leu Val Ser
485 490 495

Pro Asp Ala Leu Ser Thr Val Arg Glu Met Asp Val Ala Asn Phe Arg
500 505 510

Arg Val Pro Arg Met Pro Ile Tyr Gly Thr Ala Gln Pro Ser Ala Lys
515 520 525

Ala Leu Gly Ser Ile Leu Ala Tyr Leu Thr Asp Ala Lys Arg Arg Leu

530

535

540

Arg Lys Val Val Trp Val Ser Leu Arg Glu Glu Ala Val Leu Glu Cys
545 550 555 560

Asp Gly His Thr Tyr Ser Leu Arg Trp Pro Gly Pro Pro Val Ala Pro
565 570 575

Asp Gln Leu Glu Thr Leu Glu Ala Gln Leu Lys Ala His Leu Ser Glu
580 585 590

Pro Pro Pro Gly Lys Glu Gly Pro Leu Thr Tyr Arg Phe Gln Thr Cys
595 600 605

Leu Thr Met Gln Glu Val Phe Ser Gln His Arg Arg Ala Cys Pro Gly
610 615 620

Leu Thr Tyr His Arg Ile Pro Met Pro Asp Phe Cys Ala Pro Arg Glu
625 630 635 640

Glu Asp Phe Asp Gln Leu Leu Glu Ala Leu Arg Ala Ala Leu Ser Lys
645 650 655

Asp Pro Gly Thr Gly Phe Val Phe Ser Cys Leu Ser Gly Gln Gly Arg
660 665 670

Thr Thr Thr Ala Met Val Val Ala Val Leu Ala Phe Trp His Ile Gln
675 680 685

Gly Phe Pro Glu Val Gly Glu Glu Glu Leu Val Ser Val Pro Asp Ala
690 695 700

Lys Phe Thr Lys Gly Glu Phe Gln Val Val Met Lys Val Val Gln Leu
705 710 715 720

Leu Pro Asp Gly His Arg Val Lys Lys Glu Val Asp Ala Ala Leu Asp
725 730 735

Thr Val Ser Glu Thr Met Thr Pro Met His Tyr His Leu Arg Glu Ile
740 745 750

Ile Ile Cys Thr Tyr Arg Gln Ala Lys Ala Ala Lys Glu Ala Gln Glu
755 760 765

Met Arg Arg Leu Gln Leu Arg Ser Leu Gln Tyr Leu Glu Arg Tyr Val
770 775 780

ccaatgggtcc catcagctgc gggataatgg gcaccagaga tgatgtctaa ctacactggg
720

ggcatctatg ctgagc
736

<210> 54
<211> 1404
<212> DNA
<213> Murinae gen. sp.

<400> 54
aaaggaccgg gcggggcgctc ccgagcgctt gggcctgcgg gtcgggtcaa gaggtcgaag
60

gtgctgcgctg tgatccagga tccgaattgg cccggagcag gagcatggcg tcgtcggggg
120

cgggtgcagca gctgcccctg gtgctgctga tgttgcctgtt ggcgagtgcg gcacggggcca
180

gactctactt ccgctcgggc cagacttgct accatcccat tcgcggggac cagctggctc
240

tgctggggcg caggacttat cctcggccgc atgagtacct gtccccagcg gatctcccca
300

agaattggga ctggagaaat gtgaacggtg tcaactatgc cagcgtcacc aggaaccagc
360

acatcccaca gtactgtggt tcttgcctggg cccacggcag caccagtgcc atggcagacc
420

gaatcaacat caagaggaaa ggtgcatggc cctccatcct gctgtccgta cagaatgtca
480

ttgactgtgg caatgctggc tcttgcgaag ggggcaatga ccttccgggtg tgggagtatg
540

cccacaagca tggcatcccc gatgagacct gcaacaacta ccaggccaag gaccaagact
600

gtgacaagtt taaccagtgt gggacctgca ctgaattcaa agagtgtcac accatccaga
660

attacacctt ctggagagtg ggtgattacg gctccctgtc cgggagggag aagatgatgg
720

ccgagatcta tgccaatggt cccatcagct gcgggataat ggcaacagag atgatgtcta
780

actacactgg gggcatctat gctgagcacc aggaccaggc cgttatcaac cacatcatct
840

ctgtagctgg ctgggggtgtc agcaacgatg gcatcgagta ctggattgtc cgaaattcat
900

ggggcgaacc ctgggggtgag aaaggctgga tgaggatcgt gaccagcacc tacaaggag
960

gcacaggtga cagctacaac cttgccatcg agagtgcctg cacatttggg gaccccatg
1020

tttaggtaga tgtctctgga agcagcgctg tgaaccatga caggagggg tgattaatta
1080

ctgacactgg acatgtccag acagctataa acagtgcctg tggacatgag gaccagagt
1140

tggactgcat cccgagagga gacggtaaag gatgaaacac aactgcactg ggaccctccg
1200

ccgtaccctc caggcctgcc tcctccacca ctgagccctc caggcctgcc tcctcttcta
1260

cagtgcctgc cttcagccac ccggagaaga gagctatggt ttaggacagc tcaacttatc
1320

accagatctg gagccctgga atccatggga ggggggaaca agtccagact gcttaagaaa
1380

tgagtaaaat atctggcttc ccac
1404

<210> 55
<211> 306
<212> PRT
<213> Murinae gen. sp.

<400> 55

Met Ala Ser Ser Gly Ser Val Gln Gln Leu Pro Leu Val Leu Leu Met
1 5 10 15

Leu Leu Leu Ala Ser Ala Ala Arg Ala Arg Leu Tyr Phe Arg Ser Gly
20 25 30

Gln Thr Cys Tyr His Pro Ile Arg Gly Asp Gln Leu Ala Leu Leu Gly
35 40 45

Arg Arg Thr Tyr Pro Arg Pro His Glu Tyr Leu Ser Pro Ala Asp Leu
50 55 60

Pro Lys Asn Trp Asp Trp Arg Asn Val Asn Gly Val Asn Tyr Ala Ser
65 70 75 80

Val Thr Arg Asn Gln His Ile Pro Gln Tyr Cys Gly Ser Cys Trp Ala
85 90 95

His Gly Ser Thr Ser Ala Met Ala Asp Arg Ile Asn Ile Lys Arg Lys
100 105 110

Gly Ala Trp Pro Ser Ile Leu Leu Ser Val Gln Asn Val Ile Asp Cys

115

120

125

Gly Asn Ala Gly Ser Cys Glu Gly Gly Asn Asp Leu Pro Val Trp Glu
130 135 140

Tyr Ala His Lys His Gly Ile Pro Asp Glu Thr Cys Asn Asn Tyr Gln
145 150 155 160

Ala Lys Asp Gln Asp Cys Asp Lys Phe Asn Gln Cys Gly Thr Cys Thr
165 170 175

Glu Phe Lys Glu Cys His Thr Ile Gln Asn Tyr Thr Leu Trp Arg Val
180 185 190

Gly Asp Tyr Gly Ser Leu Ser Gly Arg Glu Lys Met Met Ala Glu Ile
195 200 205

Tyr Ala Asn Gly Pro Ile Ser Cys Gly Ile Met Ala Thr Glu Met Met
210 215 220

Ser Asn Tyr Thr Gly Gly Ile Tyr Ala Glu His Gln Asp Gln Ala Val
225 230 235 240

Ile Asn His Ile Ile Ser Val Ala Gly Trp Gly Val Ser Asn Asp Gly
245 250 255

Ile Glu Tyr Trp Ile Val Arg Asn Ser Trp Gly Glu Pro Trp Gly Glu
260 265 270

Lys Gly Trp Met Arg Ile Val Thr Ser Thr Tyr Lys Gly Gly Thr Gly
275 280 285

Asp Ser Tyr Asn Leu Ala Ile Glu Ser Ala Cys Thr Phe Gly Asp Pro
290 295 300

Ile Val
305

<210> 56
<211> 1480
<212> DNA
<213> Homo sapiens

<400> 56
ctgggccgag gccgaggccg gggcgggatc cagagcggga gccggcgccg gatctgggac
60

tcggagcggg atccggagcg ggacccagga gccggcgcgg ggccatggcg aggcgcgggc
120

cagggtggcg gccgcttctg ctgctcgtgc tgctggcggg cgcggcgcag ggccggcctct
180

acttccgccc gggacagacc tgctaccggc ctctgcgggg ggacgggctg gctccgctgg
240

ggcgcagcac atacccccgg cctcatgagt acctgtcccc agcggatctg cccaagagct
300

gggactggcg caatgtggat ggtgtcaact atgccagcat cacccggaac cagcacatcc
360

ccaatactg cggctcctgc tgggcccacg ccagcaccag cgctatggcg gatcggatca
420

acatcaagag gaagggagcg tggccctcca ccctcctgtc cgtgcagaac gtcacgact
480

gcggtaacgc tggctcctgt gaagggggta atgacctgtc cgtgtgggac tacgcccacc
540

agcacggcat ccctgacgag acctgcaaca actaccaggc caaggaccag gagtgtgaca
600

agtttaacca atgtgggaca tgcaatgaat tcaaagagtg ccacgccatc cggaactaca
660

ccctctggag ggtgggagac tacggctccc tctctgggag ggagaagatg atggcagaaa
720

tctatgcaaa tggctccatc agctgtggaa taatggcaac agaaagactg gctaactaca
780

ccggaggcat ctatgccgaa taccaggaca ccacatatat aaaccatgtc gtttctgtgg
840

ctgggtgggg catcagtgat gggactgagt actggattgt ccggaattca tggggtgaac
900

catggggcga gagaggctgg ctgaggatcg tgaccagcac ctataaggat gggaaggcg
960

ccagatacaa ccttgccatc gaggagcact gtacatttgg ggaccccatc gtttaaggcc
1020

atgtcactag aagcgcagtt taagaaaagg catggtgacc catgaccaga ggggatccta
1080

tggttatgtg tgccaggctg gctggcagga actgggggtg ctatcaatat tggatggcga
1140

ggacagcgtg gcaactggctg cgagtgttcc tgagagttga aagtgggatg acttatgaca
1200

cttgcacagc atggctctgc ctcacaatga tgcagtcagc cacctgggtga agaagtgacc
1260

tgcgacacag gaaacgatgg gacctcagtc ttcttcagca gaggacttga tattttgtat
1320

ttggcaactg tgggcaataa tatggcattt aagaggtgaa agagttcaga cttatcacca
1380

ttcttatgtc actttagaat caaggggtggg ggagggaggg agggagttgg cagtttcaaa
1440

tgcgccaagt gatgaataaa gtatctggct ctgcacgaga
1480

<210> 57
<211> 303
<212> PRT
<213> Homo sapiens

<400> 57

Met Ala Arg Arg Gly Pro Gly Trp Arg Pro Leu Leu Leu Leu Val Leu
1 5 10 15

Leu Ala Gly Ala Ala Gln Gly Gly Leu Tyr Phe Arg Arg Gly Gln Thr
20 25 30

Cys Tyr Arg Pro Leu Arg Gly Asp Gly Leu Ala Pro Leu Gly Arg Ser
35 40 45

Thr Tyr Pro Arg Pro His Glu Tyr Leu Ser Pro Ala Asp Leu Pro Lys
50 55 60

Ser Trp Asp Trp Arg Asn Val Asp Gly Val Asn Tyr Ala Ser Ile Thr
65 70 75 80

Arg Asn Gln His Ile Pro Gln Tyr Cys Gly Ser Cys Trp Ala His Ala
85 90 95

Ser Thr Ser Ala Met Ala Asp Arg Ile Asn Ile Lys Arg Lys Gly Ala
100 105 110

Trp Pro Ser Thr Leu Leu Ser Val Gln Asn Val Ile Asp Cys Gly Asn
115 120 125

Ala Gly Ser Cys Glu Gly Gly Asn Asp Leu Ser Val Trp Asp Tyr Ala
130 135 140

His Gln His Gly Ile Pro Asp Glu Thr Cys Asn Asn Tyr Gln Ala Lys
145 150 155 160

Asp Gln Glu Cys Asp Lys Phe Asn Gln Cys Gly Thr Cys Asn Glu Phe

1941-1945

165

170

175

Lys Glu Cys His Ala Ile Arg Asn Tyr Thr Leu Trp Arg Val Gly Asp
180 185 190

Tyr Gly Ser Leu Ser Gly Arg Glu Lys Met Met Ala Glu Ile Tyr Ala
195 200 205

Asn Gly Pro Ile Ser Cys Gly Ile Met Ala Thr Glu Arg Leu Ala Asn
210 215 220

Tyr Thr Gly Gly Ile Tyr Ala Glu Tyr Gln Asp Thr Thr Tyr Ile Asn
225 230 235 240

His Val Val Ser Val Ala Gly Trp Gly Ile Ser Asp Gly Thr Glu Tyr
245 250 255

Trp Ile Val Arg Asn Ser Trp Gly Glu Pro Trp Gly Glu Arg Gly Trp
260 265 270

Leu Arg Ile Val Thr Ser Thr Tyr Lys Asp Gly Lys Gly Ala Arg Tyr
275 280 285

Asn Leu Ala Ile Glu Glu His Cys Thr Phe Gly Asp Pro Ile Val
290 295 300